

# Computational and experimental studies of reactive intermediates in glycosylation reactions

Remmerswaal, W.A.

# Citation

Remmerswaal, W. A. (2024, September 12). Computational and experimental studies of reactive intermediates in glycosylation reactions. Retrieved from https://hdl.handle.net/1887/4083515

Version: Publisher's Version

Licence agreement concerning inclusion of doctoral

License: thesis in the Institutional Repository of the University of


<u>Leiden</u>

Downloaded from: https://hdl.handle.net/1887/4083515

**Note:** To cite this publication please use the final published version (if applicable).

# Chapter 8

# Influence of Acceptor Acidity on Hydrogen bond Mediated Aglycone Delivery (HAD) Through the Picoloyl Protecting Group




Abstract | The outcome of glycosylation reactions heavily relies on the specific protecting group patterns employed on both the donor and acceptor molecules. The picoloyl (Pico) protecting group stands out as it can steer the stereoselectivity in a glycosylation reaction through hydrogen bond mediated aglycone delivery (HAD). This glycosylation mechanism provides synstereoselectivity, with respect to the stereochemistry of the Pico group, by forming a hydrogen bond between the incoming acceptor and the picoloyl ring nitrogen. Here, the influence of acceptor acidity on the stereodirecting effect of the picoloyl protecting group is probed. A set of 3-O-functionalized glucosyl and mannosyl donors, each bearing different protecting groups (picolinate, nicotinate, isonicotinate, and benzoate), were synthesized for systematic evaluation. For the 3-O-picoloyl-glucose series, the picoloyl group exhibited minimal influence on stereoselectivity, with only weak nucleophiles showing a modest shift in selectivity for the 3-O-Pico protected glucosyl donor in comparison to the other C-3-acyl glucosides. In contrast, in the 3-O-picoloyl-mannose series a much stronger  $\beta$ -directing effect was observed, wherein more acidic acceptors led to increased β-selectivity. The results provide insights into the complex interplay of acceptor acidity and glycosylation stereoselectivity mediated by the picoloyl protecting group.

Published | Remmerswaal, W. A.\*; Hoogers, D.\*; Hoopman, M.; van der Marel, G. A.; Codée, J. D. C. Eur. J. Org. Chem. **2024**, e202301063.

# Introduction

One of the principal challenges in oligosaccharide synthesis is the stereoselective formation of glycosidic bonds. The stereochemical outcome of glycosylation reactions is highly dependent on the protecting group patterns on both the donor and acceptor molecule.<sup>1-4</sup> Therefore, steering the reaction towards the desired stereoisomer requires careful selection of protecting groups.<sup>5-7</sup> In recent years, there has been much interest in strategies that employ protecting groups on remote positions (C-3, C-4, or C-6) to influence the stereochemical outcome of glycosylation reactions, when one cannot rely on neighboring-group participation (NGP) from C-2.<sup>8-10</sup>

There are two distinct categories of strategies employing remote protecting groups: those that form covalent intermediates, and those that act through non-covalent interactions. 11 The first category includes the long-range participation (LRP) by remote ester groups to form a bridged bicyclic intermediate. 12-23 These bridged bicyclic intermediates direct the stereoselectivity to provide the anti-products, with respect to the orientation of the ester moiety, by blocking one side of the carbohydrate ring (Scheme 1a). In the latter category, the most common strategy is the hydrogen bond mediated aglycone delivery (HAD) developed by the group of Demchenko. 24,25 In this methodology, a remote position is functionalized with a protecting group capable of acting as a hydrogen-bond acceptor. The most common protection group used in this category, due to its advantageous installation<sup>26</sup> and deprotection conditions,<sup>27</sup> is the picoloyl ester (Pico). Contrary to the reactions of the dioxanium ions, this protecting group steers the stereoselectivity of glycosylation reactions to provide the syn-products with respect to the position of the Pico-group. The picoloyl ester influences the stereochemical outcome of glycosylation reactions by formation of a hydrogen bond between the picoloyl ring nitrogen atom and the glycosyl acceptor (Scheme 1b). Support for this modus operandi has been delivered by a plethora of reactions, involving various donors featuring the picoloyl ester on various carbohydrate positions, providing synstereoselectivity.<sup>28-40</sup> While much effort has been devoted to screening the substrate scope and tuning reaction conditions, 41-43 the role of the acceptor on HAD has not been studied systematically. Generally, stronger O-nucleophiles are less acidic and thus exhibit weaker hydrogen bonding.44 Given the central role of the hydrogen bond within the HAD mechanism, the hydrogen-bonding capacity of the *O*-acceptor is likely to be important.<sup>45</sup>



**Scheme 1.** (a) A schematic representation of the possible reactive intermediates in long range participation (LRP). (b) Hydrogen bond mediated aglycone delivery (HAD) by the picoloyl protecting group, mounted at C-3.

Here, the role of acceptor acidity on HAD is studied through a systematic investigation of 3-*O*-picoloyl-glucosyl and mannosyl donors in combination with a set of acceptors of gradually increasing acidity. To this end, the C-3-hydroxyl group was functionalized with benzyl, benzoate, picoloyl, and picoloyl-related protecting groups. Subsequently, the effect of acceptor acidity on the stereoselective outcome of glycosylation reactions was examined, employing these donors. This study shows that more acidic, *i.e.*, less nucleophilic, *O*-acceptors are better at hydrogen bond mediated aglycone delivery. The results provide insights into how acceptor tuning can be utilized to optimize the stereoselectivity provided by the picoloyl protecting group.


# **Results and Discussion**

To investigate the influence of acceptor acidity on the HAD mechanism, first acceptor aciditystereoselectivity trends for a set of glucosyl and mannosyl donors was established. As model acceptors, a set of partially fluorinated ethanol derivates (i.e., 2,2,2-trifluoroethanol, TFE; 2.2-difluoroethanol, DFE: 2-fluoroethanol, MFE: ethanol, EtOH) was used, which are wellestablished as model acceptors. 46,47 These model acceptors exhibit a gradual increase of acidity along the acceptor series, making this set of alcohols a powerful tool for investigating the acidity-stereoselectivity relationship. As for the donor systems, a set of glucosyl and mannosyl donors was employed, that are protected with benzyl ethers or a benzyl ether and benzylidene acetal to mask the C-2, C-4, and C-6 hydroxyl functions, placing different protecting groups at the C-3-OH. These donor systems were chosen because previous research has shown the HAD mechanism to be relevant for mannosyl 3-0-picoloyl donors, while playing a less important role for the glucosyl 3-0-picoloyl-donors. 42.43 Furthermore, the structurally related 3-0-benzoyl glucosyl and -mannosyl donors were investigated in chapter 7, which provide strikingly disparate stereoselectivities in their glycosylation reactions.<sup>48</sup> While LRP plays an important role in the mannosylation reactions (providing the α-products), the benzoyl ester played no major role in the glycosylation reactions of the corresponding glucosyl donors, where the stereoselectivity of the reactions critically depended on the nucleophilicity of the acceptors. This stark contrast in the reaction mechanism and the resulting stereoselectivity make the glucosyl and mannosyl 3-0protected donors an excellent system to investigate the acceptor acidity-stereoselectivity trends, and establish how they depend on the available reaction paths (Scheme 2).

To verify that any trend arising from the picoloyl protecting group is the result of HAD, donors were included in the experimental set-up that are structurally and electronically similar to the picoloyl protecting group. The nicotinate (Nico, N at meta position) and iso-nicotinate (i-Nico, N at para position) protecting groups are picoloyl-regioisomers having the pyridine nitrogen at different positions in the ring. These protecting groups have similar electron-withdrawing properties as the picoloyl protecting group but are likely less capable of HAD because hydrogen bonding with these groups would orient the acceptor too far away from the anomeric center of the donor. $^{42,49}$ 

Lastly, in the experimental design,  $Ph_2SO/Tf_2O^{50}$  mediated pre-activation conditions were used, which transform the parent donors into the corresponding glycosyl triflates prior to the addition of the acceptor.<sup>51</sup> This method of activation is well suited for this study, as it generates well-defined reactive intermediates without the use of a Brønsted acid. The non-acidic conditions are essential to study the influence of acceptor acidity, because protonation of the picoloyl group can preclude HAD.<sup>49,52</sup> To scavenge the TfOH released in the glycosylation reactions upon attack of the alcohol on the activated glycosyl donors, a non-nucleophilic base was included in the reaction mixtures. To confirm that protonation of the Pico group does not affect the stereochemical outcome of the glycosylation reactions,<sup>53</sup> the use of different equivalents (2.5 or 10) of 2,4,6-tri-tert-butylpyrimidine (TTBP), 2,6-di-tert-butylpyrimidine, and 2,4,6-tri-tert-butylpyridine, having pKaH values of 1.02, 3.58, and 4.02, respectively, was briefly explored. No effect of

these bases was observed on the stereoselectivity (See Supplementary Table 1) and therefore the application of the commonly used TTBP was continued in this study.



**Scheme 2**. General mechanism of glycosylations employing the Ph<sub>2</sub>SO/Tf<sub>2</sub>O mediated preactivation conditions.

Based on this experimental design, the set of 3-*O*-protected phenyl 2,4,6-*O*-benzyl-1-thio-glucosyl **1-5** and mannosyl donors **6-10** (See Table 1 and 2) were generated, on which the following 3-*O* protecting groups were installed: benzyl (**1** and **6**), picolinate (**2** and **7**), nicotinate (**3** and **8**), isonicotinate (**4** and **9**), and benzoyl (**5** and **10**). Each donor was treated with the four model acceptors (TFE, DFE, MFE and EtOH), and the stereoselective outcome was recorded (Tables 1-4). Results from the 3-*O*-benzyl and 3-*O*-benzoyl donors were taken from previous work, and are provided for comparison. The results of the glycosylations with the 3-*O*-benzyl donors **1** and **5** show the 'intrinsic' stereoselectivity of the donors under the used glycosylation conditions, while the glycosylations with the 3-*O*-benzoyl donors **6** and **10** show the influence of acyl groups on this selectivity.

First, the acceptor acidity-stereoselectivity relationship for glucosyl donors 1-5 was explored. As previously described,  $^{47,54}$  the stereoselectivity of the glycosylation reactions of the 2,4,6-tri-O-benzyl glucose 1 and 5 gradually shifts from  $\alpha$ - to  $\beta$ -stereoselectivity as the nucleophilicity of the acceptor increases.  $^{46}$  The 3-O-Pico-glucosyl donor 2, and the Nico and i-Nico stereoisomer counterparts 3 and 4 show identical trends. The lack of stereochemical steering of the Pico-type esters is in line with the observations of the group of Demchenko.  $^{55}$  They have shown that  $\beta$ -selective glycosylations can be achieved using 3-O-picoloyl-glucosyl donors by protonation of the picoloyl nitrogen using an excess of acid, which serves to stabilize a covalent  $\alpha$ -triflate intermediate.  $^{49,52}$  Thus, under the essentially neutral pre-activation reaction conditions used here, no  $\beta$ -directing effect would be expected.

**Table 1.** Experimentally found stereoselectivities for model glycosylation reactions with the phenyl 2,4,6-tri-*O*-benzyl-1-thio glucosyl donors **1-5**; Experimental conditions: preactivation-based glycosylation conditions; nucleophile (2 equiv),  $Tf_2O$  (1.3 equiv), Ph<sub>2</sub>SO (1.3 equiv), TTBP (2.5 equiv), DCM (0.05 M), -80 to -60 °C. The stereoselectivity of the reaction is expressed as α:β and based on  $^1H$ -NMR of the purified compounds. In all cases, the NMR spectra for both the crude and purified compounds were compared to analyze whether the measured stereoselectivity did not alter upon purification.

	но	но Г	но∕у́ Б	но 🗡 F
Donor	Product	Product	Product	Product
	α:β	α:β	α:β	α:β
	(yield)	(yield)	(yield)	(yield)
1 BnO OBn SPh	15:85 <sup>[a]</sup>	36:64 <sup>[a]</sup>	48:52 <sup>[a]</sup>	72:28 <sup>[a]</sup>
	(70%)	(75%)	(58%)	(80%)
2 BnO OBn SPh	28:72	36:64	46:54	49:51
	(43%)	(39%)	(50%)	(55%)
3 N BnO O SPh	20:80	40:60	41:59	47:53
	(48%)	(50%)	(47%)	(51%)
4 N OBn SPh	19:81	32:68	50:50	65:35
	(46%)	(50%)	(52%)	(31%)
5 BnO OBn SPh	15:85 <sup>[a]</sup>	34:66 <sup>[a]</sup>	48:52 <sup>[a]</sup>	79:21 <sup>[a]</sup>
	(76%)	(82%)	(70%)	(76%)
>90:10 >80:20	>60:40 50:50	<40:60	<20:80 <1	0:90 (α:β)

[a] Results from Hansen et al., 12 identical glycosylation conditions were used.

Next, the reactivity-stereoselectivity trends for the mannosyl donors **6-10** (Table 2) was examined. The stereoselectivity of the glycosylations with the 3-0-benzyl-mannosyl donor **6** gradually shifts from  $\alpha$ - to  $\beta$ -stereoselectivity as the nucleophilicity of the acceptor increases, while the 3-0-benzoyl-mannosyl donor **10** solely provides the  $\alpha$ -linked products. These can originate from a 1,3-dioxanium ion intermediate formed by a long-range participation mechanism. <sup>12,56-58</sup> The introduction of a nitrogen atom in the benzoyl ring on either the *meta* (Nico donor **8**) or the *para*-position (*i*-Nico donor **9**), leads to a slightly decreased stereoselectivity in the reactions. In contrast to donors **8** and **9**, the 3-0-picoloyl mannose donor **7** provides product mixtures with both anomers in approximately similar amounts for ethanol, MFE and DFE. TFE, the most acidic acceptor of the series, provides a modestly  $\beta$ -selective glycosylation, which in light of the benchmark results obtained for this acceptor with benzyl donor **6** and benzoyl mannoside **10**, stands out (Table 2). The increased  $\beta$ -selectivity in the reactions of the 3-0-Pico donor **7** can be explained by a HAD mechanism, with the most acidic acceptor experiencing the strongest stereochemical guidance.

**Table 2.** Experimentally found stereoselectivities for model glycosylation reactions with the phenyl 2,4,6-tri- $\theta$ -benzyl-1-thio mannosyl donors **6-10**; Experimental conditions: preactivation-based glycosylation conditions; nucleophile (2 equiv), Tf<sub>2</sub>0 (1.3 equiv), Ph<sub>2</sub>SO (1.3 equiv), TTBP (2.5 equiv), DCM (0.05 M), -80 to -60 °C. The stereoselectivity of the reaction is expressed as α:β and based on  $^1$ H-NMR of the purified compounds. In all cases, the NMR spectra for both the crude and purified compounds were compared to analyze whether the measured stereoselectivity did not alter upon purification.

	но	но Г	но 🗡 F	HO F
Donor	Product	Product	Product	Product
	α:β	α:β	α:β	α:β
	(yield)	(yield)	(yield)	(yield)
6 BnO OBn O SPh	33:67 <sup>[a]</sup>	60:40 <sup>[a]</sup>	80:20 <sup>[a]</sup>	>98:2 <sup>[a]</sup>
	(70%)	(75%)	(65%)	(84%)
7 BnO OBn O SPh	55:45	55:45	50:50	31:69
	(58%)	(32%)	(48%)	(59%)
8 N BnO OBn SPh	85:15	85:15	85:15	86:14
	(53%)	(60%)	(69%)	(60%)
9 N SPh	90:10	88:12	86:14	84:16
	(73%)	(94%)	(72%)	(83%)
10 BnO OBn O SPh	>98:2 <sup>[a]</sup>	>98:2 <sup>[a]</sup>	>98:2 <sup>[a]</sup>	>98:2 <sup>[a]</sup>
	(94%)	(87%)	(87%)	(79%)
>90:10 >80:20	<b>&gt;</b> 60:40 50:50	<40:60	<20:80 <10	:90 (α:β)

[a] Results from Hansen et al.,12 identical glycosylation conditions were used.

Finally, the 4,6-O-benzylidene-mannosyl and glucosyl donor systems were considered. The 4,6-O-benzylidene mannose system has been introduced for the generation of  $\beta$ -mannosidic linkages (*i.e.*, the  $\beta$ -Crich-mannosylation). $^{59,60}$  This preference of 4,6-O-benzylidene mannosyl donors in forming the  $\beta$ -product is generally considered to be the result of a S<sub>N</sub>2-like attack on the anomeric  $\alpha$ -triflate, which is stabilized for these donors due to the conformational tethering of C-4 and C-6. However, LRP by C-3-acyl groups can completely overturn the  $\beta$ -selectivity in this system. $^{23,46,61}$  In the corresponding glucose case, the  $\alpha$ - and  $\beta$ -triflates play a role, with the latter becoming the more important reactive intermediate in the reaction with decreasing nucleophilicity of the acceptor. $^{46,47,54}$  In contrast to the mannosyl system, LRP has been shown not to play a significant role in the glycosylations of the C-3-O-acyl donors. $^{48}$  As a result, the question arose whether the introduction of a 3-O-picoloyl protecting group would provide a stereoselectivity trend consistent with either a LRP, HAD, or  $\beta$ -Crich-mannosylation mechanism. $^{61}$ 

Thus, the set of phenyl 2-O-benzyl-4,6-O-benzylidene-1-thio-glucosyl donors, carrying a 3-O-benzyl (11), picolinate (12), nicolinate (13), isonicolinate (14), or benzoate (15) at C-3 and the corresponding mannosides 16-21 were generated. Table 3 reports the stereochemical outcome of the model glycosylations with the glucosyl donors, while the results of the mannosylation reactions are reported in Table 4. The data for 3-O-benzyl and 3-O-benzoyl donors 11, 15, 16, and 21 have previously been reported. He in line with the results displayed in Table 1, the nature of the C-3-O-protecting group has relatively little influence on the stereoselectivity of the reactions of the 4,O-benzylidene glucosyl donors 11-15, although the formation of the O-products slightly increases when the picoloyl, nicoloyl and O-nicoloyl groups are used (Table 3).

In contrast to the benzylidene glucose series, the benzylidene mannose series shows different stereoselectivity for the C-3-acyl donors in comparison to the C-3-benzylated donor (Table 4). 3-*O*-Benzyl donor **16** provides β-selective glycosylations, while installation of a 3-0-benzovl group (donor 20) completely overturns this stereoselectivity, leading to complete  $\alpha$ -selectivity for all acceptors.<sup>48</sup> In contrast, the donors with the Pico- (donor 17), Nico (donor 18) and i-Nico (donor 19) groups provide anomeric mixtures in which the amount of  $\beta$ -product increases with increasing acidity/lower nucleophilicity of the acceptors, indicating that LRP in these latter systems is less effective. Noticeable are the contrast with the results in Table 2, where the effect of the different C-3-acyl groups seems to differ significantly less. It was hypothesized that these differences can be explained by destabilization of the intermediate 1,3-dioxanium ion formed from the different donors. The 1,3-dioxanium ions of the benzylidene-protected donors are less stable because of the increased ring strain in these ions,  $^{48}$  forcing the dioxanium ion to take up a  $B_{2.5}$ -type conformation instead of the more favorable <sup>1</sup>C<sub>4</sub> conformation that can be attained by the 4.6di-O-benzyl donors. The results indicate that the stability of the 1,3-dioxanium ions (as gauged by the  $\alpha$ -selectivity of the reactions) further decreases with the introduction of a ring nitrogen in the acyl groups, with the destabilizing inductive effect of the ring nitrogen increasing with diminishing the distance to the dioxanium ion (Pico > Nico > i-Nico, as seen from Supplementary Table 2). The Pico-group shows the strongest  $\beta$ -directing effect, with  $\beta$ selectivity increasing with increasing acceptor acidity. This trend is consistent with a scenario in which there is competition between LRP and HAD mechanisms, in which the most acidic nucleophiles prefer the latter.

**Table 3.** Experimentally found stereoselectivities for model glycosylation reactions with the phenyl 2- $\theta$ -benzyl-4, $\theta$ - $\theta$ -benzylidene-1-thio-glucosyl donors **11-15**; Experimental conditions: pre-activation-based glycosylation conditions; nucleophile (2 equiv), Tf<sub>2</sub>O (1.3 equiv), Ph<sub>2</sub>SO (1.3 equiv), TTBP (2.5 equiv), DCM (0.05 M), -80 to -60 °C. The stereoselectivity of the reaction is expressed as α: $\theta$  and based on  $\theta$ -H-NMR of the purified compounds. In all cases, the NMR spectra for both the crude and purified compounds were compared to analyze whether the measured stereoselectivity did not alter upon purification.

	но	но∕∕-	но 👉 🖡	HO F
Donor	Product	Product	Product	Product
	α:β	α:β	α:β	α:β
	(yield)	(yield)	(yield)	(yield)
11 Ph O O SPh OBn	30:70 <sup>[a]</sup>	50:50 <sup>[a]</sup>	82:18 <sup>[a]</sup>	>98:2 <sup>[a]</sup>
	(80%)	(65%)	(95%)	(74%)
12 Ph O O O SPh OBn	<2:98	24:76	58:42	74:26
	(39%)	(49%)	(31%)	(28%)
13 Ph O O SPh OBn	<2:98	26:74	65:35	>98:2
	(47%)	(69%)	(42%)	(60%)
14 NOBh	16:84	28:72	80:20	97:3
	(51%)	(37%)	(57%)	(53%)
15 OBn SPh	25:75 <sup>[a]</sup>	45:55 <sup>[a]</sup>	85:15 <sup>[a]</sup>	>98:2 <sup>[a]</sup>
	(quant.)	(quant.)	(74%)	(84%)
>90:10 >80:20	>60:40 50:50	<40:60	<20:80 <10	):90 (α:β)

<sup>[</sup>a] Results from Remmerswaal *et al.*, <sup>48</sup> identical glycosylation conditions were used.

**Table 4.** Experimentally found stereoselectivities for model glycosylation reactions with the phenyl 2- $\theta$ -benzyl-4,6- $\theta$ -benzylidene-1-thio-mannosyl donors **16-20**; Experimental conditions: pre-activation-based glycosylation conditions; nucleophile (2 equiv), Tf<sub>2</sub>O (1.3 equiv), Ph<sub>2</sub>SO (1.3 equiv), TTBP (2.5 equiv), DCM (0.05 M), -80 to -60 °C. The stereoselectivity of the reaction is expressed as α: $\theta$  and based on <sup>1</sup>H-NMR of the purified compounds. In all cases, the NMR spectra for both the crude and purified compounds were compared to analyze whether the measured stereoselectivity did not alter upon purification.

	но	но∕∕√	но∕у́ F	но 🗡 Е
Donor	Product	Product	Product	Product
	α:β	α:β	α:β	α:β
	(yield)	(yield)	(yield)	(yield)
16 Ph O OBn O SPh	23:77 <sup>[a]</sup>	18:82 <sup>[a]</sup>	17:83 <sup>[a]</sup>	19:81 <sup>[a]</sup>
	(51%)	(59%)	(61%)	(55%)
17 Ph O OBn O SPh	73:27	69:31	55:45	32:68
	(71%)	(51%)	(64%)	(64%)
18 NOON OBNO SPh	80:20	72:28	68:32	58:42
	(48%)	(38%)	(50%)	(54%)
19 NOON SPh	>98:2	83:17	73:27	50:50
	(54%)	(59%)	(61%)	(36%)
20 Ph O OBn O SPh	>98:2 <sup>[a]</sup>	>98:2 <sup>[a]</sup>	>98:2 <sup>[a]</sup>	>98:2 <sup>[a]</sup>
	(73%)	(94%)	(72%)	(83%)
>90:10 >80:20	<b>&gt;</b> 60:40 50:50	<40:60	<20:80 <10	:90 (α:β)

[a] Results from Remmerswaal *et al.*,<sup>48</sup> identical glycosylation conditions were used.

# **Conclusions**

To conclude, the role of acceptor acidity on the β-directing effect of the C-3-O-picoloyl protecting group in glucosyl and mannosyl donors was studied. For the 3-O-picoloyl-glucose series, no significant influence of the picoloyl group on the stereoselectivity of the glycosylation reactions was observed, in line with previous studies. Only for acidic, and thus weak nucleophiles, a modest shift in stereoselectivity was observed. The 3-O-picoloylmannose series exhibit a much stronger β-directing effect, with more acidic acceptors providing more β-selective glycosylation reactions. This dichotomy between the glucose and mannose series is reminiscent of the directing effect of the C-3-O-acyl groups, which in the mannose series have a strong effect, while hardly affecting glucosylation reactions. The absence of HAD in the glucose series is likely because the HAD pathway takes place through a more dissociated mechanism. The stereoselectivity in the glucosylation reactions is dictated primarily by the competition of the substitution reactions of the  $\alpha$ - and  $\beta$ -triflates, which are in equilibrium through an in situ anomerisation scheme. The outcome of mannosylation reactions can be rationalized with the equilibrium of the anomeric  $\alpha$ -triflate with oxocarbenium<sup>17,62</sup> or dioxanium ion intermediates.<sup>48</sup> The observed trends in the mannose series are consistent with a scenario in which there is competition between LRP and HAD mechanisms, in which more acidic acceptors show stronger direction by the HAD mechanism.

# **Supporting information**

#### **General Methods**

All chemicals (Acros, Fluka, Merck, and Sigma-Aldrich) were used as received unless stated otherwise. Dichloromethane was stored over activated 4 Å molecular sieves (beads, 8-12 mesh, Sigma-Aldrich). Before use traces of water present in the donor, diphenyl sulfoxide (Ph<sub>2</sub>SO), and tri-tert-butylpyrimidine (TTBP) were removed by co-evaporation with dry toluene. The acceptors were stored in stock solutions (DCM, 0.5 M) over activated 3 Å molecular sieves (rods, size 1/16 in., Sigma-Aldrich). Trifluoromethanesulfonic anhydride (Tf<sub>2</sub>O) was distilled over  $P_2O_5$  and stored at  $-20\,^{\circ}\text{C}$  under a nitrogen atmosphere. Overnight temperature control was achieved by an FT902 Immersion Cooler (Julabo). Column chromatography was performed on silica gel 60 Å (0.04 - 0.063 mm, Screening Devices B.V.). TLC-analysis was conducted on TLC Silica gel 60 (Kieselgel 60 F254, Merck) with UV detection by (254 nm) and by spraying with 20% sulfuric acid in ethanol followed by charring at  $\pm$  150 °C or by spraying with a solution of (NH<sub>4</sub>)<sub>6</sub>Mo<sub>7</sub>O<sub>24</sub>·H<sub>2</sub>O (25 g/l) and (NH<sub>4</sub>)<sub>4</sub>Ce(SO<sub>4</sub>)<sub>4</sub>·2H<sub>2</sub>O (10 g/l) in 10% sulfuric acid in water followed by charring at ± 250 °C. High-resolution mass spectra were recorded on a Thermo Finnigan LTQ Orbitrap mass spectrometer equipped with an electrospray ion source in positive mode (source voltage 3.5 kV, sheath gas flow 10, capillary temperature 275 °C) with resolution R=60.000 at m/z=400 (mass range = 150-4000). <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker AV-300 NMR instrument (300 and 75 MHz respectively), a Bruker AV-400 NMR instrument (400 and 101 MHz respectively), a Bruker AV-500 NMR instrument (500 and 126 MHz respectively), a Bruker AV-600 NMR instrument (600 and 151 MHz respectively), or a Bruker AV-850 NMR instrument (850 and 214 MHz respectively). For samples measured in CDCl<sub>3</sub> chemical shifts ( $\delta$ ) are given in ppm relative to tetramethylsilane as an internal standard or the residual signal of the deuterated solvent. Coupling constants (J) are given in Hz. To get better resolution of signals with small coupling constants or overlapping signals a gaussian window function (LB  $\pm$  -1 and GB  $\pm$  0.5) was used on the <sup>1</sup>H NMR spectrum. All given <sup>13</sup>C APT spectra are proton decoupled. NMR peak assignment was made using COSY, and HSQC. If necessary additional NOESY, HMBC and HMBC-GATED experiments were used to elucidate the structure further. The anomeric product ratios were based on the integration of <sup>1</sup>H NMR.

### General procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations

Donor (0.1 mmol),  $Ph_2SO$  (26 mg, 0.13 mmol, 1.3 equiv) and TTBP (62 mg, 0.25 mmol, 2.5 equiv) were coevaporated twice with dry toluene (4 Å molecular sieves) and dissolved in DCM (2 mL, 0.05 M donor). Activated 3 Å molecular sieves (rods, size 1/16 in.) were added and the reaction mixture stirred for 30 min at room temperature. The solution was cooled to  $-80\,^{\circ}C$  and  $Tf_2O$  (22  $\mu L$ , 0.13 mmol, 1.3 equiv) was slowly added. The reaction mixture was allowed to warm to  $-60\,^{\circ}C$  in approximately 45 min, followed by recooling to  $-80\,^{\circ}C$  and addition of the acceptor (0.2 mmol, 2 equiv) in DCM (0.4 mL, 0.5 M). The reaction mixture was allowed to warm to  $-60\,^{\circ}C$  in approximately 45 min and stirred for an additional 18 h. The reaction was quenched with sat. NaHCO3 solution (1 mL) at  $-60\,^{\circ}C$  and diluted with DCM. The solution was transferred to a separatory funnel and water was added, the layers were separated, and the water phase extracted once more with DCM.

The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated *in vacuo*. Purification by silica gel flash column chromatography yielded the glycosylation product as a mixture of anomers.

#### General computational procedure

To keep the calculation time manageable, the 2-O-Bn and 4,6-O-Benzylidene protection groups were substituted with electronically comparable smaller groups (2-0-Me and 4,6-0-Ethylidene). For each studied donor, conformation libraries of the  $\alpha$ -OTf,  $\beta$ -OTf, oxocarbenium and dioxolenium ion were constructed through the 'conformer distribution search' option included in the Spartan 14 program by utilizing MMFF as the level of theory.<sup>63</sup> For the oxocarbenium and dioxolenium ions additional conformational libraries were constructed in which the conformation of the carbohydrate ring was fixated by constraining the dihedral angles of C1-C2-C3-C4 (D1), C3C4-C5-O (D3) and C5-O-C1-C2 (D5). The dihedral constraints were based on to the lowest energy conformations found in previous conformational energy landscapes of 2-O-Me-3-O-Bz-4,6-O-Ethylidene glucoside and mannoside cations: (D1;D2;D3) = (-30;-60;-15), (30;45;-60), (-45;-60;-15), (30;-60;-15)60;0), (-45;-45;-15), (0;-60;0), (15;45;-60), (-15;-60;15), (15;-60;15), (45;45;-45).48 All generated geometries without with PCM(CH<sub>2</sub>Cl<sub>2</sub>)/M062X/6further optimized constraints 311++G(d,p)//PCM(CH<sub>2</sub>Cl<sub>2</sub>)/B3LYP/6-31+ G(d) at T= 213.15 K using Gaussian 09 rev D.01 employing the superfine integration grid, tight optimization and SCF cycle criteria.<sup>64</sup> The final denoted free Gibbs energy is constructed from the quasi-harmonic  $\Delta G$  from the PCM(CH<sub>2</sub>Cl<sub>2</sub>)/B3LYP/6-31+G(d) calculation at T= 213.15K which is corrected with the  $\Delta E$  of the PCM(CH<sub>2</sub>Cl<sub>2</sub>)/M06-2X/6-311++G(d,p) calculation.<sup>65</sup> The quasi-harmonic  $\Delta G$  correction of Cramer and Truhlar was applied through the GoodVibes python toolkit. 65,66

#### **Supplementary Computational Results**

Supplementary table S1. Experimentally found stereoselectivities for model glycosylation reactions with the phenyl 2-0-benzyl-4,6-benzylidene-3-0-picoloyl-1-thio-mannosyl donor 9; Experimental conditions: preactivation-based glycosylation conditions; nucleophile (2 equiv),  $Tf_2O$  (1.3 equiv),  $Ph_2SO$  (1.3 equiv), base (2.5 equiv or 10 equiv), DCM (0.05 M), -80 to -60 °C. The stereoselectivity of the reaction is expressed as  $\alpha:\beta$  and based on  $^1H$ -NMR of the purified compounds. In all cases, product ratios were based on NMR spectra for the crude compounds.

Acceptor	Base	рК <sub>а</sub> Н	Equiv	Product (α:β)
EtOH	2,4,6-tri- <i>tert</i> -butylpyrimidine	1.02	2.5	73:27
EtOH	2,4,6-tri- <i>tert</i> -butylpyrimidine	1.02	10.0	69:31
EtOH	2,6-di- <i>tert</i> -butylpyrimidine	3.58	2.5	79:21
EtOH	2,4,6-tri- <i>tert</i> -butylpyridine	4.02	2.5	79:21
TFE	2,4,6-tri- <i>tert</i> -butylpyrimidine	1.02	2.5	32:68
TFE	2,4,6-tri- <i>tert</i> -butylpyrimidine	1.02	10.0	31:69
TFE	2,6-di- <i>tert</i> -butylpyrimidine	3.58	2.5	29:71
TFE	2,4,6-tri- <i>tert</i> -butylpyridine	4.02	2.5	35:65

**Supplementary table S2.** Computed triflyl bond dissociation enthalpy (BDE) for triflyl 2,4,6-tri-O-methyl-1-O-mannose and triflyl 4,6-ethylidene-2-O-methyl-1-O-mannose donors, towards either the oxocarbenium or dioxanium ion in kcal mol<sup>-1</sup>. The geometry and energy of all the conformers were computed in solution phase using PCM(CH<sub>2</sub>Cl<sub>2</sub>)/M06-2X/6-311++G(d,p)//PCM(CH<sub>2</sub>Cl<sub>2</sub>)/B3LYP/6-31+G(d) at T= 213.15 K.

Entry	Donor	<b>BDE</b> (Δ <i>H</i> )
1	$R^1 = C_6H_5$ (Bz), $R^2 = Methyl$	19.2
2	$R^1 = p\text{-}C_6H_4N$ (Pico), $R^2 = Methyl$	20.6
3	$R^1 = m$ -C <sub>6</sub> H <sub>4</sub> N (Nico), $R^2 = Methyl$	20.9
4	$R^1 = i-C_6H_4N$ (i-Nico), $R^2 = Methyl$	21.9
5	$R^1 = p\text{-}C_6H_4N$ (Bz), $R^2 =$ Ethylidene	26.6
6	$R^1 = m-C_6H_4N$ (Pico), $R^2 = Ethylidene$	28.7
7	$R^1 = i-C_6H_4N$ (Nico), $R^2 = Ethylidene$	29.3
8	$R^1 = p-C_6H_4N$ ( <i>i</i> -Nico), $R^2 = Ethylidene$	31.1

# **Experimental procedures Donor Synthesis**

Phenyl 2,4,6-tri-O-benzyl-3-O-picoloyl-1-thio-β-p-glucopyranoside (2). Phenyl 2,4,6-tri-O-benzyl-1-thioβ-p-glucopyranoside<sup>12</sup> (0.53 g, 1.0 mmol) was co-evaporated with toluene, dissolved in DCM, molecular sieves (3 Å) were added, and the mixture was stirred for 10 min. To the solution DMAP (0.12 g, 1.0 mmol, 1.0 equiv), EDC·HCl (0.58 g, 3.0 mmol, 3.0 equiv), and Picolinic Acid (0.19 g, 1.5 mmol, 1.5 equiv) were added. The reaction was stirred for 1 h and subsequently diluted with DCM. The mixture was washed with water, sat. aq. NaHCO<sub>3</sub> solution, brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. Flash column chromatography (9:1 to 6:4, pentane:EtOAc) yielded the title compound (0.56 g, 0.88 mmol, 88%) as a white solid. TLC: R<sub>f</sub> 0.20, (80:20, pentane:EtOAc, v:v); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC): δ 8.73 (ddd, J = 4.7, 1.8, 0.9 Hz, 1H, CH<sub>arom</sub> Pico), 8.03 (dt, J = 7.8, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.80 (td, J = 7.7, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.65 - 7.57 (m, 2H,  $CH_{arom}$ , 7.46 (ddd, I = 7.6, 4.8, 1.3 Hz, 1H,  $CH_{arom}$ ), 7.42 – 6.99 (m, 13H,  $CH_{arom}$ ), 5.63 (t, I = 9.3 Hz, 1H, H-3), 4.80 (d, / = 10.8 Hz, 1H, CHH Bn), 4.75 (d, / = 9.6 Hz, 1H, H-1), 4.65 (d, / = 11.8 Hz, 1H, CHH Bn), 4.60 - 4.48 (m, 4H, CHH Bn, CHH Bn, CH<sub>2</sub> Bn), 3.97 (t, J = 9.6 Hz, 1H, H-4), 3.83 (dd, J = 11.0, 2.2 Hz, 1H, H-6), 3.79 (dd, J = 11.1, 3.9 Hz, 1H, H-6), 3.73 (t, J = 9.4 Hz, 1H, H-2), 3.63 (ddd, J = 9.8, 3.8, 2.1 Hz, 1H, H-5);  $^{13}$ C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC): δ 164.5 (C=0 Pico), 149.8 (CH<sub>arom</sub> Pico), 147.9, 138.4, 137.7 (C<sub>q</sub>), 137.0 (CH<sub>arom</sub>), 133.2 (C<sub>q</sub>), 132.6, 129.1, 128.5, 128.3, 128.3, 128.3, 128.1, 127.8, 127.7, 127.7, 125.8 (CH<sub>arom</sub>), 87.2 (C-1), 79.3 (C-3), 79.2 (C-5), 78.5 (C-2), 75.9 (C-4), 75.0 (CH<sub>2</sub> Bn), 74.8 (CH<sub>2</sub> Bn), 73.6 (CH<sub>2</sub> Bn), 68.9 (C-6); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>): δ 87.2 (J<sub>C1,H1</sub> = 155.2 Hz, C-1 β); HRMS: [M+H]<sup>+</sup> calcd for C<sub>39</sub>H<sub>38</sub>NO<sub>6</sub>S 648.2414, found 648.2411.

Phenyl 2,4,6-tri-*O*-benzyl-3-*O*-nicotinoyl-1-thio-β-p-glucopyranoside (3). Phenyl 2,4,6-tri-*O*-benzyl-1thio-B-p-glucopyranoside<sup>12</sup> (0.53 g. 1.0 mmol) was co-evaporated with toluene, dissolved in DCM, molecular sieves (3 Å) were added, and the mixture was stirred for 10 min. To the solution DMAP (0.12 g, 1.0 mmol, 1.0 equiv), EDC·HCl (0.58 g, 3.0 mmol, 3.0 equiv), and Nicotinic Acid (0.19 g, 1.5 mmol, 1.5 equiv) were added. The reaction was stirred for 1 h and subsequently diluted with DCM. The mixture was washed with water, sat. aq. NaHCO3 solution, brine, dried over MgSO4, and concentrated under reduced pressure. Flash column chromatography (9:1 to 6:4, pentane:EtOAc) yielded the title compound (0.45 g, 0.71 mmol, 71%) as a white solid. TLC:  $R_f$  0.22, (80:20, pentane:EtOAc, v:v); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSOC):  $\delta$  8.96 (dd, I = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.75 (dd, *J* = 4.9, 1.7 Hz, 1H, CH<sub>arom</sub> Nico), 8.06 (dt, *J* = 7.9, 2.0 Hz, 1H, CH<sub>arom</sub> Nico), 7.66 -7.56 (m, 2H, CH<sub>arom</sub>), 7.43 - 7.23 (m, 7H, CH<sub>arom</sub>), 7.14 - 6.96 (m, 7H), 5.51 (t, J = 9.3 Hz, 1H, H-3), 4.82 (d, J = 1.00 (d, J = 1.00 (m, 7H), 5.50 (m 11.1 Hz, 1H, CHH Bn), 4.76 (d, / = 9.7 Hz, 1H, H-1), 4.67 (d, / = 11.9 Hz, 1H, CHH Bn), 4.58 (d, / = 12.0 Hz, 1H, CHH Bn), 4.51 (d, J = 11.4 Hz, 1H, CHH Bn), 4.48 (d, J = 11.3 Hz, 1H, 1H3.74 (m, 3H, H-4, H-6, H-6), 3.65 – 3.55 (m, 2H, H-2, H-5);  $^{13}$ C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC):  $\delta$  164.2 (C=0 Nico), 153.5, 150.9 (CH<sub>arom</sub> Nico), 138.2, 137.4 (C<sub>q</sub>), 137.2 (CH<sub>arom</sub> Nico), 133.6 (C<sub>q</sub>), 132.2, 129.2, 128.6, 128.4, 128.3, 128.1, 128.0, 127.9, 127.8 (CH<sub>arom</sub>), 125.9 (C<sub>a</sub>), 123.3 (CH<sub>arom</sub> Nico), 87.7 (C-1), 79.1 (C-5), 78.6 (C-3), 78.2 (C-2), 75.8 (C-4), 74.9 (CH<sub>2</sub> Bn), 74.6 (CH<sub>2</sub> Bn), 73.7 (CH<sub>2</sub> Bn), 68.6 (C-6); HRMS: [M+H]+ calcd for C<sub>39</sub>H<sub>38</sub>NO<sub>6</sub>S 648.2414. found 648.2400.

Phenyl 2,4,6-tri-*O*-benzyl-3-*O*-isonicotinoyl-1-thio-β-**D**-glucopyranoside (4). Phenyl 2,4,6-tri-*O*-benzyl-1thio-B-p-glucopyranoside<sup>12</sup> (0.53 g, 1.0 mmol) was co-evaporated with toluene, dissolved in DCM, molecular sieves (3 Å) were added, and the mixture was stirred for 10 min. To the solution DMAP (0.12 g, 1.0 mmol, 1.0 equiv), EDC·HCl (0.58 g. 3.0 mmol, 3.0 equiv), and iso-Nicotinic Acid (0.19 g. 1.5 mmol, 1.5 equiv) were added. The reaction was stirred for 1 h and subsequently diluted with DCM. The mixture was washed with water, sat. ag. NaHCO3 solution, brine, dried over MgSO4, and concentrated under reduced pressure. Flash column chromatography (9:1 to 6:4, pentane:EtOAc) yielded the title compound (0.50 g, 0.80 mmol, 80%) as a white solid. TLC: R<sub>f</sub> 0.21, (80:20, pentane:EtOAc, v:v); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSOC): δ 8.73 – 8.67 (m, 2H, CH<sub>arom</sub> i-Nico), 7.65 - 7.60 (m, 2H, CH<sub>arom</sub>), 7.60 - 7.55 (m, 2H, CH<sub>arom</sub> i-Nico), 7.43 - 7.23 (m, 6H, CH<sub>arom</sub>), 7.12 - 6.95 (m, 7H, CH<sub>arom</sub>), 5.49 (t, I = 9.3 Hz, 1H, H-3), 4.81 (d, I = 11.2 Hz, 1H, CHH Bn), 4.75 (d, I = 9.7 Hz, 1H, H-1), 4.67 (d, J = 11.9 Hz, 1H, CHH Bn), 4.58 (d, J = 11.9 Hz, 1H, CHH Bn), 4.51 (d, J = 11.3 Hz, 1H, CHH Bn), 4.47 (d, J = 11.1 Hz, 1H, CHH Bn), 4.39 (d, J = 11.2 Hz, 1H, CHH Bn), 3.87 - 3.74 (m, 3H, H-4, H-6, H-6), 3.64 - 3.54 (m, H-6, H-6), 3.64 (m, H-6, H-6),2H, H-2, H-5); <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC): δ 164.1 (C=0 i-Nico), 150.6 (CH<sub>arom</sub> i-Nico), 138.1, 137.4, 137.0, 133.5 (C<sub>q</sub>), 129.2, 128.6, 128.4, 128.4, 128.4, 128.1, 128.0, 128.0, 123.0 (CH<sub>arom</sub>), 87.7 (C-1), 79.1 (C-5), 78.6 (C-2), 78.5 (C-3), 75.7 (C-4), 74.9 (CH<sub>2</sub> Bn), 74.6 (CH<sub>2</sub> Bn), 73.7 (CH<sub>2</sub> Bn), 68.6 (C-6); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>): δ 87.7 (J<sub>C1,H1</sub> = 156.2 Hz, C-1 β); HRMS: [M+H]<sup>+</sup> calcd for C<sub>39</sub>H<sub>38</sub>NO<sub>6</sub>S 648.2414, found 648.2410.

**Phenyl 2,4,6-tri-***O***-benzyl-3-***O***-picoloyl-1-thio-**β**-p-mannopyranoside** (7). Phenyl 2,4,6-tri-*O***-benzyl-1**thio-β-p-mannopyranoside<sup>12</sup> (0.53 g, 1.0 mmol) was co-evaporated with toluene, dissolved in DCM, molecular sieves (3 Å) were added, and the mixture was stirred for 10 min. To the solution DMAP (0.12 g, 1.0 mmol, 1.0 equiv), EDC·HCl (0.58 g, 3.0 mmol, 3.0 equiv), and Picolinic Acid (0.19 g, 1.5 mmol, 1.5 equiv) were added. The reaction was stirred for 1 h and subsequently diluted with DCM. The mixture was washed with water, sat. aq. NaHCO<sub>3</sub> solution, brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. Flash column chromatography (9:1 to 6:4, pentane:EtOAc) yielded the title compound (0.57 g, 0.91 mmol, 91%) as a colorless oil. TLC: Ry 0.19, (80:20, pentane:EtOAc, v.v); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC): δ 8.79 (ddd, J = 4.7, 1.8, 0.9 Hz, 1H, CH<sub>arom</sub> Pico), 7.92 (dt, J = 7.8, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.78 (td, J = 7.7, 1.8 Hz, 1H, CH<sub>arom</sub> Pico), 7.59 – 7.51 (m, 2H, CH<sub>arom</sub>), 7.49 (ddd, J = 7.6, 4.7, 1.3 Hz, 1H, CH<sub>arom</sub> Pico), 7.41 – 7.06 (m, 13H, CH<sub>arom</sub>), 5.28 (dd, J = 9.8, 3.2 Hz, 1H, H-3), 4.97 (d, J = 1.1 Hz, 1H, H-1), 4.86 (d, J = 11.5 Hz, 1H, CHH Bn), 4.80 (d, J = 11.6 Hz, 1H, CHH Bn), 4.76 (d, J = 11.7 Hz, 1H, CHH Bn), 4.91 (dd, J = 3.3, 1.1 Hz, 1H, CHH Bn), 4.91 (d, J = 11.1 Hz, 1H, CHH Bn), 4.91 (dd, J = 3.3, 1.1 Hz, 1H, H-2), 4.24 (t, J = 9.8 Hz, 1H, H-4), 3.87 (dd, J = 11.0, 5.7 Hz, 1H, H-6), 3.65 (ddd, J = 9.7, 5.7, 2.0 Hz, 1H, H-5); <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC): δ 164.5 (C=0 Pico), 150.2 (CH<sub>arom</sub> Pico), 147.6, 138.5, 137.8 (C<sub>a</sub>), 137.0 (CH<sub>arom</sub> Pico), 135.1

 $(C_0)$ , 131.3, 129.1, 128.5, 128.4, 128.4, 128.3, 128.0, 128.0, 127.8, 127.6, 125.4  $(CH_{arom})$ , 87.8 (C-1), 80.1 (C-5), 78.8 (C-3), 78.2 (C-2), 75.8  $(CH_2 Bn)$ , 75.1  $(CH_2 Bn)$ , 73.7  $(CH_2 Bn)$ , 73.2 (C-4), 69.6 (C-6); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  87.8  $(J_{CL,H_1} = 153.5 Hz, C-1 \beta)$ ; HRMS:  $[M+H]^+$  calcd for  $C_{39}H_{38}NO_6S$  648.2414, found 648.2411.

Phenyl 2,4,6-tri-*O*-benzyl-3-*O*-nicotinoyl-1-thio-β-p-mannopyranoside (8). Phenyl 2,4,6-tri-*O*-benzyl-1thio-B-p-mannopyranoside<sup>12</sup> (0.53 g. 1.0 mmol) was co-evaporated with toluene, dissolved in DCM, molecular sieves (3 Å) were added, and the mixture was stirred for 10 min. To the solution DMAP (0.12 g, 1.0 mmol, 1.0 equiv), EDC-HCl (0.58 g, 3.0 mmol, 3.0 equiv), and Nicotinic Acid (0.19 g, 1.5 mmol, 1.5 equiv) were added. The reaction was stirred for 1 h and subsequently diluted with DCM. The mixture was washed with water, sat. aq. NaHCO3 solution, brine, dried over MgSO4, and concentrated under reduced pressure. Flash column chromatography (9:1 to 6:4, pentane:EtOAc) yielded the title compound (0.59 g. 0.93 mmol, 93%) as a colorless oil. TLC: R<sub>f</sub> 0.21, (80:20, pentane:EtOAc, v:v); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSOC): δ 9.12 (dd, *J* = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub>, Nico), 8.81 (dd, J = 4.9, 1.7 Hz, 1H, CH<sub>arom</sub> Nico), 8.15 - 8.09 (m, 1H, CH<sub>arom</sub> Nico), 7.64 - 7.53 (m, 2H, CH<sub>arom</sub>), 7.50 – 7.06 (m, 14H, CH<sub>arom</sub>), 5.25 (dd, / = 9.9, 3.3 Hz, 1H, H-3)), 4.99 (d, / = 1.1 Hz, 1H, H-1), 4.90 (d, J = 11.6 Hz, 1H, CHH Bn), 4.72 (d, J = 11.8 Hz, 1H, CHH Bn), 4.70 (d, J = 11.6 Hz, 1H, CHH Bn), 4.64 (d, J = 2.4 Hz, 1H,  $CH_2$  Bn), 4.62 (d, J = 11.8 Hz, 1H, CHH Bn), 4.41 (dd, J = 3.4, 1.1 Hz, 1H, H-2), 4.23 (t, J = 9.8 Hz, 1H, H-4), 3.94 - 3.82 (m, 2H, H-6, H-6), 3.67 (ddd, / = 9.7, 5.1, 2.5 Hz, 1H, H-5); <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC): δ 164.6 (C=0 Nico), 153.8, 151.1 (CH<sub>arom</sub> Nico), 138.4, 137.7 (C<sub>q</sub>), 137.3 (CH<sub>arom</sub> Nico), 135.0 (C<sub>q</sub>), 131.3, 129.2, 128.5, 128.4, 128.3, 128.1, 127.9, 127.9, 127.7, 127.6, 125.5 (CH<sub>arom</sub>), 123.4 (C<sub>q</sub>), 87.8 (C-1), 80.2 (C-5), 78.6 (C-2), 78.1 (C-3), 76.1 (CH<sub>2</sub> Bn), 75.2 (CH<sub>2</sub> Bn), 73.8 (CH<sub>2</sub> Bn), 73.4 (C-4), 69.5 (C-6); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>): δ 87.8 (/c<sub>1,H1</sub> = 153.9 Hz, C-1 β); HRMS: [M+H]+ calcd for C<sub>39</sub>H<sub>38</sub>NO<sub>6</sub>S 648.2414, found 648.2410.

Phenyl 2,4,6-tri-*O*-benzyl-3-*O*-isonicotinoyl-1-thio-β-p-mannopyranoside (9). Phenyl 2,4,6-tri-*O*-benzyl-1-thio-β-p-mannopyranoside<sup>12</sup> (0.53 g, 1.0 mmol) was co-evaporated with toluene, dissolved in DCM, molecular sieves (3 Å) were added, and the mixture was stirred for 10 min. To the solution DMAP (0.12 g, 1.0 mmol, 1.0 equiv), EDC·HCl (0.58 g, 3.0 mmol, 3.0 equiv), and iso-Nicotinic Acid (0.19 g, 1.5 mmol, 1.5 equiv) were added. The reaction was stirred for 1 h and subsequently diluted with DCM. The mixture was washed with water, sat. aq. NaHCO3 solution, brine, dried over MgSO4, and concentrated under reduced pressure. Flash column chromatography (9:1 to 6:4, pentane:EtOAc) yielded the title compound (0.62 g, 0.98 mmol, 98%) as a colorless oil. TLC: R<sub>f</sub> 0.21, (80:20, pentane: EtOAc, v:v); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC): δ 8.84 – 8.71 (m, 2H, CH<sub>arom</sub> i-Nico), 7.70 – 7.64 (m, 2H, CH<sub>arom</sub> i-Nico), 7.64 – 7.53 (m, 2H, CH<sub>arom</sub>), 7.46 – 7.05 (m, 13H, CH<sub>arom</sub>), 5.24 (dd, / = 9.9, 3.3 Hz, 1H, H-3), 4.99 (d, / = 1.1 Hz, 1H, H-1), 4.92 (d, / = 11.6 Hz, 1H, CHH Bn), 4.74 (d, / = 11.7 Hz, 1H, H-1), 4.92 (d, / = 11.6 Hz, 1H, CHH Bn), 4.74 (d, / = 11.7 Hz, 1H, H-1), 4.92 (d, / = 11.6 Hz, 1H, CHH Bn), 4.74 (d, / = 11.7 Hz, 1H, H-1), 4.92 (d, / = 11.6 Hz, 1H, CHH Bn), 4.74 (d, / = 11.7 Hz, 1H, H-1), 4.92 (d, / = 11.6 Hz, 1H, CHH Bn), 4.74 (d, / = 11.7 Hz, 1H, H-1), 4.92 (d, / = 11.6 Hz, 1H, CHH Bn), 4.74 (d, / = 11.7 Hz, 1H, H-1), 4.92 (d, / = 11.6 Hz, 1H, CHH Bn), 4.74 (d, / = 11.7 Hz, 1H, H-1), 4.92 (d, / = 11.6 Hz, 1H, CHH Bn), 4.74 (d, / = 11.7 Hz, 1H, H-1), 4.92 (d, / = 11.6 Hz, 1H, CHH Bn), 4.74 (d, / = 11.7 Hz, 1H, H-1), 4.92 (d, / = 11.6 Hz, 1H, CHH Bn), 4.74 (d, / = 11.7 Hz, 1H, H-1), 4.92 (d, / = 11.6 Hz, 1H, CHH Bn), 4.74 (d, / = 11.7 Hz, 1H, H-1), 4.92 (d, / = 11.6 Hz, 1H, CHH Bn), 4.74 (d, / = 11.7 Hz, 1H, H-1), 4.92 (d, / = 11.6 Hz, 1H, CHH Bn), 4.74 (d, / = 11.7 Hz, 1H, H-1), 4.92 (d, / = 11.6 Hz, 1H, CHH Bn), 4.74 (d, / = 11.7 Hz, 1H, H-1), 4.92 (d, / = 11.6 Hz, 1H, CHH Bn), 4.74 (d, / = 11.7 Hz, 1H, H-1), 4.92 (d, / = 11.6 Hz, 1H, CHH Bn), 4.74 (d, / = 11.7 Hz, 1H, H-1), 4.92 (d, / = 11.6 Hz, 1H, CHH Bn), 4.74 (d, / = 11.7 Hz, 1H, H-1), 4.92 (d, / = 11.6 Hz, 1H, CHH Bn), 4.74 (d, / = 11.7 Hz, 1H, H-1), 4.92 (d, / = 11.6 Hz, 1H, CHH Bn), 4.74 (d, / = 11.7 Hz, 1H, CHH Bn), 4. Hz, 1H, CHH Bn), 4.68 (d, J = 11.7 Hz, 1H, CHH Bn), 4.63 (s, 2H, CH<sub>2</sub> Bn), 4.62 (d, J = 11.8 Hz, 1H, CHH Bn), 4.40(dd, J = 3.4, 1.1 Hz, 1H, H-2), 4.24 (t, J = 9.8 Hz, 1H, H-4), 3.91 (dd, J = 11.1, 2.8 Hz, 1H, H-6), 3.87 (dd, J = 11.1, 4.8 Hz, 1H, H-6), 3.67 (ddd, I = 9.7, 4.8, 2.7 Hz, 1H, H-5); <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC):  $\delta$  164.4 (C=0 i-Nico), 150.7 (CH<sub>arom</sub> i-Nico), 138.3, 137.6, 136.5, 134.8 (C<sub>q</sub>), 131.2, 129.1, 128.4, 128.4, 128.0, 128.0, 127.8, 127.8, 127.6, 122.8 (CH<sub>arom</sub>), 87.7 (C-1), 80.1 (C-5), 78.6 (C-2), 78.2 (C-3), 76.1 (CH<sub>2</sub> Bn), 75.0 (CH<sub>2</sub> Bn), 73.7 (CH<sub>2</sub> Bn), 73.3 (C-4), 69.3 (C-6);  ${}^{13}$ C-GATED NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  87.7 ( $f_{C1,H1}$  = 153.1 Hz, C-1  $f_{C1}$ ); HRMS: HRMS: [M+H]\* calcd for C<sub>39</sub>H<sub>38</sub>NO<sub>6</sub>S 648.2414, found 648.2411.

Phenyl 2-*O*-benzyl-4,6-*O*-benzylidene-3-*O*-picoloyl-1-thio- $\beta$ -p-glucopyranoside (12). Phenyl 2-*O*-benzyl-4,6-*O*-benzylidene-1-thio- $\beta$ -p-glucopyranoside<sup>48</sup> (0.45 g, 1.0 mmol) was co-evaporated with toluene, dissolved in DCM, molecular sieves (3 Å) were added, and the mixture was stirred for 10 min. To the solution DMAP (0.12 g, 1.0 mmol, 1.0 equiv), EDC-HCl (0.58 g, 3.0 mmol, 3.0 equiv), and Picolinic Acid (0.19 g, 1.5 mmol, 1.5 equiv) were added. The reaction was stirred for 1 h and subsequently diluted with DCM. The mixture was washed with water, sat. aq. NaHCO<sub>3</sub> solution, brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. Flash column chromatography (9:1 to 6:4, pentane:EtOAc) yielded the title compound (0.50 g, 0.90 mmol, 90%) as a white solid. TLC: R<sub>f</sub> 0.50, (65:35, pentane:EtOAc, v:v); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC): δ 8.77 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H, CH<sub>arom</sub> Pico), 8.13 (dt, J = 7.8, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.84 (td, J = 7.8, 1.8 Hz, 1H, CH<sub>arom</sub>

Pico), 7.64 - 7.55 (m, 2H,  $CH_{arom}$ ), 7.52 - 7.48 (m, 2H,  $CH_{arom}$ ), 7.45 - 7.27 (m, 3H), 7.23 - 7.09 (m, 4H), 5.77 (dd, J = 9.9, 8.8 Hz, 1H, 1H-3), 5.51 (s, 1H, CHPh), 4.90 (d, J = 9.7 Hz, 1H, 1H,

Phenyl 2-0-benzyl-4,6-0-benzylidene-3-0-nicotinoyl-1-thio-β-p-glucopyranoside (13). Phenyl 2-0benzyl-4,6-O-benzylidene-1-thio-β-p-glucopyranoside<sup>48</sup> (0.45 g, 1.0 mmol) was co-evaporated with toluene, dissolved in DCM, molecular sieves (3 Å) were added, and the mixture was stirred for 10 min. To the solution DMAP (0.12 g. 1.0 mmol, 1.0 equiv), EDC-HCl (0.58 g. 3.0 mmol, 3.0 equiv), and Nicotinic Acid (0.19 g. 1.5 mmol, 1.5 equiv) were added. The reaction was stirred for 1 h and subsequently diluted with DCM. The mixture was washed with water, sat. aq. NaHCO3 solution, brine, dried over MgSO4, and concentrated under reduced pressure. Flash column chromatography (9:1 to 6:4, pentane:EtOAc) yielded the title compound (0.48 g, 0.87 mmol, 87%) as a white solid. TLC: R<sub>f</sub> 0.50, (65:35, pentane:EtOAc, v:v); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC):  $\delta$  9.10 (dd, J = 2.3, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.76 (dd, J = 4.9, 1.7 Hz, 1H, CH<sub>arom</sub> Nico), 8.20 (dt, J = 7.9, 2.0 Hz, 1H, CH<sub>arom</sub> Nico), 7.62 – 7.52 (m, 2H, CH<sub>arom</sub>), 7.43 – 7.32 (m, 4H, CH<sub>arom</sub>), 7.20 – 7.05 (m, 5H), 5.65 (dd, *I* = 9.8, 8.7 Hz, 1H, H-3), 5.49 (s, 1H, CHPh), 4.90 (d, J = 11.3 Hz, 1H, CHH Bn), 4.90 (d, J = 9.5 Hz, 1H, H-1), 4.59 (d, J = 11.0 Hz, 1H, CH/H Bn), 4.41 (dd, I = 10.5, 4.9 Hz, 1H, H-6), 3.83 (t, I = 10.3 Hz, 1H, H-6), 3.77 (t, I = 9.6 Hz, 1H, H-4), 3.71 (dd, J = 9.7, 8.8 Hz, 1H, H-2), 3.62 (td, J = 9.7, 5.0 Hz, 1H, H-5);  $^{13}$ C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC):  $\delta$  164.2 (Cq), 153.7, 151.0, 137.4 (CH<sub>arom</sub>), 136.8, 133.0 (Cq), 132.5, 129.3, 129.2, 128.5, 128.4, 128.3, 128.3, 128.0, 126.2 (CH<sub>arom</sub>), 125.8 (C<sub>a</sub>), 123.4 (CH<sub>arom</sub>), 101.6 (CHPh), 88.8 (C-1), 79.2 (C-2), 78.6 (C-4), 75.5 (CH<sub>2</sub> Bn), 75.4 (C-3), 70.6 (C-5), 68.8 (C-6); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>): δ 88.8 (/<sub>C1,H1</sub> = 157.6 Hz, C-1 β); HRMS: [M+H]+ calcd for C<sub>32</sub>H<sub>30</sub>NO<sub>6</sub>S 556.1788, found 556.1786.

Phenyl 2-0-benzyl-4,6-0-benzylidene-3-0-isonicotinoyl-1-thio-β-p-glucopyranoside (14). Phenyl 2-0benzyl-4,6-*O*-benzylidene-1-thio-β-p-glucopyranoside<sup>48</sup> (0.45 g, 1.0 mmol) was co-evaporated with toluene, dissolved in DCM, molecular sieves (3 Å) were added, and the mixture was stirred for 10 min. To the solution DMAP (0.12 g, 1.0 mmol, 1.0 equiv), EDC·HCl (0.58 g, 3.0 mmol, 3.0 equiv), and iso-Nicotinic Acid (0.19 g, 1.5 mmol, 1.5 equiv) were added. The reaction was stirred for 1 h and subsequently diluted with DCM. The mixture was washed with water, sat. aq. NaHCO3 solution, brine, dried over MgSO4, and concentrated under reduced pressure. Flash column chromatography (9:1 to 6:4, pentane:EtOAc) yielded the title compound (0.51 g, 0.91 mmol, 91%) as a white solid. TLC:  $R_f$  0.55, (65:35, pentane:EtOAc, v:v); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC: δ 8.80 - 8.74 (m, 1H, CH<sub>arom</sub> i-Nico), 7.79 - 7.73 (m, 1H, CH<sub>arom</sub> i-Nico), 7.66 - 7.56 (m, 1H, CH<sub>arom</sub> i-Nico), 7.42 - 7.36 (m, 4H, CH<sub>arom</sub>), 7.35 - 7.31 (m, 2H, CH<sub>arom</sub>), 7.19 - 7.10 (m, 5H, CH<sub>arom</sub>), 5.66 (dd, J = 9.8, 8.7 Hz, 1H, H-3), 5.52 (s, 1H, CHPh), 4.93 (d, I = 11.0 Hz, 1H, CHH Bn), 4.93 (d, I = 9.7 Hz, 1H, H-1), 4.60 (d, I = 11.0 Hz, 1H, CHH Bn), 4.44 (dd, / = 10.5, 5.0 Hz, 1H, H-6), 3.86 (t, / = 10.3 Hz, 1H, H-6), 3.79 (t, / = 9.6 Hz, 1H, H-4), 3.74 (dd, / = 9.7, 8.8 Hz, 1H, H-2), 3.65 (td, / = 9.7, 5.0 Hz, 1H, H-5); <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC): δ 164.9 (C<sub>q</sub>), 151.4, 150.6 (CH<sub>arom</sub>), 137.1, 136.7, 132.8 (C<sub>q</sub>), 132.4, 129.2, 129.1, 128.4, 128.2, 128.2, 128.2, 128.0, 126.1, 123.9 (CH<sub>arom</sub>), 99.7 (CHPh), 88.1 (C-1), 80.2 (C-2), 78.4 (C-4), 75.7 (C-3), 75.4 (CH<sub>2</sub> Bn), 71.6 (C-5), 68.2 (C-6); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  88.1 ( $f_{C1,H1}$  = 157.9 Hz, C-1  $\beta$ ); HRMS: [M+H]+ calcd for C<sub>32</sub>H<sub>30</sub>NO<sub>6</sub>S 556.1788, found 556.1785.

Phenyl **2-0-benzyl-4,6-0-benzylidene-3-0-picoloyl-1-thio-β-p-mannopyranoside** (**17**). Phenyl 2-0-benzyl-4,6-0-benzylidene-1-thio-β-p-mannopyranoside<sup>48</sup> (0.45 g, 1.0 mmol) was co-evaporated with toluene, dissolved in DCM, molecular sieves (3 Å) were added, and the mixture was stirred for 10 min. To the solution DMAP (0.12 g, 1.0 mmol, 1.0 equiv), EDC-HCl (0.58 g, 3.0 mmol, 3.0 equiv), and Picolinic Acid (0.19 g, 1.5 mmol, 1.5 equiv) were added. The reaction was stirred for 1 h and subsequently diluted with DCM. The mixture was

washed with water, sat. aq. NaHCO<sub>3</sub> solution, brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. Flash column chromatography (9:1 to 6:4, pentane:EtOAc) yielded the title compound (0.49 g, 0.88 mmol, 88%) as a white foam. TLC:  $R_f$  0.51, (65:35, pentane:EtOAc, v:v); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC): δ 9.19 (dd, J = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Pico), 8.79 (dd, J = 4.9, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 8.22 (dt, J = 8.0, 2.0 Hz, 1H, CH<sub>arom</sub> Pico), 7.66 – 7.03 (m, 16H, CH<sub>arom</sub>), 5.62 (s, 1H, CHPh), 5.32 (dd, J = 10.4, 3.3 Hz, 1H, H-3), 5.07 (d, J = 1.3 Hz, 1H, H-1), 4.87 (d, J = 11.3 Hz, 1H, CHH Bn), 4.71 (d, J = 11.2 Hz, 1H, CHH Bn), 4.52 (dd, J = 3.4, 1.3 Hz, 1H, H-2), 4.41 (dd, J = 10.4, 9.3 Hz, 1H, H-4), 4.37 (dd, J = 10.5, 4.9 Hz, 1H, H-6), 3.99 (t, J = 10.3 Hz, 1H, H-6), 3.60 (td, J = 9.8, 4.9 Hz, 1H, H-5); <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC): δ 164.9 (C=0 Pico), 153.9, 151.2, 137.4 (CH<sub>arom</sub> Pico), 137.3, 137.1, 134.3 (Cq), 131.8, 129.3, 129.2, 128.5, 128.4, 128.4, 128.1, 128.0, 126.2 (CH<sub>arom</sub>), 125.5 (Cq), 123.5 (CH<sub>arom</sub>), 101.9 (CHPh), 89.2 (C-1), 78.9 (C-2), 76.8 (CH<sub>2</sub> Bn), 75.6 (C-4), 74.7 (C-3), 71.9 (C-5), 68.6 (C-6); HRMS: [M+H]<sup>+</sup> calcd for C<sub>32</sub>H<sub>30</sub>NO<sub>6</sub>S 556.1788, found 556.1785.

Phenyl 2-0-benzyl-4,6-0-benzylidene-3-0-nicotinoyl-1-thio-β-p-glucopyranoside (18). Phenyl 2-0benzyl-4,6-O-benzylidene-1-thio-β-p-mannopyranoside<sup>48</sup> (0.45 g, 1.0 mmol) was co-evaporated with toluene, dissolved in DCM, molecular sieves (3 Å) were added, and the mixture was stirred for 10 min. To the solution DMAP (0.12, 1.0 mmol, 1.0 equiv), EDC·HCl (0.58, 3.0 mmol, 3.0 equiv), and Nicotinic Acid (0.19, 1.5 mmol, 1.5 equiv) were added. The reaction was stirred for 1 h and subsequently diluted with DCM. The mixture was washed with water, sat. aq. NaHCO3 solution, brine, dried over MgSO4, and concentrated under reduced pressure. Flash column chromatography (9:1 to 6:4, pentane:EtOAc) yielded the title compound (0.51 g, 0.91 mmol, 91%) as a white foam. TLC: R<sub>f</sub> 0.53, (65:35, pentane:EtOAc, v:v); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC):  $\delta$  9.20 (dd, J = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.79 (dd, J = 4.8, 1.7 Hz, 1H, CH<sub>arom</sub> Nico), 8.22 (dt, J = 8.0, 2.0 Hz, 1H, CH<sub>arom</sub> Nico), 7.58 - 7.12 (m, 16H, CH<sub>arom</sub>), 5.62 (s, 1H, CHPh), 5.32 (dd, / = 10.4, 3.3 Hz, 1H, H-3), 5.07 (d, I = 1.2 Hz, 1H, H-1), 4.87 (d. I = 11.2 Hz, 1H, CHH Bn), 4.71 (d. I = 11.3 Hz, 1H, CHH Bn), 4.52 (dd. I = 3.4, 1.3 Hz, 1H, H-2), 4.46 - 4.38 (dd, J = 10.6, 9.4 Hz, 1H, H-4), 4.37 (dd, J = 10.8, 5.2 Hz, 1H, H-6), 3.99 (t, J = 10.3 Hz, 1H, H-4), 4.37 (dd, J = 10.8, 5.2 Hz, 1H, H-6), 3.99 (t, J = 10.3 Hz, 1H, H-4), 4.37 (dd, J = 10.8, 5.2 Hz, 1H, H-6), 3.99 (t, J = 10.3 Hz, 1H, H-4), 4.37 (dd, J = 10.8, 5.2 Hz, 1H, H-6), 3.99 (t, J = 10.3 Hz, 1H, H-4), 4.37 (dd, J = 10.8, 5.2 Hz, 1H, H-6), 3.99 (t, J = 10.3 Hz, 1H, H-4), 4.37 (dd, J = 10.8, 5.2 Hz, 1H, H-6), 3.99 (t, J = 10.3 Hz, 1H, H-4), 4.37 (dd, J = 10.8, 5.2 Hz, 1H, H-6), 3.99 (t, J = 10.3 Hz, 1H, H-6), 3.99 (t, J = 10.36), 3.60 (td, I = 9.9, 4.9 Hz, 1H, H-5);  ${}^{13}$ C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSOC);  $\delta$  164.9 (C<sub>0</sub>), 153.9, 151.3, 137.4 (CH<sub>arom</sub>), 137.1, 134.3 (Cq), 131.8, 129.3, 128.5, 128.4, 128.1, 126.2 (CH<sub>arom</sub>), 125.5 (Cq), 123.5 (CH<sub>arom</sub>), 101.4 (CHPh), 88.5 (C-1), 78.9 (C-2), 76.8 (CH<sub>2</sub> Bn), 75.6 (C-4), 74.8 (C-3), 71.9 (C-5), 69.0 (C-6); HRMS: [M+H]+ calcd for C<sub>32</sub>H<sub>30</sub>NO<sub>6</sub>S 556.1788, found 556.1788.

Phenyl 2-0-benzyl-4,6-0-benzylidene-3-0-isonicotinoyl-1-thio-β-p-glucopyranoside (19). Phenyl 2-0benzyl-4,6-O-benzylidene-1-thio-β-p-mannopyranoside<sup>48</sup> (0.45 g, 1.0 mmol) was co-evaporated with toluene, dissolved in DCM, molecular sieves (3 Å) were added, and the mixture was stirred for 10 min. To the solution DMAP (0.12 g, 1.0 mmol, 1.0 equiv), EDC·HCl (0.58 g, 3.0 mmol, 3.0 equiv), and iso-Nicotinic Acid (0.19 g, 1.5 mmol, 1.5 equiv) were added. The reaction was stirred for 1 h and subsequently diluted with DCM. The mixture was washed with water, sat. aq. NaHCO3 solution, brine, dried over MgSO4, and concentrated under reduced pressure. Flash column chromatography (9:1 to 6:4, pentane:EtOAc) yielded the title compound (0.53 g, 0.95 mmol, 95%) as a white foam. TLC: Rf 0.54, (65:35, pentane:EtOAc, v:v); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC): 88.81 - 8.71 (m, 1H, CH<sub>arom</sub> i-Nico), 7.84 - 7.75 (m, 1H, CH<sub>arom</sub> i-Nico), 7.58 - 7.47 (m, 1H, CH<sub>arom</sub> i-Nico), 7.46 - 7.13 (m, 11H, CH<sub>arom</sub>), 5.61 (s, 1H, CHPh), 5.32 (dd, J = 10.3, 3.4 Hz, 1H, H-3), 5.06 (d, J = 1.2 Hz, 1H, H-1), 4.89 (d, J = 11.3 Hz, 1H, CHH Bn), 4.69 (d, J = 11.3 Hz, 1H, CHH Bn), 4.50 (dd, J = 3.4, 1.2 Hz, 1H, H-2), 4.40 (dd, J = 10.5, 9.3 Hz, 1H, 1H-4, 4.37 (dd, / = 10.9, 4.6 Hz, 1H, 1H-6), 3.99 (t, / = 10.3 Hz, 1H, 1H-6), 3.60 (td, / = 9.9, 4.9 Hz, 1H, 1H-6), 3.99 (t, / = 10.3 Hz, 1H, 1H-6), 3.60 (td, / = 9.9, 4.9 Hz, 1Hz, 1Hz)1H, H-5); <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC): δ 164.8 (C<sub>q</sub>), 150.8 (CH<sub>arom</sub>), 137.1, 136.6, 134.2 (C<sub>q</sub>), 129.3, 128.5, 128.4, 128.3, 128.2, 128.1, 126.2, 123.1 (CH<sub>arom</sub>), 101.9 (CHPh), 89.2 (C-1), 78.9 (C-2), 76.9 (CH<sub>2</sub> Bn), 75.6 (C-4), 75.0 (C-3), 71.9 (C-5), 68.6 (C-6);  $^{13}$ C-GATED NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  89.2 ( $f_{CI,H1}$  = 154.5 Hz, C-1  $\beta$ ); HRMS: [M+H]+ calcd for C<sub>32</sub>H<sub>30</sub>NO<sub>6</sub>S 556.1788, found 556.1790.

#### **Model Glycosylation Reactions**

Ethyl 2-0-benzyl-4,6-0-benzylidene-3-picoloyl-p-mannopyranoside (S1). The title compound was prepared from donor 17 and ethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0  $\rightarrow$  60:40, pentane:EtOAc, v:v) yielded glycosylation product **S1** (34.9 mg, 0.071 mmol, 71%,  $\alpha:\beta = 73:27$ ), TLC:  $R_f = 0.65$ , (70:30, pentane: EtOAc, v:v): Data for the  $\alpha$ -anomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.80 (td, *J* = 1.8, 0.9 Hz, 1H, CH<sub>arom</sub> Pico), 8.09 (dt, *J* = 7.8, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.81 (td, J = 7.8, 1.8 Hz, 1H, CH<sub>arom</sub> Pico), 7.57 - 6.96 (m, 11H, CH<sub>arom</sub>), 5.66 (dd, J = 10.4, 3.5 Hz, 1H, H-3), 5.62 (s, 1H, CHPh), 4.95 (d, J = 12.3 Hz, 1H, CHH Bn), 4.88 (d, J = 1.6 Hz, 1H, H-1), 4.72 (d, J = 12.4 Hz, 1H, CHH Bn), 4.42 (dd, J = 10.3, 9.2 Hz, 1H, H-4), 4.29 (dd, J = 10.0, 4.5 Hz, 1H, H-6), 4.08 (dd, J = 3.5, 1.6 Hz, 1H, H-6) 2), 4.04 - 3.96 (m, 1H, H-5), 3.91 (t, I = 10.2 Hz, 1H, H-6), 3.85 - 3.70 (m, 1H, CHHCH<sub>3</sub> Et), 3.68 - 3.43 (m, 1H, CHHCH<sub>3</sub> Et), 1.24 (t, I = 7.1 Hz, 3H, CH<sub>3</sub> Et); 13C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSOC, HMBC): δ 164.4 (C=O Pico) 150.1 (CH<sub>arom</sub> Pico), 148.0, 137.7, 137.5 (C<sub>q</sub>), 137.0, 131.2, 129.5, 129.0, 128.7, 128.4, 128.3, 128.2, 128.0, 127.0, 126.3, 125.6 (CH<sub>arom</sub>), 101.8 (CHPh), 98.9 (C-1), 76.5 (C-2), 76.4 (C-4), 73.8 (CH<sub>2</sub> Bn), 72.2 (C-3), 69.0 (C-6), 64.1 (C-5), 63.6 ( $CH_2CH_3$  Et), 15.1 ( $CH_3$  Et);  $^{13}C$ -GATED NMR (101 MHz,  $CDCl_3$ ):  $\delta$  98.9 ( $J_{C1,H1}$  = 169.7 Hz, C-1  $\alpha$ ); Diagnostic peaks β-anomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSOC, HMBC): δ 8.80 (td, J = 1.8, 0.9 Hz, 1H, CH<sub>arom</sub> Pico), 8.01 (dt, / = 7.9, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 5.25 (dd, / = 10.4, 3.3 Hz, 1H, H-3), 4.22 (dd, / = 3.4, 0.9 Hz, 1H, H-2), 4.07 - 4.01 (m, 1H CHHCH3 Et), 3.68 - 3.57 (m, 1H, CHHCH3 Et); 13C-APT NMR (101 MHz, CDCl3, HSQC, HMBC): δ 101.8 (CHPH), 101.8 (C-1), 75.8 (C-2), 75.7 (C-4), 73.7 (CH<sub>2</sub> Bn), 68.8 (C-6), 66.0 (CH<sub>2</sub>CH<sub>3</sub> Et); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>): δ 101.8 (J<sub>C1,H1</sub> = 155.7 Hz, C-1 β); HRMS: [M+H]<sup>+</sup> calcd for C<sub>28</sub>H<sub>30</sub>NO<sub>7</sub> 492.2017, found 492.2016.

2-Fluoroethyl 2-0-benzyl-4,6-0-benzylidene-3-picoloyl-p-mannopyranoside (S2). The title compound was prepared from donor 17 and 2-fluoroethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0  $\rightarrow$  60:40, pentane:EtOAc, v:v) yielded glycosylation product **S2** (26.1 mg, 0.051 mmol, 51%,  $\alpha$ :β = 69:31). TLC:  $R_f$  0.56, (70:30, pentane: EtOAc, v:v); Data for the  $\alpha$ anomer: 1H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): 8 8.80 (dd, / = 1.8, 0.9 Hz, 1H, CH<sub>arom</sub> Pico), 8.09 (dt, J = 7.8, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.81 (td, J = 7.8, 1.8 Hz, 1H, CH<sub>arom</sub> Pico), 7.54 – 6.98 (m, 11H, CH<sub>arom</sub>), 5.69 (dd, / = 10.4, 3.5 Hz, 1H, H-3), 5.65 (s, 1H, CHPh), 4.97 (d, / = 1.6 Hz, 1H, H-1), 4.74 - 4.69 (m, 2H, CHH Bn, CHH Bn), 4.68 - 4.52 (m, 1H, CH<sub>2</sub>F), 4.44 (dd, J = 10.4, 9.3 Hz, 1H, H-4), 4.30 - 4.26 (m, 1H, CHHCH<sub>2</sub>F), 4.15 (dd, J = 3.5, 1.6 Hz, 1H, H-2), 4.10 - 3.95 (m, 1H, H-5), 3.94 - 3.86 (m, 2H, CHHCH<sub>2</sub>F, H-6), 3.86 - 3.68 (m, 1H, H-6);  $^{13}$ C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.4 (C=O Pico), 150.1 (CH<sub>arom</sub> Pico), 147.9, 137.6, 137.4 (C<sub>q</sub>), 137.0, 129.1, 128.8, 128.5, 128.3, 128.2, 128.0, 127.0, 126.3, 126.3, 125.7, 125.6 (CH<sub>arom</sub>), 101.9 (CHPh), 99.4 (C-1), 82.6 (d, J = 170.3 Hz,  $CH_2F$ ), 76.3 (C-2), 76.1 (C-4), 73.9 ( $CH_2B_1$ ), 71.9 (C-3), 68.9 (C-6), 67.0 (d,  $I = 20.0 \text{ Hz } CH_2CH_2F$ ), 64.3 (C-5);  $^{13}$ C-GATED NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  99.3 ( $f_{CLH1}$  = 170.4 Hz, C-1  $\alpha$ ); Diagnostic peaks  $\beta$ -anomer:  $^{1}$ H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.01 (dt, J = 7.9, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 5.71 (dd, J = 10.5, 3.5 Hz, 1H, H-3), 5.61 (s, 1H, CHPh), 4.80 (d, J = 1.0 Hz, 1H, H-1), 4.13 (dd, J = 3.3, 1.7 Hz, 1H, H-2); 13C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 136.9 (CH<sub>arom</sub> Pico), 101.9 (CHPh), 101.8 (C-1), 82.8 (d, J = 170.3 Hz, CH<sub>2</sub>F), 76.4 (C-2), 76.3 (C-4), 69.2 (d, J = 20.1 Hz,  $CH_2CH_2F$ ); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  101.8 ( $J_{C1,H1} = 156.9$ Hz, C-1 β). HRMS: [M+H]<sup>+</sup> calcd for C<sub>28</sub>H<sub>29</sub>FNO<sub>7</sub> 510.1923, found 510.1923.

**2,2-Difluoroethyl 2-***O***-benzyl-4,6-***O***-benzylidene-3-picoloyl-p-mannopyranoside (S3). The title compound was prepared from donor <b>17** and 2,2-difluoroethanol using the general procedure for Tf<sub>2</sub>*O*/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0  $\rightarrow$  60:40, pentane:EtOAc, v:v) yielded glycosylation product **S3** (33.7 mg, 0.064 mmol, 64%,  $\alpha$ :  $\alpha$  = 55:45). TLC:  $\alpha$  = 70.61, (70:30, pentane:EtOAc, v:v); Data for the  $\alpha$ -anomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC):  $\alpha$  8.80 (dd,  $\alpha$  = 1.8, 0.9 Hz, 1H, CH<sub>arom</sub> Pico), 8.08 (dt,  $\alpha$  = 2.1, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 8.02 (dt,  $\alpha$  = 7.7, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.82 (dd,  $\alpha$  = 7.7, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.54 - 6.98 (m, 10H, CH<sub>arom</sub>), 5.93 (tt,  $\alpha$  = 53.4, 4.2 Hz, 1H, CHF<sub>2</sub>), 5.71 (dd,  $\alpha$  = 10.4, 3.4 Hz, 1H, H-3), 5.61 (s, 1H, CHPh), 5.03 (d,  $\alpha$  = 1.1.4 Hz, 1H, CHH Bn), fff 4.91 (d,  $\alpha$  = 11.2 Hz, 1H, CHH Bn), 4.45 (dd,  $\alpha$  = 10.5,

9.2 Hz, 1H, H-4), 4.40 – 4.23 (m, 1H, H-5), 4.13 (dd, J = 3.4, 1.7 Hz, 1H, H-2), 3.98 (t, J = 10.4 Hz, 1H, H-6), 3.94 – 3.68 (m, 1H, H-6,  $CH_2$ CHF2);  $^{13}$ C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC):  $\delta$  164.4 (C=0 Pico), 150.1 (CH<sub>arom</sub> Pico), 147.8, 147.5, 137.7 (C<sub>q</sub>), 137.0, 129.1, 128.8, 128.8, 128.6, 128.5, 128.4, 128.3, 128.2, 127.8, 127.2, 126.3 (CH<sub>arom</sub>), 114.0 (t, J = 240.9 Hz, CHF2), 101.9 (CHPh), 99.7 (C-1), 76.4 (C-2), 76.3 (CH<sub>2</sub> Bn), 76.0 (C-4), 71.8 (C-3), 68.5 (C-6), 67.9 (C-5), 66.8 (t, J = 32.3 Hz,  $CH_2$ CHF2);  $^{13}$ C-GATED NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  99.7 (JC<sub>1,H1</sub> = 171.7 Hz, C-1 JC af MHz, CDCl<sub>3</sub>, HSQC, HMBC):  $\delta$  102.0 (CHPh), 101.9 (C-1), 74.4 (C-3),  $^{13}$ C-GATED NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  101.9 (JC<sub>1,H1</sub> = 157.6 Hz, C-1 JC); HRMS: [M+H]+ calcd for JC<sub>2</sub>H<sub>2</sub>gF<sub>2</sub>NO<sub>7</sub> 528.1828, found 528.1829.

2,2,2-Trifluoroethyl 2-0-benzyl-4,6-0-benzylidene-3-picoloyl-p-mannopyranoside (S4). The title compound was prepared from donor 17 and 2,2,2-trifluoroethanol using the general procedure for Tf20/Ph2SO mediated glycosylations. Flash column chromatography (100:0 → 60:40, pentane:EtOAc, v:v) yielded glycosylation product **S4** (34.7 mg, 0.064 mmol, 64%,  $\alpha:\beta = 32:68$ ). TLC: R<sub>f</sub> 0.69, (70:30, pentane:EtOAc, v:v); Data for the β-anomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.83 – 8.72 (m, 1H, CH<sub>arom</sub> Pico). 8.17 - 6.89 (m, 13H, CH<sub>arom</sub>), 5.61 (s, 1H, CHPh), 5.26 (dd, J = 10.4, 3.4 Hz, 1H, H-3), 4.93 (d, J = 12.3 Hz, 1H, CHH Bn), 4.85 (d, I = 1.0 Hz, 1H, H-1), 4.68 (d, I = 12.0 Hz, 1H, CHH Bn), 4.42 (t, I = 10.1 Hz, 1H, 1.1 Hz, 1H, H-2), 4.00 (q, I = 9.4 Hz, 2H,  $CH_2CF_3$ ), 3.94 – 3.58 (m, 2H, H-6), 3.54 (td, I = 9.7, 4.7 Hz, 1H, H-5);  $^{13}C_7$ APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 153.2 (C=O Pico), 150.2 (CH<sub>arom</sub>), 147.5, 137.5 (C<sub>q</sub>), 137.0, 132.5, 129.3, 129.2, 128.8, 128.4, 128.3, 128.3, 127.9, 127.2, 126.3, 125.7, 123.1 (CH<sub>arom</sub>), 101.9 (CHPh), 101.8 (C-1), 75.5 (CH<sub>2</sub> Bn), 75.5 (C-2), 74.9 (C-4), 73.3 (C-3), 68.5 (C-6), 68.0 (C-5), 66.4 (q, J = 30.3 Hz, CH<sub>2</sub>CF<sub>3</sub>); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>): δ 101.8 (/<sub>C1.H1</sub> = 158.3 Hz, C-1 β); Diagnostic peaks α-anomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC):  $\delta$  5.63 (dd, J = 9.2, 4.4 Hz, 1H, H-3), 5.49 (s, 1H, CHPh), 4.95 (d, J = 0.9 Hz, 1H, H-1), 4.18 (dd, J = 4.4, 1.0 Hz, 1H, H-2); <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC):  $\delta$  101.2 (CHPh), 99.4 (C-1), 75.8 (C-3), 75.4 (C-2), 70.5 (C-5);  ${}^{13}\text{C-GATED NMR}$  (101 MHz, CDCl<sub>3</sub>):  $\delta$  99.4 ( $J_{\text{C1,H1}}$  = 170.1 Hz, C-1  $\alpha$ ); HRMS: [M+H]+ calcd for C<sub>28</sub>H<sub>27</sub>F<sub>3</sub>NO<sub>7</sub> 546.1734, found 546.1732.

Ethyl 2-O-benzyl-4,6-O-benzylidene-3-nicotinoyl-p-mannopyranoside (S5). The title compound was prepared from donor 18 and ethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0  $\rightarrow$  60:40, pentane:EtOAc, v:v) yielded glycosylation product **S5** (23.4 mg, 0.048 mmol, 48%,  $\alpha$ :β = 80:20). TLC: R<sub>f</sub> 0,64, (70:30, pentane:EtOAc, v:v); Data for the  $\alpha$ -anomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 7.86 – 7.77 (m, 2H, CH<sub>arom</sub> Nico), 7.69 – 7.61 (m, 2H, CH<sub>arom</sub> Nico), 7.55 - 7.34 (m, 10H, CH<sub>arom</sub>), 5.59 (s, 1H, CHPh), 5.12 (d, *J* = 12.1 Hz, 1H, CHH Bn), 4.98 (d, *J* = 12.0 Hz, 1H, CHH Bn), 4.40 (d. J = 7.7 Hz, 1H, H-1), 4.35 (dd, J = 10.5, 4.9 Hz, 1H, H-6), 3.96 (dq, J = 9.7, 7.1 Hz, 1H,  $CHHCH_3$  Et), 3.85 - 1.003.78 (m, 2H, H-4, H-6), 3.78 - 3.64 (m, 1H, H-3), 3.71 - 3.60 (m, 1H, CHHCH3 Et), 3.63 - 3.54 (m, 1H, H-2), 3.50 - 3.41 (m, 1H, H-5), 1.35 - 1.11 (m, 3H, CH<sub>3</sub> Et); <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSOC, HMBC); δ 161.1 (C=0 Nico), 137.4, 135.9 (Cq), 131.2, 129.5, 129.2, 128.4, 128.1, 127.8, 127.0, 126.2, 126.1, 124.9 (CH<sub>arom</sub>), 103.2 (C-1), 101.5 (CHPh), 81.5 (C-3), 80.2 (C-4), 74.7 (CH<sub>2</sub> Bn), 74.6 (C-2), 68.9 (C-6), 66.6 (C-5), 66.0 (CH<sub>2</sub>CH<sub>3</sub> Et), 15.3 (CH<sub>3</sub> Et);  $^{13}$ C-GATED NMR (101 MHz, CDCl<sub>3</sub>): δ 103.2 ( $f_{C1,H1}$  = 169.9 Hz, C-1  $\alpha$ ); Diagnostic peaks  $\beta$ -anomer:  $^{1}$ H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSOC, HMBC): δ 7.75 – 7.70 (m, 2H, CH<sub>arom</sub> Nico), 5.12 (d, *I* = 12.0 Hz, 1H, CH<sub>2</sub> Bn), 4.99 (d, J = 11.9 Hz, 1H, CH<sub>2</sub> Bn), 4.93 (d, J = 4.0 Hz, 1H, H-1), 4.29 (dd, J = 10.1, 4.7 Hz, 1H, H-6).; <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 98.8 (C-1), 82.0 (C-3), 79.3 (C-4), 74.9 (CH<sub>2</sub> Bn), 64.0 (CH<sub>2</sub>CH<sub>3</sub> Et), 15.2 (CH<sub>3</sub> Et); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>): δ 98.8 ( $f_{C1,H1}$  = 159.9 Hz, C-1 β); HRMS: [M+H]+ calcd for C<sub>28</sub>H<sub>30</sub>NO<sub>7</sub> 492.2017, found 492.2012.

**2-Fluoroethyl 2-***0***-benzyl-4,6-***0***-benzylidene-3-nicotinoyl-n-mannopyranoside (S6)**. The title compound was prepared from donor **18** and 2-fluoroethanol using the general procedure for Tf<sub>2</sub>0/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0  $\rightarrow$  60:40, pentane:EtOAc, v:v) yielded glycosylation product **S6** (19.3 mg, 0.038 mmol, 38%, α:β = 72:28). TLC: R<sub>f</sub> 0.57, (70:30, pentane:EtOAc, v:v); Data for the α-anomer: ¹H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 9.20 (ddd, J = 7.5, 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.79 (dt, J = 4.8, 1.6 Hz, 1H, CH<sub>arom</sub> Nico), 8.25 (dt, J = 7.9, 1.9 Hz, 1H, CH<sub>arom</sub> Nico), 7.68 = 7.63 (m, 1H, CH<sub>arom</sub> Nico)

Nico), 7.49 - 7.04 (m, 10H,  $CH_{arom}$ ), 5.63 (s, 1H, CHPh), 5.57 (dd, J = 10.4, 3.5 Hz, 1H, H - 3), 4.96 (d, J = 1.7 Hz, 1H, H - 1), 4.94 (d, J = 12.1 Hz, 1H, CHH Bn), 4.87 (d, J = 11.6 Hz, 1H, CHH Bn), 4.75 - 4.48 (m, 2H,  $CH_2CH_2P$ ), 4.35 (dd, J = 10.6, 9.2 Hz, 1H, H - 4), 4.32 - 4.25 (m, 1H, H - 6), 4.16 (dd, J = 3.5, 1.6 Hz, 1H, H - 2), 4.05 - 3.68 (m, 2H, 1H, 1H,

2,2-Difluoroethyl 2-0-benzyl-4,6-0-benzylidene-3-nicotinoyl-p-mannopyranoside (S7). The title compound was prepared from donor 18 and 2,2-difluoroethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0 → 60:40, pentane:EtOAc, v:v) yielded glycosylation product **S7** (26.4 mg, 0.050 mmol, 50%,  $\alpha$ :  $\beta$  = 68:32). TLC:  $R_f$  0.62, (70:30, pentane:EtOAc, v:v); Data for the α-anomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 9.21 (dd, *J* = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.80 - 8.75 (m, 1H, CH<sub>arom</sub> Nico), 8.25 (dt, / = 8.0, 1.9 Hz, 1H, CH<sub>arom</sub> Nico), 7.48 - 7.05 (m, 11H, CH<sub>arom</sub>), 5.93 (dd, I = 55.3, 4.7, 3.6 Hz, 2H, CH<sub>2</sub>CHF<sub>2</sub>), 5.63 (s, 1H, CHPh), 5.52 (dd, I = 10.5, 3.5 Hz, 1H, H-3), 4.93 (d, I = 10.5, 31.7 Hz, 1H, H-1), 4.67 (d, / = 12.0 Hz, 1H, CHH Bn), 4.57 (d, / = 12.0 Hz, 1H, CHH Bn), 4.36 (dd, / = 10.5, 9.0 Hz, 1H, H-4), 4.32 - 4.27 (m, 2H, H-5, H-6), 4.16 (dd, J = 3.5, 1.7 Hz, 1H, H-2), 4.07 - 3.90 (m, 1H, H-6), 3.91 - 3.80 (m, 1H, CHHCHF<sub>2</sub>), 3.79 – 3.67 (m, 1H, CHHCHF<sub>2</sub>); <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.6 (C=0 Nico), 153.7, 151.2, 137.4 (CH<sub>arom</sub>), 137.1 (C<sub>q</sub>), 129.2, 128.6, 128.4, 128.3, 128.2, 126.2 (CH<sub>arom</sub>), 125.8 (C<sub>q</sub>), 123.4 (CH<sub>arom</sub>), 114.0 (t, *I* = 241.6 Hz, CH<sub>2</sub>CHF<sub>2</sub>), 102.0 (CHPh), 99.4 (C-1), 76.0 (C-2), 75.9 (C-4), 74.0 (CH<sub>2</sub>Bn), 71.3 (C-3), 68.7 (C-6), 66.9 (t, I = 28.5 Hz,  $CH_2CHF_2$ ), 64.6 (C-5);  $^{13}C$ -GATED NMR (101 MHz,  $CDCl_3$ ):  $\delta$  99.4 ( $I_{CLH1}$ = 171.2 Hz, C-1 α); Diagnostic peaks β-anomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 9.14 (dd,  $J = 2.2, 0.9 \text{ Hz}, 1\text{H}, \text{CH}_{arom} \text{ Nico}), 8.17 \text{ (dt, } J = 7.9, 2.0 \text{ Hz}, 1\text{H}, \text{CH}_{arom} \text{ Nico}), 5.16 \text{ (dd, } J = 10.4, 3.3 \text{ Hz}, 1\text{H}, \text{H}-3), 4.79 \text{ (dt, } J = 1.04, 3.3 \text{ Hz}, 1.04, 3.3 \text{ Hz}, 1.04, 3.04)$ (d, J = 1.0 Hz, 1H, H-1), 3.53 (td, J = 9.7, 4.9 Hz, 1H, CHHCHF<sub>2</sub>); <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 102.1 (C-1), 101.9 (CHPh), 75.6 (CH<sub>2</sub> Bn), 75.6 (C-2), 75.4 (C-4), 73.0 (C-3), 68.5 (C-6), 67.8 (C-5); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>): δ 102.1 (I<sub>C1.H1</sub> = 157.9 Hz, C-1 β); HRMS: [M+H]<sup>+</sup> calcd for C<sub>28</sub>H<sub>28</sub>F<sub>2</sub>NO<sub>7</sub> 528.1828, found 528.1827.

2,2,2-Trifluoroethyl 2-0-benzyl-4,6-0-benzylidene-3-nicotinoyl-p-mannopyranoside (S8). The title compound was prepared from donor 18 and 2,2,2-trifluoroethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0 → 60:40, pentane:EtOAc, v:v) yielded glycosylation product **S8** (29.4 mg, 0.054 mmol, 54%,  $\alpha$ : $\beta$  = 58:42). TLC:  $R_f$  0.71, (70:30, pentane:EtOAc, v:v); Data for the α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 9.22 (dd, *J* = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.78 (dd, J = 4.8, 1.8 Hz, 1H, CH<sub>arom</sub> Nico), 8.25 (dt, J = 7.9, 1.9 Hz, 1H, CH<sub>arom</sub> Nico), 7.65 (dd, J = 8.2, 1.5 Hz, 1H, CH<sub>arom</sub> Nico), 7.54 - 7.05 (m, 10H, CH<sub>arom</sub>), 5.62 (s, 1H, CHPh), 5.54 (dd, / = 10.5, 3.6 Hz, 1H, H-3), 4.96 (d, I = 1.6 Hz, 1H, H-1), 4.66 (d, I = 12.0 Hz, 1H, CHH Bn), 4.59 (d, I = 12.0 Hz, 1H, CHH Bn), 4.37 (dd, I = 10.6, 9.3 Hz, 1H, H-4), 4.30 (dd, J = 10.2, 4.6 Hz, 1H, H-6), 4.19 (dd, J = 3.6, 1.6 Hz, 1H, H-2), 4.03 - 3.92 (m, 3H, CHHCF<sub>3</sub>, CHHCF<sub>3</sub>, H-5), 3.91 (t, / = 10.3 Hz, 1H, H-6); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.5 (C=O Nico), 153.8, 151.2 (CH<sub>arom</sub> Nico), 137.5 (CH<sub>arom</sub>), 137.4, 137.1, 137.1 (C<sub>q</sub>), 129.5, 129.2, 128.7, 128.6, 128.4, 128.3 (CH<sub>arom</sub>), 128.2, 126.2 (CH<sub>arom</sub> Nico), 124.3 (1, J = 276.6 Hz, CF<sub>3</sub>), 102.0 (CHPh), 99.4 (C-1), 75.9 (C-4), 75.8 (C-4), 75 2), 74.1 (CH<sub>2</sub> Bn), 71.2 (C-3), 68.6 (C-6), 64.9 (C-5), 64.6 (q, J = 35.2 Hz, CH<sub>2</sub>CF<sub>3</sub>); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>):  $\delta$  99.4 ( $I_{CL,H1}$  = 172.1 Hz, C-1  $\alpha$ ); Diagnostic peaks  $\beta$ -anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC):  $\delta$  9.14 (dd, J = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.78 (dd, J = 4.8, 1.8 Hz, 1H, CH<sub>arom</sub> Nico), 8.17 (dt, J = 7.9, 1.9 Hz, 1H, CH<sub>arom</sub> Nico), 7.65 (dd, J = 8.2, 1.5 Hz, 1H, CH<sub>arom</sub> Nico), 7.56 - 7.06 (m, 10H, CH<sub>arom</sub>), 5.61 (s, 1H, CHPh), 5.16 (dd, / = 10.4, 3.4 Hz, 1H, H-3), 4.84 (d, / = 1.0 Hz, 1H, H-1), 4.33 (dd, / = 10.4, 9.3 Hz, 1H, H-4), 3.53 (td, J = 9.7, 4.9 Hz, 1H, H-5);  $^{13}$ C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC):  $\delta$  164.6 (C=0 Nico), 137.5, 137.3  $(CH_{arom}, Nico)$ , 137.2, 129.5, 129.3  $(C_0)$ , 128.7, 128.4, 128.4, 128.0, 126.2  $(CH_{arom}, Nico)$ , 123.4  $(q, f = 276.5, CF_3)$ , 101.9 (CHPh), 101.7 (C-1), 75.6 (CH<sub>2</sub> Bn), 75.5 (C-2), 75.1 (C-3), 72.9 (C-4), 68.4 (C-6), 67.9 (C-5), 66.4 (q, *J* = 35.0 Hz,  $CH_2CF_3$ ); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>):  $\delta$  101.7 ( $J_{C1,H1}$  = 159.2 Hz, C-1  $\beta$ ); HRMS: [M+H]<sup>+</sup> calcd for  $C_{28}H_{27}F_3NO_7$  546.1734, found 546.1730.

Ethyl 2-*O*-benzyl-4,6-*O*-benzylidene-3-isonicotinoyl-α-p-mannopyranoside (S9). The title compound was prepared from donor 19 and ethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0  $\rightarrow$  60:40, pentane:EtOAc, v:v) yielded glycosylation product S9 (26.5 mg, 0.054 mmol, 54%, α:β = >98:2). TLC: R<sub>f</sub> 0.62, (70:30, pentane:EtOAc, v:v) † H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.80 – 8.73 (m, 1H, CH<sub>arom</sub> *i*-Nico), 7.80 – 7.76 (m, 1H, CH<sub>arom</sub> *i*-Nico), 7.45 – 7.17 (m, 8H, CH<sub>arom</sub>), 5.61 (s, 1H, CHPh), 5.32 (dd, J = 10.4, 3.3 Hz, 1H, H-3), 5.06 (d, J = 1.2 Hz, 1H, H-1), 4.89 (d, J = 12.0 Hz, 1H, CHH Bn), 4.69 (d, J = 11.2 Hz, 1H, CHH Bn), 4.50 (dd, J = 3.4, 1.2 Hz, 1H, H-2), 4.40 (dd, J = 10.4, 9.3 Hz, 1H, H-4), 4.37 – 4.27 (m, 1H, H-6), 3.99 (t, J = 10.3 Hz, 1H, H-6), 3.78 (dq, J = 9.6, 7.0 Hz, 1H, CHHCH<sub>3</sub> Et), 3.60 (td, J = 9.8, 4.9 Hz, 1H, H-5), 3.51 (dq, J = 9.7, 7.0 Hz, 1H, CHHCH<sub>3</sub> Et), 1.29 – 1.22 (m, 3H, CH<sub>3</sub> Et); <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.8 (C=0 *i*-Nico), 150.8 (CH<sub>arom</sub> *i*-Nico), 137.1, 136.6 (c<sub>0</sub>), 134.2, 131.8, 129.3, 128.5, 128.4, 128.3, 128.2, 126.2 (CH<sub>arom</sub>), 101.9 (CHPh), 98.6 (C-1), 78.9 (C-2), 75.6 (C-4), 75.0 (C-3), 73.8 (CH<sub>2</sub> Bn), 71.9 (C-5), 68.5 (C-6), 63.7 (CH<sub>2</sub>CH<sub>3</sub> Et), 15.1 (CH<sub>3</sub> Et); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>): δ 98.6 (J<sub>C1,H1</sub> = 170.0 Hz, C-1 (a); HRMS: [M+H]+ calcd for C<sub>28</sub>H<sub>30</sub>NO<sub>7</sub> 492.2017, found 492.2016.

2-Fluoroethyl 2-O-benzyl-4.6-O-benzylidene-3-isonicotinoyl-p-mannopyranoside (S10). The title compound was prepared from donor 19 and 2-fluoroethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0 → 60:40, pentane:EtOAc, v:v) yielded glycosylation product **S10** (30.0 mg, 0.059 mmol, 59%,  $\alpha$ : $\beta$  = 83:17). TLC:  $R_f$  0.51, (70:30, pentane:EtOAc, v:v); Data for the α-anomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.81 – 8.71 (m, 2H, CH<sub>arom</sub> i-Nico), 7.79 (ddd, J = 12.2, 4.4, 1.7 Hz, 2H, CH<sub>arom</sub> i-Nico), 7.57 - 7.50 (m, 2H, CH<sub>arom</sub>), 7.50 - 7.11 (m, 8H, CH<sub>arom</sub>), 5.62 (s, 1H, CHPh), 5.56 (dd, / = 10.4, 3.5 Hz, 1H, H-3), 4.96 (d, / = 1.6 Hz, 1H, H-1), 4.89 (d, / = 11.3 Hz, 1H, CHH Bn),  $4.69 \text{ (d, } / = 11.7 \text{ Hz, } 1\text{H, } \text{CH}/\text{B} \text{ m), } 4.67 - 4.52 \text{ (m, } 2\text{H, } \text{CH}_2\text{C}/\text{F}), } 4.43 - 4.37 \text{ (m, } 1\text{H, } \text{H-6), } 4.34 \text{ (t, } / = 10.4 \text{ Hz, } 1\text{H, }$ H-4), 4.14 (dd, J=3.5, 1.6 Hz, 1H, H-2), 3.99 (t, J=10.5 Hz, 1H, H-6), 3.81 (ddd, J=12.3, 5.7, 3.3 Hz, 1H,  $CHHCH_2F$ ), 3.74 (ddd, J = 12.3, 5.7, 3.4 Hz, 1H, CHHCH<sub>2</sub>F), 3.60 (td, J = 9.7, 4.9 Hz, 1H, H-5); <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.7 (C=0 i-Nico), 150.7 (CH<sub>arom</sub> i-Nico), 137.1, 134.2 (C<sub>0</sub>), 131.8, 129.3, 128.6, 128.4, 128.1, 126.2, 123.2 (CH<sub>arom</sub>), 101.9 (CHPh), 99.0 (C-1), 82.6 (d, J = 170.3 Hz, CH<sub>2</sub>CH<sub>2</sub>F), 76.3 (C-2), 76.2 (C-4), 73.9 (CH<sub>2</sub> Bn), 71.9 (C-3), 71.9 (C-5), 68.9 (C-6), 67.0 (d, J = 19.9 Hz,  $CH_2CH_2F$ );  $^{13}C$ -GATED NMR (101 MHz,  $CDCl_3$ ):  $\delta$  99.0 (J<sub>C1.H1</sub> = 170.3 Hz, C-1 α); Diagnostic peaks β-anomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSOC, HMBC): δ 5.16  $(dd, J = 10.4, 3.4 Hz, 1H, H-3), 4.80 (d, J = 0.9 Hz, 1H, H-1), 3.53 (td, J = 9.8, 4.9 Hz, 1H, H-5); {}^{13}C-APT NMR (101)$ MHz, CDCl<sub>3</sub>, HSQC, HMBC):  $\delta$  101.9 (C-1), 82.8 (d, J = 170.2 Hz, CH<sub>2</sub>CH<sub>2</sub>F), 69.2 (d, J = 19.9 Hz, CH<sub>2</sub>CH<sub>2</sub>F); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>): δ 101.9 (/c<sub>1.H1</sub> = 156.3 Hz, C-1 β); HRMS: [M+H]<sup>+</sup> calcd for C<sub>28</sub>H<sub>29</sub>FNO<sub>7</sub> 510.1923, found 510.1922.

**2,2-Difluoroethyl 2-***O***-benzyl-4,6-***O***-benzylidene-3-isonicotinoyl-p-mannopyranoside (S11). The title compound was prepared from donor <b>19** and 2,2-difluoroethanol using the general procedure for Tf<sub>2</sub>*O*/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0  $\rightarrow$  60:40, pentane:EtOAc, v:v) yielded glycosylation product **S11** (32.2 mg, 0.061 mmol, 61%, α:β = 73:27). TLC: R<sub>f</sub> 0.60, (70:30, pentane:EtOAc, v:v); pata for the α-anomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.80 (m, 2H, CH<sub>arom</sub> *i*-Nico), 7.82  $\rightarrow$  7.80 (m, 2H, CH<sub>arom</sub> *i*-Nico), 7.59  $\rightarrow$  7.54 (m, 2H CH<sub>arom</sub>), 7.49  $\rightarrow$  7.21 (m, 8H, CH<sub>arom</sub>), 5.97 (ddd, *J* = 55.2, 4.7, 3.6 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.65 (s, 1H, CHPh), 5.55 (dd, *J* = 10.5, 3.6 Hz, 1H, H-3), 4.97 (d, *J* = 1.6 Hz, 1H, H-1), 4.92 (d, *J* = 11.3 Hz, 1H, CHH Bn), 4.72 (d, *J* = 11.3 Hz, 1H, CHH Bn), 4.48  $\rightarrow$  4.40 (m, 1H, H-6), 4.41  $\rightarrow$  4.34 (m, 1H, H-4), 4.18 (dd, *J* = 3.5, 1.6 Hz, 1H, H-2), 4.02 (t, *J* = 10.4 Hz, 1H, H-6), 3.95  $\rightarrow$  3.83 (m, 1H, CHHCHF<sub>2</sub>), 3.80 (td, *J* = 12.4, 4.7 Hz, 1H, CHHCHF<sub>2</sub>), 3.63 (td, *J* = 9.7, 4.9 Hz, 1H, H-5), <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.6 (C=0 *i*-Nico), 150.7 (CH<sub>arom</sub> *i*-Nico), 137.0, 134.1 (C<sub>q</sub>), 131.7, 129.2, 128.4, 128.3, 128.2, 128.0, 126.1 (CH<sub>arom</sub>), 113.9 (t, *J* = 240.2 Hz, CHF<sub>2</sub>), 101.8 (CHPh), 99.2 (C-1), 75.9 (C-2), 75.5 (C-4), 73.9 (CH<sub>2</sub> Bn), 71.7 (C-3), 71.6 (C=5), 68.4 (C-6), 66.8 (t, *J* = 28.3 Hz, CH<sub>2</sub>CHF<sub>2</sub>); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>): δ 99.2 (*J*<sub>C1,H1</sub> = 171.7 Hz, C-1

α); Diagnostic peaks β-anomer:  $^{1}$ H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 5.97 (ddd, J = 54.5, 5.2, 2.9 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.19 (dd, J = 10.4, 3.4 Hz, 1H, H-3), 4.82 (d, J = 1.0 Hz, 1H, H-1), 3.56 (td, J = 9.8, 4.9 Hz, 1H, H-5);  $^{13}$ C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 101.9 (CHPh), 101.8 (C-1), 75.6 (CH<sub>2</sub> Bn), 68.6 (C-6);  $^{13}$ C-GATED NMR (101 MHz, CDCl<sub>3</sub>): δ 101.8 (J<sub>C1,H1</sub> = 158.0 Hz, C-1 β); HRMS: [M+H]\* calcd for C<sub>28</sub>H<sub>28</sub>F<sub>2</sub>NO<sub>7</sub> 528.1828, found 528.1827.

2,2,2-Trifluoroethyl 2-0-benzyl-4,6-0-benzylidene-3-isonicotinoyl-p-mannopyranoside (S12). The title compound was prepared from donor  $\mathbf{19}$  and 2,2,2-trifluoroethanol using the general procedure for  $\mathrm{Tf_2O/Ph_2SO}$ mediated glycosylations. Flash column chromatography (100:0 → 60:40, pentane:EtOAc, v:v) yielded glycosylation product **S12** (19.6 mg, 0.036 mmol, 36%,  $\alpha$ : $\beta$  = 50:50). TLC: R<sub>f</sub> 0.68, (70:30, pentane:EtOAc, v:v); Data for the α-anomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.76 (d, / = 5.7 Hz, 2H, CH<sub>arom</sub> i-Nico), 7.79 (dd, J = 12.9, 6.0 Hz, 2H, CH<sub>arom</sub> i-Nico), 7.56 - 7.50 (m, 2H, CH<sub>arom</sub>), 7.49 - 7.14 (m, 8H, CH<sub>arom</sub>), 5.62 (s, 1H, CHPh), 5.53 (dd, J = 10.5, 3.5 Hz, 1H, H-3), 4.97 (d, J = 1.6 Hz, 1H, H-1), 4.67 (d, J = 12.0 Hz, 1H, CHH Bn),4.57 (d, / = 12.0 Hz, 1H, CHH Bn), 4.42 - 4.35 (m, 1H, H-4), 4.33 - 4.25 (m, 2H, H-6, CHHCF<sub>3</sub>), 4.18 (dd, / = 3.5, 1.6 Hz, 1H, H-2), 4.09 – 3.87 (m, 2H, H-6, CHHCF<sub>3</sub>), 3.60 (td, J = 9.7, 4.9 Hz, 1H, H-5); <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSOC, HMBC): δ 164.4 (C=0 *i*-Nico), 150.8 (CH<sub>arom</sub> *i*-Nico), 137.1, 136.7 (C<sub>0</sub>), 135.6 (q, *J* = 282.6 Hz, CF<sub>3</sub>), 131.8, 129.3, 128.6, 128.4, 128.1, 126.2, 123.1 (CH<sub>arom</sub>), 102.0 (CHPh), 99.3 (C-1), 75.9 (C-2), 75.6 (C-4), 74.1 (CH<sub>2</sub> Bn), 71.9 (C-3), 71.5 (C-5), 68.6 (C-6), 66.4 (q, / = 34.9 Hz, CH<sub>2</sub>CF<sub>3</sub>); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>): δ 99.3 ( $J_{C1,H1}$  = 171.6 Hz, C-1  $\alpha$ ); Diagnostic peaks  $\beta$ -anomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC):  $\delta$  8.76 (d, I = 5.7 Hz, 2H, CH<sub>arom</sub> i-Nico), 7.79 – 7.72 (m, 2H, CH<sub>arom</sub> i-Nico), 7.49 – 7.14 (m, 10H, CH<sub>arom</sub>), 5.61 (s, 1H, CHPh), 5.16 (dd, *J* = 10.4, 3.4 Hz, 1H, H-3), 4.84 (d, *J* = 0.9 Hz, 1H, H-1), 4.67 (d, *J* = 12.0 Hz, 1H, CHH Bn), 4.59  $(d, l = 12.1 \text{ Hz}, 1H, CHH Bn), 4.30 (dd, l = 5.5, 2.0 \text{ Hz}, 1H, H-2), 3.53 (td, l = 10.1, 4.9 \text{ Hz}, 1H, H-5); {}^{13}C-APT NMR$ (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.8 (C=0 i-Nico), 101.9 (CHPh), 101.9 (C-1), 68.4 (C-6); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  101.9 ( $J_{C1,H1}$  = 158.6 Hz, C-1  $\beta$ ); HRMS: [M+H]<sup>+</sup> calcd for  $C_{28}H_{27}F_{3}NO_{7}$  546.1734, found 546.1731.

Ethyl 2-*O*-benzyl-4,6-*O*-benzylidene-3-picoloyl-β-D-glucopyranoside (S13). The title compound was prepared from donor 12 and ethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0 → 60:40, pentane:EtOAc, v:v) yielded glycosylation product S13 (19.1 mg, 0.039 mmol, 39%, α:β = <2:98). TLC: R<sub>f</sub> 0.59, (70:30, pentane:EtOAc, v:v); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.77 (ddt, J = 4.7, 1.7, 0.8 Hz, 1H, CH<sub>arom</sub> Pico), 8.15 (dt, J = 7.9, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.85 (td, J = 7.8, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.48 (ddd, J = 7.6, 4.7, 1.2 Hz, 1H, CH<sub>arom</sub> Pico), 7.43 − 7.35 (m, 2H, CH<sub>arom</sub>), 7.34 − 7.25 (m, 2H, CH<sub>arom</sub>), 7.20 − 7.06 (m, 6H, CH<sub>arom</sub>), 5.66 (t, J = 9.6 Hz, 1H, H-3), 5.47 (s, 1H, CHPh), 4.83 (d, J = 11.7 Hz, 1H, CHH Bn), 4.67 (d, J = 7.7 Hz, 1H, H-1), 4.66 (d, J = 11.6 Hz, 1H, CHH Bn), 4.38 (dd, J = 10.5, 5.0 Hz, 1H, H-6), 4.03 (dq, J = 9.6, 7.1 Hz, 1H, CHHCH<sub>3</sub> Et), 3.86 (t, J = 9.5 Hz, 1H, H-4), 3.81 (t, J = 10.3 Hz, 1H, H-6), 3.−3.69 (m, 1H, 73 CHHCH<sub>3</sub> Et), 3.71 − 3.62 (m, 1H, H-2), 3.58 (td, J = 9.7, 5.0 Hz, 1H, H-5), 1.32 (t, J = 7.1 Hz, 1H, CH<sub>3</sub> Et); <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 165.4 (C=0 Pico), 150.0, 137.1, 137.0, 129.1, 128.2, 127.6, 127.0, 126.3, 125.8, 125.3 (CH<sub>arom</sub>), 104.2 (C-1), 101.5 (CHPh), 79.6 (C-2), 78.6 (C-4), 74.6 (CH<sub>2</sub> Bn), 74.2 (C-3), 68.9 (C-6), 66.4 (C-5), 66.4 (CH<sub>2</sub>CH<sub>3</sub> Et), 15.5 (CH<sub>3</sub> Et); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>): δ 104.2 (J<sub>C1,H1</sub> = 160.7 Hz, C-1 β); HRMS: [M+H]\* calcd for C<sub>28</sub>H<sub>30</sub>NO<sub>7</sub> 492.2017, found 492.2018.

**2-Fluoroethyl 2-***O***-benzyl-4,6-***O***-benzylidene-3-picoloyl-p-glucopyranoside (S14)**. The title compound was prepared from donor **12** and 2-fluoroethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0  $\rightarrow$  60:40, pentane:EtOAc, v:v) yielded glycosylation product **S14** (25.0 mg, 0.049 mmol, 49%, α:β = 24:76). TLC: R<sub>f</sub>0.50, (70:30, pentane:EtOAc, v:v); Data for the β-anomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.79 (ddd, J = 4.7, 1.8, 0.9 Hz, 1H, CH<sub>arom</sub> Pico), 8.17 (dt, J = 7.9, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.87 (td, J = 7.8, 1.8 Hz, 1H, CH<sub>arom</sub> Pico), 7.50 (ddd, J = 7.6, 4.7, 1.2 Hz, 1H, CH<sub>arom</sub> Pico), 7.45 – 7.34 (m, 3H, CH<sub>arom</sub>), 7.34 – 7.26 (m, 7H, CH<sub>arom</sub>), 5.69 (dd, J = 9.8, 9.2 Hz, 1H, H-3), 5.50 (s, 1H, CHPh), 4.87 (d, J = 11.6 Hz, 1H, CHH Bn), 4.74 (d, J = 7.6 Hz, 1H, H-1), 4.72 – 4.70 (m, 1H, CH<sub>2</sub>CHHF), 4.68 (d, J = 11.6 Hz, 1H, CHH Bn), 4.60 (td, J = 6.0, 2.7 Hz, 1H, CH<sub>2</sub>CHHF), 4.40 (dd, J = 10.5, 5.0 Hz, 1H, H-6), 4.11

(dddd, J = 32.0, 12.1, 4.8, 2.6 Hz, 1H, CHHCH<sub>2</sub>F), 3.91 (dddd, J = 32.0, 12.0, 4.7, 2.6 Hz, 1H, CHHCH<sub>2</sub>), 3.90 (t, J = 9.6 Hz, 1H, H-4), 3.83 (t, J = 10.3 Hz, 1H, H-6), 3.73 (dd, J = 9.3, 7.6 Hz, 1H, H-2), 3.61 (td, J = 9.7, 5.0 Hz, 1H, H-5);  $^{13}$ C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC): 8 165.3 (C=0 Pico), 149.9 (CH<sub>arom</sub> Pico), 148.3 , 137.7 (C<sub>q</sub>), 137.0, 129.0, 128.3, 128.2, 128.1, 127.6, 126.9, 126.2, 125.1 (CH<sub>arom</sub>), 104.4 (C-1), 101.4 (CHPh), 82.4 (d, J = 170.3 Hz, CH<sub>2</sub>CH<sub>2</sub>F), 79.3 (C-2), 78.4 (C-2), 74.5 (CH<sub>2</sub> Bn), 73.9 (C-3), 69.4 (d, J = 19.8 Hz, CH<sub>2</sub>CH<sub>2</sub>F), 68.7 (C-6), 66.4 (C-5);  $^{13}$ C-GATED NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  104.4 (J<sub>C1,H1</sub> = 161.4 Hz, C-1  $\beta$ ); Diagnostic peaks  $\alpha$ -anomer:  $^{14}$ H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC):  $\delta$  4.94 (d, J = 3.6 Hz, 1H, H-1);  $^{13}$ C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC):  $\delta$  98.1 (C-1);  $^{13}$ C-GATED NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  98.1 (J<sub>C1,H1</sub> = 169.7 Hz, C-1  $\alpha$ ); HRMS: [M+H]+ calcd for J<sub>C28</sub>H<sub>29</sub>FNO<sub>7</sub> 510.1923, found 510.1922.

**2.2-Difluoroethyl 2-***O***-benzyl-4,6-***O***-benzylidene-3-picoloyl-n-glucopyranoside (S15). The title compound was prepared from donor <b>12** and 2,2-difluoroethanol using the general procedure for Tf<sub>2</sub>*O*/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0  $\rightarrow$  60:40, pentane:EtOAc, v:v) yielded glycosylation product **S15** (16.3 mg, 0.031 mmol, 31%, α:β = 58:42). TLC:  $R_f$  0.60, (70:30, pentane:EtOAc, v:v); Data for the α-anomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.80 (ddd, J = 4.7, 1.8, 0.9 Hz, 1H, CH<sub>arom</sub> Pico), 8.17 (dt, J = 7.9, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.87 (td, J = 7.7, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.50 (ddd, J = 7.6, 4.8, 1.3 Hz, 1H, CH<sub>arom</sub> Pico), 7.20 – 7.05 (m, 10H, CH<sub>arom</sub>), 5.97 (tdd, J = 55.3, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.68 (dd, J = 9.8, 9.2 Hz, 1H, H-3), 5.50 (s, 1H, CHPh), 4.83 (d, J = 11.6 Hz, 1H, CHH Bn), 4.73 (d, J = 7.6 Hz, 1H, H-1), 4.66 (d, J = 11.6 Hz, 1H, CHH Bn), 4.40 (dd, J = 10.5, 5.0 Hz, 1H, H-6), 4.19 – 4.01 (m, 1H, CHHCHF<sub>2</sub>), 3.98 – 3.93 (m, 1H, CHHCHF<sub>2</sub>), 3.90 (t, J = 9.6 Hz, 1H, H-4), 3.83 (t, J = 10.2 Hz, 1H, H-6), 3.73 (dd, J = 9.2, 7.5 Hz, 1H, H-2), 3.62 (td, J = 9.8, 5.0 Hz, 1H, H-5); <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 165.3 (C=0 Pico), 149.3 (CH<sub>arom</sub> Pico), 148.3 (C<sub>q</sub>), 136.5, 130.5, 129.0, 128.2, 128.2, 127.7, 126.9, 126.2, 125.1 (CH<sub>arom</sub>), 104.4 (C-1), 101.4 (CHPh), 79.0 (C-2), 78.2 (C-4), 74.6 (CH<sub>2</sub> Bn), 73.8 (C-3), 68.6 (C-6), 66.4 (C-5); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>); δ 104.4 (J<sub>C1,H1</sub> = 171.2 Hz, C-1 α); Diagnostic peaks β-anomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 98.2 (C-1).

**2.2.2-Trifluoroethyl 2-***O***-benzyl-4,6-***O***-benzylidene-3-picoloyl-p-glucopyranoside (S16). The title compound was prepared from donor <b>12** and 2,2,2-trifluoroethanol using the general procedure for Tf<sub>2</sub>*O*/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0  $\rightarrow$  60:40, pentane:EtOAc, v:v) yielded glycosylation product **S16** (15.3 mg, 0.028 mmol, 28%, α:β = 74:26). TLC: R<sub>f</sub> 0.67, (70:30, pentane:EtOAc, v:v); pata for the β-anomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.80 (ddd, J = 4.7, 1.8, 0.9 Hz, 1H, CH<sub>arom</sub> Pico), 8.17 (dt, J = 7.9, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.87 (td, J = 7.8, 1.8 Hz, 1H, CH<sub>arom</sub> Pico), 7.51 (ddd, J = 7.6, 4.7, 1.2 Hz, 1H, CH<sub>arom</sub> Pico), 7.20 – 7.07 (m, 10H, CH<sub>arom</sub>), 5.68 (t, J = 9.5 Hz, 1H, H-3), 5.33 (s, 1H, CHPh), 4.85 (d, J = 11.5 Hz, 1H, CHH Bn), 4.79 (d, J = 7.5 Hz, 1H, H-1), 4.65 (d, J = 11.8 Hz, 1H, CHH Bn), 4.40 (dd, J = 10.6, 5.0 Hz, 1H, H-6), 4.35 – 4.22 (m, 1H, CHHCF<sub>3</sub>), 4.13 – 4.00 (m, 1H, CHHCF<sub>3</sub>), 3.91 (t, J = 9.6 Hz, 1H, H-4), 3.83 (t, J = 9.4 Hz, 1H, H-6), 3.80 – 3.71 (m, 1H, H-2), 3.61 (dt, J = 9.7, 4.9 Hz, 1H, H-5); <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 103.4 (C-1), 101.4 (CHPh), 77.1 (C-4), 77.0 (C-2), 74.5 (C-3), 67.7 (C-6), 66.3 (C-5); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>): δ 103.4 (J<sub>C1,H1</sub> = 162.9 Hz, C-1 β); HRMS: [M+H]+ calcd for C<sub>28</sub>H<sub>27</sub>F<sub>3</sub>NO<sub>7</sub> 546.1734, found 546.17320.

Ethyl 2-*O*-benzyl-4,6-*O*-benzylidene-3-nicotinoyl-β-**D**-glucopyranoside (S17). The title compound was prepared from donor 13 and ethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0  $\rightarrow$  60:40, pentane:EtOAc, v:v) yielded glycosylation product S17 (23.1 mg, 0.047 mmol, 47%, α:β = 2:98). TLC: R<sub>f</sub> 0.63, (70:30, pentane:EtOAc, v:v); Data for the β-anomer: ¹H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 9.09 (ddd, J = 11.2, 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.76 (dt, J = 4.9, 2.0 Hz, 1H, CH<sub>arom</sub> Nico), 8.18 (ddt, J = 9.9, 7.9, 1.8 Hz, 1H, CH<sub>arom</sub> Nico), 7.62 – 7.53 (m, 1H, CH<sub>arom</sub> Nico), 7.44 – 7.17 (m, 8H, CH<sub>arom</sub>), 7.16 – 6.98 (m, 2H, CH<sub>arom</sub>), 5.56 (t, J = 9.5 Hz, 1H, H-3), 5.46 (s, 1H, CHPh), 4.83 (d, J = 11.8 Hz, 1H, CHH Bn), 4.68 (d, J = 7.6 Hz, 1H, H-1), 4.65 (d, J = 11.9 Hz, 1H, CHH Bn), 4.40 (dd, J = 11.3, 10.5 Hz, 1H, H-6), 4.03 (dd, J = 9.6, 7.1 Hz, 1H, CHHCH<sub>3</sub> Et), 3.85 – 3.74 (m, 2H, H-6, CHHCH<sub>3</sub> Et), 3.72 (dd, J = 9.6, 7.1 Hz, 1H, H-4), 3.62 (td, J = 9.7, 5.0 Hz, 1H, H-5), 3.56 (dd, J = 9.2, 7.6 Hz, 1H, H-2), 1.40 – 1.23 (m, 3H, CH<sub>3</sub> Et); <sup>13</sup>C-APT

NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC):  $\delta$  164.3 (C=0 Nico), 153.5, 151.1 (CH<sub>arom</sub> Nico), 137.4 (C<sub>q</sub>), 137.4, 132.4, 129.3, 128.5, 128.3, 127.8, 126.2 (CH<sub>arom</sub>), 125.9 (C<sub>q</sub>), 123.3 (CH<sub>arom</sub>), 104.2 (C-1), 101.5 (CHPh), 78.8 (C-2), 75.4 (C-4), 74.3 (CH<sub>2</sub> Bn), 73.6 (C-3), 70.5 (C-5), 68.8 (C-6), 66.3 (CH<sub>2</sub>CH<sub>3</sub> Et), 15.4 (CH<sub>3</sub> Et);  $^{13}$ C-GATED NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  104.2 ( $^{13}$ C- $^$ 

**2-Fluoroethyl 2-***O***-benzyl-4,6-***O***-benzylidene-3-nicotinoyl-n-glucopyranoside (S18)**. The title compound was prepared from donor **13** and 2-fluoroethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0 → 60:40, pentane:EtOAc, v:v) yielded glycosylation product **S18** (35.1 mg, 0.069 mmol, 69%, α:β = 26:74). TLC: R<sub>f</sub>0.49, (70:30, pentane:EtOAc, v:v); Data for the β-anomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 9.14 (dd, *J* = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.80 (td, *J* = 5.0, 1.7 Hz, 1H, CH<sub>arom</sub> Nico), 8.25 – 8.19 (m, 1H, CH<sub>arom</sub> Nico), 7.63 – 7.59 (m, 2H, CH<sub>arom</sub>), 7.45 – 7.07 (m, 8H, CH<sub>arom</sub>), 5.61 (t, *J* = 9.4 Hz, 1H, H-3), 5.51 (s, 1H, CHPh), 4.88 (d, *J* = 11.8 Hz, 1H, CHH Bn), 4.76 (d, *J* = 7.6 Hz, 1H, H-1), 4.76 – 4.70 (m, 1H, CH<sub>2</sub>CHHF), 4.69 (d, *J* = 11.8 Hz, 1H, CHH Bn), 4.63 – 4.59 (m, 1H, CH<sub>2</sub>CHHF), 4.45 (dd, *J* = 10.5, 5.0 Hz, 1H, H-6), 4.19 (dddd, *J* = 31.9, 12.1, 4.7, 2.6 Hz, 1H, CHHCH<sub>2</sub>F), 3.97 (dddd, *J* = 31.9, 12.1, 6.4, 2.9 Hz, 1H, CHHCH<sub>2</sub>F), 3.86 (t, *J* = 10.3 Hz, 1H, H-6), 3.75 (dd, *J* = 9.7, 8.7 Hz, 1H, H-4), 3.64 (dd, *J* = 9.1, 7.6 Hz, 1H, H-2), 3.62 (td, *J* = 9.7, 4.7 Hz, 1H, H-5); <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.1 (CHo Nico), 153.5, 150.9, 137.3 (CH<sub>arom</sub> Nico), 136.7, 132.9 (C<sub>q</sub>), 132.3, 129.2, 129.1, 128.4, 128.3, 128.2, 126.1 (CH<sub>arom</sub>), 104.3 (C-1), 101.4 (CHPh), 82.4 (d, *J* = 170.5 Hz, CH<sub>2</sub>CH<sub>2</sub>F), 78.8 (C-2), 78.6 (C-4), 74.2 (CH<sub>2</sub> Bn), 73.4 (C-3), 70.4 (C-5), 69.4 (d, *J* = 19.9 Hz, CH<sub>2</sub>CH<sub>2</sub>F), 68.6 (C-6); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>): δ 104.3 (*J*<sub>C1,H1</sub> = 162.1 Hz, C-1 β); HRMS: [M+H]\* calcd for C<sub>28</sub>H<sub>29</sub>FNO<sub>7</sub> 510.1923, found 510.1923.

**2,2-Difluoroethyl 2-***O***-benzyl-4,6-***O***-benzylidene-3-nicotinoyl-<b>p**-glucopyranoside (S19). The title compound was prepared from donor **13** and 2,2-difluoroethanol using the general procedure for Tf<sub>2</sub>*O*/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0  $\rightarrow$  60:40, pentane:EtOAc, v:v) yielded glycosylation product **S19** (22.1 mg, 0.042 mmol, 42%, α:β = 65:35). TLC: R<sub>f</sub> 0.61, (70:30, pentane:EtOAc, v:v); pata for the β-anomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 9.14 (dd, J = 2.2, 0.9 Hz, 1H, CHarom Nico), 8.79 (dd, J = 4.9, 1.7 Hz, 1H, CH<sub>arom</sub> Nico), 8.23 (dt, J = 8.0, 2.0 Hz, 1H, CH<sub>arom</sub> Nico), 7.65 – 7.57 (m, 3H, CH<sub>arom</sub>), 7.45 – 7.09 (m, 8H, CH<sub>arom</sub>), 6.00 (tdd, J = 55.3, 4.8, 3.3 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.60 (dd, J = 9.7, 9.1 Hz, 1H, H-3), 5.50 (s, 1H, CHPh), 4.84 (d, J = 11.8 Hz, 1H, CHH Bn), 4.75 (d, J = 7.5 Hz, 1H, H-1), 4.65 (d, J = 12.0 Hz, 1H, CHH Bn), 4.44 (dd, J = 10.6, 5.0 Hz, 1H, H-6), 4.12 (dddd, J = 16.9, 12.7, 11.7, 3.3 Hz, 1H, CHHCHF<sub>2</sub>), 4.00 – 3.84 (m, 1H, CHHCHF<sub>2</sub>), 3.86 – 3.78 (m, 1H, H-6), 3.75 (dd, J = 9.7, 8.8 Hz, 1H, H-4), 3.70 – 3.57 (m, 2H, H-2, H-5); <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.2 (C=0 Nico), 153.6, 151.0, 137.5 (CH<sub>arom</sub> Nico), 136.8, 133.0 (C<sub>q</sub>), 132.5, 129.3, 129.2, 128.4, 128.4, 126.2, 123.4 (CH<sub>arom</sub>), 104.5 (C-1), 101.6 (CHPh), 78.9 (C-2), 78.6 (C-4), 74.5 (CH<sub>2</sub> Bn), 73.4 (C-3), 69.0 (t, J = 28.9 Hz,  $CH_2$ CHF<sub>2</sub>), 68.7 (C-6), 66.4 (C-5); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>): δ 104.5 (C<sub>11</sub>H<sub>1</sub> = 162.6 Hz, C-1 β); HRMS: [M+H]+ calcd for  $C_{28}H_{28}F_{2}$ NO7, 528.1828, found 528.1832.

**2,2,2-Trifluoroethyl 2-***0***-benzyl-4,6-***0***-benzylidene-3-nicotinoyl-p-glucopyranoside (S20). The title compound was prepared from donor <b>13** and 2,2,2-trifluoroethanol using the general procedure for Tf<sub>2</sub>0/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0  $\rightarrow$  60:40, pentane:EtOAc, v:v) yielded glycosylation product **S20** (32.7 mg, 0.060 mmol, 60%, α:β = 92:8). TLC:  $R_f$  0.65, (70:30, pentane:EtOAc, v:v); bata for the α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 9.18 (dd, J = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.78 (dd, J = 4.8, 1.8 Hz, 1H, CH<sub>arom</sub> Nico), 8.27 (dt, J = 7.9, 2.0 Hz, 1H, CH<sub>arom</sub> Nico), 7.42 – 7.07 (m, 11H, CH<sub>arom</sub>), 5.83 (t, J = 9.7 Hz, 1H, H-3), 5.47 (s, 1H, CHPh), 4.94 (d, J = 3.7 Hz, 1H, H-1), 4.61 (d, J = 1.2 Hz, 2H, CH<sub>2</sub> Bn), 4.29 (dd, J = 10.5, 4.9 Hz, 1H, H-6), 4.01 – 3.94 (m, 3H, H-5, CHHCF<sub>3</sub>), CHHCF<sub>3</sub>), 3.77 – 3.70 (m, 3H, H-2, H-4, H-6); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.1 (C=0 Nico), 153.5, 150.9 (CH<sub>arom</sub> Nico), 137.5 (CH<sub>arom</sub>), 137.3, 136.7 (C<sub>q</sub>), 132.4, 129.1, 128.5, 128.2, 128.2, 128.0, 126.2 (CH<sub>arom</sub>), 126.1 (C<sub>q</sub>), 123.6 (q, J = 279.1 Hz, CF<sub>3</sub>), 123.4 (CH<sub>arom</sub>), 101.6 (CHPh), 98.3 (C-1), 79.1 (C-4), 77.0 (C-2), 72.8 (CH<sub>2</sub> Bn), 71.2 (C-3), 68.6 (C-6), 65.3 (q, J = 35.1 Hz, CH<sub>2</sub>CF<sub>3</sub>), 63.23 (C-5); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>): δ 98.3 (J<sub>C1,H1</sub> = 170.4 Hz, C-1 α); Diagnostic peaks β-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 9.08 (dd, J = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.76 (dd, J = 4.8, 1.8 Hz, 1H, CH<sub>arom</sub> Nico), 8.17 (dt, J = 7.9, 2.0 Hz, 1H, CH<sub>arom</sub> Nico), 5.56 (dd, J = 9.7, 2.0 9 Hz, 1H, CH<sub>arom</sub> Nico), 5.56 (dd, J = 9.7, 2.0 Hz, 1H, CH<sub>arom</sub> Nico), 5.56 (dd, J = 9.7, 2.0 Hz, 1H, CH<sub>arom</sub> Nico), 5.56 (dd, J = 9.7, 2.0 Hz, 1H, CH<sub>arom</sub> Nico), 5.56 (dd, J = 9.7, 2.0 Hz, 1H, CH<sub>arom</sub> Nico), 5.56 (dd, J = 9.7, 2.0 Hz, 1H, CH<sub>arom</sub> Nico), 5.56 (dd, J = 9.7, 2.0 Hz, 1H, CH<sub>arom</sub> Nico), 5.56 (dd, J = 9.7, 2.0 Hz, 1H, CH<sub>arom</sub> Nico), 5.56 (dd, J =

9.0 Hz, 1H, H-3), 4.77 (d, J = 7.4 Hz, 1H), 4.38 (dd, J = 10.6, 5.0 Hz, 1H, H-6);  $^{13}$ C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC):  $\delta$  101.5 (C-1);  $^{13}$ C-GATED NMR (214 MHz, CDCl<sub>3</sub>):  $\delta$  101.5 (J<sub>C1,H1</sub> = 162.6 Hz, C-1  $\beta$ ); HRMS: [M+H]<sup>+</sup> calcd for C<sub>28</sub>H<sub>27</sub>F<sub>3</sub>NO<sub>7</sub> 546.1734, found 546.1739.

Ethyl 2-*O*-benzyl-4,6-*O*-benzylidene-3-isonicotinoyl-p-glucopyranoside (S21). The title compound was prepared from donor 14 and ethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0 → 60:40, pentane:EtOAc, v:v) yielded glycosylation product S21 (25.1 mg, 0.051 mmol, 51%, α:β = 16:84). TLC: R<sub>f</sub> 0.62, (70:30, pentane:EtOAc, v:v); Data for the β-anomer: ¹H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.74 (dt, J = 4.4, 1.3 Hz, 2H, CH<sub>arom</sub> I-Nico), 7.74 − 7.71 (m, 2H, CH<sub>arom</sub> I-Nico), 7.62 − 7.52 (m, 2H, CH<sub>arom</sub>), 7.43 − 7.25 (m, 8H CH<sub>arom</sub>), 5.63 (dd, J = 9.8, 8.8 Hz, 1H, H-3), 5.48 (s, 1H, CHPh), 4.90 (d, J = 11.0 Hz, 1H, CHH Bn), 4.67 (d, J = 7.7 Hz, 1H, H-1), 4.57 (d, J = 11.0 Hz, 1H, CHH Bn), 4.41 (dd, J = 10.6, 5.0 Hz, 1H, H-6), 4.04 (dq, J = 9.6, 7.1 Hz, 1H, CHHCH<sub>3</sub> Et), 3.87 − 3.77 (m, 2H, H-6, CHHCH<sub>3</sub> Et), 3.77 − 3.67 (m, 2H, H-2, H-4), 3.62 (td, J = 9.7, 4.9 Hz, 1H, H-5), 1.32 − 1.21 (m, 3H, CH<sub>3</sub> Et);  $^{13}$ C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.0 (C=0 I-Nico), 150.5 (CH<sub>arom</sub> I-Nico), 136.7, 132.9 (cq), 132.4, 129.2, 128.4, 128.2, 128.0, 126.1, 123.0 (CH<sub>arom</sub>), 104.1 (C-1), 101.4 (CHPh), 78.9 (C-2), 78.7 (C-4), 74.2 (CH<sub>2</sub> Bn), 73.9 (C-3), 70.4 (C-5), 68.6 (C-6), 66.3 (CH<sub>2</sub>CH<sub>3</sub> Et), 15.4 (CH<sub>3</sub> Et); I<sup>3</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>): δ 104.1 (I<sub>C1,H1</sub> = 160.7 Hz, C-1 β); HRMS: [M+H]+ calcd for C<sub>28</sub>H<sub>30</sub>NO<sub>7</sub> 492.2017, found 492.2016.

**2-Fluoroethyl 2-0-benzyl-4,6-0-benzylidene-3-isonicotinoyl-p-glucopyranoside** (S22). The title compound was prepared from donor **14** and 2-fluoroethanol using the general procedure for Tf<sub>2</sub>0/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0 → 60:40, pentane:EtOAc, v:v) yielded glycosylation product **S22** (18.8 mg, 0.037 mmol, 37%, α:β = 28:72). TLC: R<sub>f</sub> 0.57, (70:30, pentane:EtOAc, v:v); Data for the β-anomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.78 – 8.69 (m, 2H, CH<sub>arom</sub> *i*-Nico), 7.76 – 7.68 (m, 2H, CH<sub>arom</sub> *i*-Nico), 7.61 – 7.54 (m, 2H, CH<sub>arom</sub>), 7.42 – 7.24 (m, 2H, CH<sub>arom</sub>), 7.22 – 7.03 (m, 6H, CH<sub>arom</sub>), 5.55 (t, *J* = 9.5 Hz, 1H, H-3), 5.46 (s, 1H, CHPh), 4.84 (d, *J* = 11.8 Hz, 1H, CHH Bn), 4.72 (d, *J* = 7.4 Hz, 1H, H-1), 4.73 – 4.67 (m, 1H, CH<sub>2</sub>CHHF), 4.64 (d, *J* = 11.9 Hz, 1H, CHH Bn), 4.63 – 4.55 (m, 1H, CH<sub>2</sub>CHHF), 4.41 (dd, *J* = 10.5, 5.0 Hz, 1H, H-6), 4.20 (dddd, *J* = 32.0, 12.0, 4.7, 2.6 Hz, 1H, CHHCH<sub>2</sub>F), 3.97 (dddd, *J* = 26.5, 12.1, 6.4, 2.9 Hz, 1H, CHHCH<sub>2</sub>F), 3.82 (t, *J* = 10.2 Hz, 1H, H-6), 3.74 – 3.68 (m, 1H, H-4), 3.67 – 3.52 (m, 2H, H-2, H-5); <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>), HSQC, HMBC): δ 164.1 (C=0 *i*-Nico), 150.6 (CH<sub>arom</sub> *i*-Nico), 136.8, 133.0 (C<sub>q</sub>), 132.5, 129.3, 129.2, 128.5, 128.3, 128.3, 126.2, 123.1 (CH<sub>arom</sub>), 104.4 (C-1), 101.5 (CHPh), 82.5 (d, *J* = 170.4 Hz, CH<sub>2</sub>CH<sub>2</sub>F), 78.6 (C-4), 74.3 (CH<sub>2</sub> Bn), 73.9 (C-3), 69.5 (d, *J* = 19.9 Hz, CH<sub>2</sub>CH<sub>2</sub>F) 68.7 (C-6), 66.3 (C-5); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>): δ 104.4 (*J*<sub>C1,H1</sub> = 161.9 Hz, C-1 β); HRMS: [M+H]+ calcd for C<sub>28</sub>H<sub>29</sub>FNO<sub>7</sub> 510.1923, found 510.1920.

2,2-Difluoroethyl 2-0-benzyl-4,6-0-benzylidene-3-isonicotinoyl-p-glucopyranoside (S23). The title compound was prepared from donor 14 and 2,2-difluoroethanol using the general procedure for Tf2O/Ph2SO mediated glycosylations. Flash column chromatography (100:0 → 60:40, pentane:EtOAc, v:v) yielded glycosylation product **S23** (30.1 mg, 0.057 mmol, 57%, α:β = 80:20). TLC: R<sub>f</sub> 0.61, (70:30, pentane:EtOAc, v:v); Data for the α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.78 – 8.76 (m, 2H, CH<sub>arom</sub> i-Nico), 7.81 - 7.78 (m, 2H, CH<sub>arom</sub> i-Nico), 7.40 - 7.07 (m, 10H, CH<sub>arom</sub>), 5.99 (tdd, J = 55.2, 4.7, 3.8 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.79 (t, J = 9.7 Hz, 1H, H-3), 5.47 (s, 1H, CHPh), 4.93 (d, J = 3.6 Hz, 1H, H-1), 4.61 (d, J = 12.4 Hz, 1H, CHH Bn), 4.58 (d, J = 12.5 Hz, 1H, CHH Bn), 4.30 (dd, J = 10.5, 4.9 Hz, 1H, H-6), 3.99 (td, J = 9.9, 4.9 Hz, 1H, H-5), 3.77 - 3.68 (m, 5H, H-2, H-4, H-6, CHHCHF2, CHHCHF2); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.0 (C=0 *i*-Nico), 150.6 ( $CH_{arom}$  *i*-Nico), 137.2, 136.9, 136.7 ( $C_q$ ), 132.4, 126.1 ( $CH_{arom}$ ), 123.0 ( $CH_{arom}$  *i*-Nico), 114.0 (t, J = 241.5Hz, CHF<sub>2</sub>), 101.6 (CHPh), 98.1 (C-1), 78.5 (C-4), 77.2 (C-2), 72.9 (CH<sub>2</sub> Bn), 71.6 (C-3), 68.7 (C-6), 67.4 (t, J = 28.9 Hz, C $H_2$ CHF<sub>2</sub>), 62.98 (C-5);  ${}^{13}$ C-GATED NMR (214 MHz, CDCl<sub>3</sub>): δ 98.1 ( $J_{C1,H1}$  = 169.8 Hz, C-1 α); Diagnostic peaks β-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.75 – 8.74 (m, 2H, CH<sub>arom</sub> i-Nico), 7.71 – 7.69 (m, 2H, CH<sub>arom</sub> i-Nico), 7.42 – 7.06 (m, 10H, CH<sub>arom</sub>), 5.96 (tdd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4, 4.8, 3.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.54 (dd, J = 55.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>CHF<sub>2</sub>C9.7, 9.0 Hz, 1H, H-3), 4.71 (d, J = 7.5 Hz, 1H, H-1), 4.38 (dd, J = 10.7, 5.0 Hz, 1H, H-6); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.0 (C=0 i-Nico), 150.5 (CH<sub>arom</sub> i-Nico), 101.6 (CHPh), 101.5 (C-1), 73.7 (C-4), 66.2 (C-1) 5);  $^{13}$ C-GATED NMR (214 MHz, CDCl<sub>3</sub>):  $\delta$  101.5 ( $J_{C1,H1}$  = 162.2 Hz, C-1  $\beta$ ); HRMS: [M+H]\* calcd for C<sub>28</sub>H<sub>28</sub>F<sub>2</sub>NO<sub>7</sub> 528.1828, found 528.1829.

**2,2,2-Trifluoroethyl 2-***0***-benzyl-4,6-***0***-benzylidene-3-isonicotinoyl-p-glucopyranoside (S24). The title compound was prepared from donor <b>14** and 2,2,2-trifluoroethanol using the general procedure for Tf<sub>2</sub>*O*/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0  $\rightarrow$  60:40, pentane:EtOAc, v:v) yielded glycosylation product **S24** (28.9 mg, 0.053 mmol, 53%, α:β = 97:3). TLC:  $R_f$  0.69, (70:30, pentane:EtOAc, v:v); pata for the α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.82 – 8.78 (m, 2H, CH<sub>arom</sub> *i*-Nico), 7.84 – 7.80 (m, 2H, CH<sub>arom</sub> *i*-Nico), 7.44 – 7.10 (m, 10H, CH<sub>arom</sub>), 5.84 (t, J = 9.7 Hz, 1H, H-3), 5.50 (s, 1H, *CHP*h), 4.99 (d, J = 3.7 Hz, 1H, H-2), 4.64 (d, J = 12.5 Hz, 1H, *CHH* Bn), 4.61 (d, J = 12.4 Hz, 1H, CH*H* Bn), 4.32 (dd, J = 10.5, 4.9 Hz, 1H, H-6), 4.04 – 3.96 (m, 3H, H-5, *CHHCF*<sub>3</sub>, *CHHCF*<sub>3</sub>), 3.81 – 3.71 (m, 3H, H-2, H-4, H-6); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.0 (C=0 *i*-Nico), 150.6 (CH<sub>arom</sub> *i*-Nico), 137.2, 137.2, 136.7 (C<sub>q</sub>), 132.4, 129.1, 128.5, 128.2, 128.0, 126.1, 123.6 (CH<sub>arom</sub>), (q, J = 279.8 Hz, CF<sub>3</sub>), 123.0 (CH<sub>arom</sub> *i*-Nico), 101.6 (CHPh), 98.2 (C-1), 79.0 (C-4), 76.9 (C-2), 72.8 (CH<sub>2</sub> Bn), 71.5 (C-3), 68.6 (C-6), 65.3 (q, J = 35.2 Hz, *CH*<sub>2</sub>CF<sub>3</sub>), 63.21 (C-5); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>): δ 98.2 (J<sub>C1,H1</sub> = 169.3 Hz, C-1 α); HRMS: [M+H]+ calcd for C<sub>28</sub>H<sub>27</sub>F<sub>3</sub>NO<sub>7</sub> 546.1734, found 546.1730.

Ethyl 2,4,6-tri-O-benzyl-3-picoloyl-n-mannopyranoside (S25). The title compound was prepared from donor 7 and ethanol using the general procedure for Tf2O/Ph2SO mediated glycosylations. Flash column chromatography ( $100:0 \rightarrow 60:40$ , pentane:EtOAc, v:v) yielded glycosylation product **S25** (33.8 mg, 0.058 mmol, 58%, α:β = 55:45). TLC:  $R_f$  0.65, (60:40, pentane:EtOAc, v:v); Data for the α-anomer:  ${}^{1}$ H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC):  $\delta$  8.79 (dt, J = 1.7, 0.9 Hz, 1H, CH<sub>arom</sub> Pico), 8.01 (dt, J = 7.8, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.79 (td, / = 7.8, 1.8 Hz, 1H, CH<sub>arom</sub> Pico), 7.66 - 7.63 (m, 2H, CH<sub>arom</sub>), 7.50 - 7.45 (m, 1H, CH<sub>arom</sub> Pico), 7.46 - 7.42  $(m, 2H, CH_{arom}), 7.40 - 6.98 (m, 11H, CH_{arom}), 5.57 (dd, J = 9.5, 3.4 Hz, 1H, H-3), 4.94 (d, J = 12.6 Hz, 1H, CHH Bn),$ 4.93 (d, / = 2.0 Hz, 1H, H-1), 4.76 (d, / = 11.0 Hz, 1H, CHH Bn), 4.75 (d, / = 11.0 Hz, 1H, CHH Bn), 4.62 (d, / = 12.4 Hz, 1H, CHH Bn), 4.56 (d, J = 10.9 Hz, 1H, CHH Bn), 4.53 (d, J = 11.0 Hz, 1H, CHH Bn), 4.28 (t, J = 9.7 Hz, 1H, H-4), 4.00 (dd, J = 3.5, 1.9 Hz, 1H, H-2), 3.91 (ddd, J = 9.8, 4.5, 1.9 Hz, 1H, H-5), 3.84 (dd, J = 10.7, 4.2 Hz, 1H, H-6), 3.76 (dq, J = 9.7, 7.1 Hz, 1H, CHHCH<sub>3</sub> Et), 3.74 (dd, J = 10.8, 1.9 Hz, 1H, H-6), 3.49 (dq, J = 9.7, 7.0 Hz, 1H, CHHCH<sub>3</sub> Et),1.20 (t, / = 7.1 Hz, 3H, CH<sub>3</sub> Et); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.3 (C=O Pico), 150.1 (CH<sub>arom</sub> Pico), 148.1, 138.5, 138.4, 138.1 (Cq), 136.9 (CH<sub>arom</sub> Pico), 131.2, 129.4, 128.5, 128.4, 128.3, 128.1, 128.0, 128.0, 127.7 (CH<sub>arom</sub>), 126.9, 125.3 (CH<sub>arom</sub> Pico), 97.7 (C-1), 76.0 (C-2), 75.7 (C-3), 75.0 (CH<sub>2</sub> Bn), 74.6 (CH<sub>2</sub> Bn), 73.6 (C-4), 73.0 (CH<sub>2</sub> Bn), 71.5 (C-5), 69.1 (C-6), 63.3 (CH<sub>2</sub>CH<sub>3</sub> Et), 15.1 (CH<sub>3</sub> Et); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>): δ 97.7 (J<sub>C1,H1</sub> = 168.8 Hz, C-1 α); Diagnostic peaks β-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.79 (dt, J = 1.7, 0.9 Hz, 1H, CH<sub>arom</sub> Pico), 7.92 (dt, J = 7.8, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.78 (td, J = 7.7, 1.7 Hz, 1H, CHarom Pico), 7.66 - 7.63 (m, 2H, CHarom), 7.49 - 7.46 (m, 1H, CHarom Pico), 7.46 - 6.97 (m, 13H, CHarom), 5.13 (dd, J = 9.8, 3.3 Hz, 1H, H-3), 4.76 (d, J = 11.0 Hz, 1H, CHH Bn), 4.71 (d, J = 12.4 Hz, 1H, CHH Bn), 4.68 (d, J = 11.4 Hz, 1H, CHH Bn), 4.62 (d, J = 12.4 Hz, 1H, CHH Bn), 4.62 (d, J = 0.8 Hz, 1H, H-1), 4.58 (d, J = 12.0 Hz, 1H, CHH Bn), 4.56 (d, J = 10.9 Hz, 1H, CHH Bn), 4.18 (t, J = 9.7 Hz, 1H, H-4), 4.04 (dq, J = 9.4, 7.1 Hz, 1H, CHHCH<sub>3</sub> Et), 4.00 (dd, J = 3.5, 1.9 Hz, 1H, H-2, 3.84 (dd, J = 10.7, 4.2 Hz, 1H, H-6), 3.81 (dd, J = 10.8, 5.2 Hz, 1H, H-6), 3.60 – 3.56 (m, 2H, CHHCH<sub>3</sub> Et); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.2 (C=0 Pico), 150.1 (CH<sub>arom</sub> Pico), 147.8, 138.4, 138.2, 138.1 (C<sub>q</sub>), 136.9 (CH<sub>arom</sub> Pico), 128.4, 128.3, 128.0, 127.7, 127.6, 127.6, 127.4 (CH<sub>arom</sub>), 127.0, 125.4 (CH<sub>arom</sub> Pico), 101.1 (C-1), 77.5 (C-3), 75.8 (C-5), 75.0 (CH<sub>2</sub> Bn), 74.9 (CH<sub>2</sub> Bn), 73.7 (CH<sub>2</sub> Bn), 73.6 (C-2), 73.5 (C-4), 69.5 (C-6), 65.6 ( $CH_2CH_3$ ), 15.4 ( $CH_3$  Et); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>):  $\delta$  101.1 ( $J_{C1,H1}$  = 155.1 Hz, C-1 β); HRMS: [M+H]+ calcd for C<sub>35</sub>H<sub>38</sub>NO<sub>7</sub> 584.2643, found 584.2635.

**2-Fluoroethyl 2,4,6-tri-***0***-benzyl-3-picoloyl-n-mannopyranoside (S26)**. The title compound was prepared from donor **7** and 2-fluoroethanol using the general procedure for Tf<sub>2</sub>0/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0  $\rightarrow$  60:40, pentane:EtOAc, v:v) yielded glycosylation product **S26** (19.2 mg, 0.032 mmol, 32%, α:β = 55:45). TLC: R<sub>f</sub> 0.52, (60:40, pentane:EtOAc, v:v); Data for the α-anomer: <sup>1</sup>H NMR (850)

MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.80 (dd, J = 1.7, 0.8 Hz, 1H, CH<sub>arom</sub> Pico), 8.00 (dt, J = 7.8, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.79 (td. / = 7.9, 1.8 Hz, 1H, CH<sub>arom</sub> Pico), 7.51 - 7.43 (m, 1H, CH<sub>arom</sub> Pico), 7.39 - 6.98 (m, 15H, CH<sub>arom</sub>), 5.56 (dd, / = 9.4, 3.4 Hz, 1H, H-3), 4.98 (d, / = 2.0 Hz, 1H, H-1), 4.93 (d, / = 12.4 Hz, 1H, CHH Bn), 4.76 (d, J = 11.0 Hz, 1H, CHH Bn), 4.76 (d, J = 11.0 Hz, 1H, CHH Bn), 4.68 – 4.66 (m, 1H, CHHCH<sub>2</sub>F), 4.62 (d, J = 12.3 Hz, 1H, CHH Bn), 4.61 - 4.57 (m, 1H, CHHCH<sub>2</sub>F), 4.56 (d, I = 11.1 Hz, 1H, CHH Bn), 4.53 (d, I = 12.2 Hz, 1H, CHH Bn), 4.28 (t, *J* = 9.6 Hz, 1H, H-4), 4.06 (dd, *J* = 3.5, 2.0 Hz, 1H, H-2), 3.93 (ddd, *J* = 9.7, 4.4, 1.9 Hz, 1H, H-5), 3.91 – 3.83 (m, 1H, CH<sub>2</sub>CHHF), 3.82 (t, *I* = 5.6 Hz, 1H, H-6), 3.80 – 3.75 (m, 1H, CH<sub>2</sub>CHHF), 3.74 (dd, *I* = 10.9, 2.0 Hz, 1H, H-6) 6); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.3 (C=0 Pico), 150.1 (CH<sub>arom Pico</sub>, 148.1 (C<sub>q</sub>), 138.3, 138.2, 138.0 (Cq), 137.0 (CH<sub>arom</sub> Pico), 128.6, 128.5, 128.4, 128.1, 128.0, 127.8, 127.8, 127.7, 127.5 (CH<sub>arom</sub>), 127.0, 125.4 (CH<sub>arom</sub> Pico), 98.4 (C-1), 82.6 (d, I = 169.9 Hz, CH<sub>2</sub>CH<sub>2</sub>F), 75.8 (C-2), 75.4 (C-3), 74.9 (CH<sub>2</sub>Bn), 73.7 (CH<sub>2</sub>Bn), 75.7 (CH<sub>2</sub>Bn), 75.8 (C-2), 75.4 (C-3), 74.9 (CH<sub>2</sub>Bn), 75.7 (CH<sub>2</sub>Bn), 75.8 (C-2), 75.8 (C-3), 75.8 (C-3), 74.9 (CH<sub>2</sub>Bn), 75.7 (CH<sub>2</sub>Bn), 75.8 (C-3), 75.8 (C Bn), 73.5 (C-4), 73.1 (CH<sub>2</sub> Bn), 71.7 (C-5), 69.0 (C-6), 66.8 (d, *J* = 20.2 Hz, CH<sub>2</sub>CH<sub>2</sub>F); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>):  $\delta$  98.4 ( $I_{CLH1}$  = 169.9 Hz, C-1  $\alpha$ ); Diagnostic peaks  $\beta$ -anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSOC, HMBC):  $\delta$  8.79 (dd, J = 1.7, 0.8 Hz, 1H, CH<sub>arom</sub> Pico), 7.93 (dd, J = 7.9, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.78 (td, J = 7.9, 1.8 Hz, 1H, CH<sub>arom</sub> Pico), 7.48 (ddd, J = 7.7, 4.7, 1.2 Hz, 1H, CH<sub>arom</sub> Pico), 7.40 - 6.97 (m, 15H, CH<sub>arom</sub>), 5.13 (dd, J = 9.7, 3.4 Hz, 1H, H-3), 4.69 (d, I = 3.0 Hz, 1H, H-1), 4.20 (t, I = 9.7 Hz, 1H, H-4), 4.18 – 4.17 (m, 1H, H-6), 4.13 (ddd, I = 12.2, 4.4, 2.5 Hz, 1H, CHHCH<sub>2</sub>F), 3.82 - 3.81 (m, 1H, H-6), 3.58 (ddd, I = 9.6, 4.5, 2.8 Hz, 1H, H-5); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.2 (C=0 Pico), 150.1 (CH<sub>arom</sub> Pico), 147.7, 138.3, 138.3, 138.0 (C<sub>0</sub>), 136.9 (CH<sub>arom</sub> Pico), 128.5, 128.4, 128.3, 128.1, 127.7 (CH<sub>arom</sub>), 127.0, 125.4 (CH<sub>arom</sub> Pico), 101.4 (C-1), 82.9 (d, J = 169.7 Hz, CH<sub>2</sub>CH<sub>2</sub>F), 77.2 (C-3), 75.7 (C-5), 75.0 (CH<sub>2</sub> Bn), 74.8 (C-2), 74.7 (CH<sub>2</sub> Bn), 73.6 (CH<sub>2</sub> Bn), 73.3 (C-2), 74.7 (CH<sub>2</sub> Bn), 73.6 (CH<sub>2</sub> Bn), 73.6 (CH<sub>2</sub> Bn), 73.8 (C-2), 74.7 (CH<sub>2</sub> Bn), 73.8 (CH<sub>2</sub> Bn), 74.8 (C-2), 74.7 (CH<sub>2</sub> Bn), 74.8 (C-2), 74.7 (CH<sub>2</sub> Bn), 73.8 (CH<sub>2</sub> Bn), 73.8 (CH<sub>2</sub> Bn), 74.8 (C-2), 74.7 (CH<sub>2</sub> Bn), 74.8 (C-2), 74.7 (CH<sub>2</sub> Bn), 73.8 (CH<sub>2</sub> Bn), 73.8 (CH<sub>2</sub> Bn), 73.8 (CH<sub>2</sub> Bn), 74.8 (CH<sub>2</sub> Bn), 74 4), 69.4 (C-6), 68.9 (d, J = 19.9 Hz, CH<sub>2</sub>CH<sub>2</sub>F); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>): δ 101.4 (J<sub>C1,H1</sub> = 155.8 Hz, C-1 β); HRMS: [M+H]+ calcd for C<sub>35</sub>H<sub>37</sub>FNO<sub>7</sub> 602.2549, found 602.2544.

2,2-Difluoroethyl 2,4,6-tri-0-benzyl-3-picoloyl-p-mannopyranoside (S27). The title compound was prepared from donor 7 and 2,2-difluoroethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography ( $100:0 \rightarrow 60:40$ , pentane:EtOAc, v:v) yielded glycosylation product **S27** (29.7 mg, 0.048 mmol, 48%,  $\alpha:\beta = 50.50$ ). TLC:  $R_f$  0.65, (60:40, pentane:EtOAc, v:v); Data for the α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.79 (dt, J = 1.8, 0.8 Hz, 1H, CH<sub>arom</sub> Pico), 8.00 (dt, J = 7.8, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.80 (td, J = 7.6, 1.8 Hz, 1H, CH<sub>arom</sub> Pico), 7.51 - 7.44 (m, 1H, CH<sub>arom</sub> Pico), 7.40 - 6.97 (m, 15H, CH<sub>arom</sub>), 5.93 (tdd, J = 55.3, 4.9, 3.7 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.51 (dd, J = 9.2, 3.4 Hz, 1H, 1H-3), 1.96(d, J = 2.1 Hz, 1H, H-1), 4.89 (d, J = 12.4 Hz, 1H, CHH Bn), 4.77 (d, J = 11.1 Hz, 1H, CHH Bn), 4.69 (d, J = 12.1 Hz, 1H, CHH Bn)1H, CHH Bn), 4.63 (d, J = 12.3 Hz, 1H, CHH Bn), 4.58 - 4.51 (m, 2H, CHH Bn), CHH Bn), 4.27 (t, J = 9.5 Hz, 1H, H-4), 4.06 (dd, *J* = 3.5, 2.0 Hz, 1H, H-2), 3.90 (ddd, *J* = 9.8, 4.7, 2.0 Hz, 1H, H-5), 3.87 – 3.83 (m, 1H, CHHCHF<sub>2</sub>), 3.82 -3.78 (m, 1H, H-6), 3.77 - 3.74 (m, 1H, CHHCHF<sub>2</sub>), 3.73 (dd, J = 10.8, 1.9 Hz, 1H, H-6);  $^{13}$ C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.4 (C=O Pico), 150.2 (CH<sub>arom</sub> Pico), 148.0, 138.2, 138.1, 137.9 (C<sub>q</sub>), 137.0 (CH<sub>arom</sub> Pico), 128.5, 128.4, 128.1, 128.1, 128.0, 128.0, 127.9, 127.8, 127.6 (CH<sub>arom</sub>), 127.1, 125.4 (CH<sub>arom</sub> Pico), 114.1 (t, J = 241.2 Hz, CH<sub>2</sub>CHF<sub>2</sub>), 98.9 (C-1), 75.4 (C-2), 75.0 (C-3), 74.8 (CH<sub>2</sub> Bn), 74.7 (CH<sub>2</sub> Bn), 73.6 (CH<sub>2</sub> Bn), 73.3 (C-4), 72.1 (C-5), 69.2 (C-6), 67.0 (t, J = 28.8 Hz,  $CH_2CHF_2$ );  $^{13}C$ -GATED NMR (214 MHz,  $CDCl_3$ ):  $89.9 (J_{C1,H1} = 169.5)$ Hz, C-1 α); Diagnostic peaks β-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.79 (dt, J = 1.8, 0.8 Hz, 1H, CH<sub>arom</sub> Pico), 7.93 (dt, J = 7.8, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.79 (td, J = 7.6, 1.8 Hz, 1H, CH<sub>arom</sub> Pico), 7.48 (ddd, J = 7.7, 4.7, 1.2 Hz, 1H, CH<sub>arom</sub> Pico), 7.39 - 6.97 (m, 15H, CH<sub>arom</sub>), 5.96 (dddd, J = 54.9, 56.1, 5.3, 3.0 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.12 (dd, J = 9.7, 3.3 Hz, 1H, H-3), 4.77 (d, J = 11.0 Hz, 1H, CHH Bn), 4.68 (d, J = 0.9 Hz, 1H, H-1), 4.65 (d, J = 12.4 Hz, 1H, CHH Bn), 4.20 (t, J = 9.7 Hz, 1H, H-4), 4.17 (dd, J = 3.4, 0.8 Hz, 1H, H-2), 3.83 – 3.79 (m, 1H, H-6), 3.59 - 3.57 (m, 1H, H-5); 13C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): 8 164.2 (C=0 Pico), 150.2 (CH<sub>arom</sub> Pico), 147.7, 138.2, 138.0, 137.7 (Cq), 136.9 (CH<sub>arom</sub> Pico), 128.5, 128.5, 128.4, 128.4, 128.1, 128.1, 128.0, 128.0, 127.8 (CH<sub>arom</sub>), 127.0, 125.4 (CH<sub>arom</sub> Pico), 114.3 (dd, J = 242.3, 239.6 Hz, CH<sub>2</sub>CHF<sub>2</sub>), 101.5 (C-1), 77.1 (C-3), 75.9 (C-5), 75.1 (CH<sub>2</sub> Bn), 74.6 (C-2), 73.7 (CH<sub>2</sub> Bn), 73.2 (CH<sub>2</sub> Bn), 73.1 (C-4), 68.9 (C-6), 68.6 (dd, J = 30.9, 26.3 Hz, CH<sub>2</sub>CHF<sub>2</sub>); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>):  $\delta$  101.5 ( $f_{C1,H1}$  = 156.6 Hz, C-1  $\beta$ ); HRMS: [M+H]+ calcd for C<sub>35</sub>H<sub>36</sub>F<sub>2</sub>NO<sub>7</sub> 620.2454, found 620.2451.

**2,2,2-Trifluoroethyl 2,4,6-tri-0-benzyl-3-picoloyl-p-mannopyranoside** (S28). The title compound was prepared from donor **7** and 2,2,2-trifluoroethanol using the general procedure for  $Tf_2O/Ph_2SO$  mediated glycosylations. Flash column chromatography ( $100:0 \rightarrow 60:40$ , pentane:EtOAc, v:v) yielded glycosylation product **S28** (35.7 mg, 0.056 mmol, 56%,  $\alpha$ : $\beta$  = 31:69). TLC:  $R_f$  0.74, (60:40, pentane:EtOAc, v:v); Data for the  $\beta$ -anomer:  $^1$ H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC):  $\delta$  8.79 (ddd, f = 4.8, 1.8, 0.9 Hz, 1H, CH<sub>arom</sub> Pico),

7.94 (dt, J = 7.8, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.79 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.68 – 7.62 (m, 1H, CH<sub>arom</sub> Pico), 7.68 – 7.62 (m, 1H, CH<sub>arom</sub> Pico), 7.68 – 7.62 (m, 1H, CH<sub>arom</sub> Pico), 7.79 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.68 – 7.62 (m, 1H, CH<sub>arom</sub> Pico), 7.79 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.68 – 7.62 (m, 1H, CH<sub>arom</sub> Pico), 7.79 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.68 – 7.62 (m, 1H, CH<sub>arom</sub> Pico), 7.79 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.68 – 7.62 (m, 1H, CH<sub>arom</sub> Pico), 7.79 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.79 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.68 – 7.62 (m, 1H, CH<sub>arom</sub> Pico), 7.79 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.79 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.79 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, Th), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, Th), 7.70 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, Pico), 7.53 - 6.99 (m, 15H,  $CH_{arom}$ ), 5.13 (dd, J = 9.7, 3.3 Hz, 1H, H-3), 4.90 (d, J = 12.4 Hz, 1H, CHH Bn), 4.77 (d, J = 1.00) = 11.0 Hz, 1H, CHH Bn), 4.73 (d, / = 0.9 Hz, 1H, H-1), 4.67 (d, / = 12.3 Hz, 1H, CHH Bn), 4.66 (d, / = 12.6 Hz, 1H, CHH Bn), 4.57 (d, J = 11.0 Hz, 1H, CHH Bn), 4.56 (d, J = 12.0 Hz, 1H, CHH Bn), 4.30 - 4.23 (m, 1H, CHHCF<sub>3</sub>), 4.21 (t, I = 9.6 Hz, 1H, H-4), 4.18 (dd, I = 3.4, 0.9 Hz, 1H, H-2), 3.97 (ddd, I = 16.6, 8.3, 3.7 Hz, 1H, CHHCF<sub>3</sub>), 3.84 - 3.78(m, 2H, H-6, H-6), 3.58 (ddd, I = 9.6, 4.5, 2.8 Hz, 1H, H-5);  ${}^{13}$ C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC):  $\delta$  164.1 (C=0 Pico), 150.1 (CH<sub>arom</sub> Pico), 147.6, 138.2, 137.9, 137.9 (C<sub>q</sub>), 136.9 (CH<sub>arom</sub> Pico), 131.2, 129.4, 128.6, 128.5, 128.4, 128.1, 128.1, 128.0, 127.8 (CH<sub>arom</sub>), 127.1, 125.4 (CH<sub>arom</sub> Pico), 123.8 (q, J = 278.1 Hz, CH<sub>2</sub>CF<sub>3</sub>), 101.0 (C-1), 76.8 (C-3), 76.0 (C-5), 75.1 (CH<sub>2</sub> Bn), 74.7 (CH<sub>2</sub> Bn), 74.2 (C-2), 73.7 (CH<sub>2</sub> Bn), 73.0 (C-4), 69.1 (C-6), 66.1 (q. I = 34.8 Hz,  $CH_2$ CF<sub>3</sub>): <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>): δ 101.0 ( $I_{C1,H1} = 157.6$  Hz, C-1 β): Diagnostic peaks αanomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.79 (ddd, / = 4.8, 1.8, 0.9 Hz, 1H, CH<sub>arom</sub> Pico), 8.01 (dt, J = 7.9, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.79 (ddd, J = 7.7, 2.4, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.66 – 7.62 (m, 1H, CH<sub>arom</sub> Pico) Pico), 7.48 - 6.99 (m, 15H, CH<sub>arom</sub>), 5.53 (dd, I = 9.0, 3.4 Hz, 1H, H-3), 5.01 (d, I = 2.1 Hz, 1H, H-1), 4.78 (d, I = 2.1 Hz, 1H, H-1), 11.0 Hz, 1H, CHH Bn), 4.68 (d, J = 12.4 Hz, 1H, CHH Bn), 4.68 (d, J = 12.1 Hz, 1H, CHH Bn), 4.65 (d, J = 12.3 Hz, 1H, CH/HBn), 4.54 (d, J = 11.0 Hz, 1H, CH/HBn), 4.51 (d, J = 12.0 Hz, 1H, CH/HBn), 4.28 (t, J = 9.4 Hz, 1H, H-4), 4.09(dd, / = 3.4, 2.1 Hz, 1H, H-2), 3.88 (ddd, / = 9.8, 4.5, 1.9 Hz, 1H, H-5), 3.81 (dd, / = 3.8, 1.6 Hz, 1H, H-6), 3.72 (dd, / = 10.9, 2.0 Hz, 1H, H-6); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.4 (C=O Pico), 150.1 (CH<sub>arom</sub> Pico), 147.9, 138.2, 138.0, 137.6 (C<sub>a</sub>), 137.0 (CH<sub>arom</sub>), 131.2, 129.4, 128.5, 128.4, 128.4, 128.1, 128.0, 128.0, 127.6 (CH<sub>arom</sub>), 127.0, 125.4 (CH<sub>arom</sub> Pico), 123.8 (q, J = 278.1 Hz, CH<sub>2</sub>CF<sub>3</sub>), 98.8 (C-1), 75.2 (C-2), 74.8 (C-3), 74.8 (CH<sub>2</sub>CF<sub>3</sub>) Bn), 73.6 (CH<sub>2</sub> Bn), 73.2 (CH<sub>2</sub> Bn), 73.2 (C-4), 72.3 (C-5), 68.8 (C-6), 64.3 (q, J = 35.0 Hz, CH<sub>2</sub>CF<sub>3</sub>); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>);  $\delta$  98.8 ( $I_{C1\,H1}$  = 171.3 Hz, C-1  $\alpha$ ); HRMS; [M+H]+ calcd for C<sub>35</sub>H<sub>35</sub>F<sub>3</sub>NO<sub>7</sub> 638,2360, found 638.2355.

Ethyl 2,4,6-tri-0-benzyl-3-nicotinoyl-p-mannopyranoside (S29). The title compound was prepared from donor 8 and ethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0 → 60:40, pentane:EtOAc, v:v) yielded glycosylation product **S29** (30.9 mg, 0.053 mmol, 53%,  $\alpha:\beta = 85:15$ ]. TLC: R<sub>f</sub> 0.68, (60:40, pentane: EtOAc, v:v); Data for the  $\alpha$ -anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSOC, HMBC): δ 9.16 (dd, I = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.78 (dd, I = 4.8, 1.7 Hz, 1H, CH<sub>arom</sub> Nico), 8.16 (dt, / = 7.9, 2.0 Hz, 1H, CH<sub>arom</sub> Nico), 7.48 - 7.37 (m, 2H, CH<sub>arom</sub>), 7.35 (ddd, / = 7.9, 4.8, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 7.30 - 7.00 (m, 13H,  $CH_{arom}$ ), 5.52 (dd, J = 9.6, 3.4 Hz, 1H, H-3), 4.95 (d, J = 1.9 Hz, 1H, H-1), 4.73 (d, J = 1.9 Hz, 1H, H-1) 12.0 Hz, 1H, CHH Bn), 4.68 (d, J = 12.3 Hz, 1H, CHH Bn), 4.60 (d, J = 11.2 Hz, 1H, CHH Bn), 4.55 (d, J = 12.0 Hz, 1H, CHH Bn), 4.53 (d, J = 11.2 Hz, 1H, CHH Bn), 4.52 (d, J = 12.7 Hz, 1H, CHH Bn), 4.22 (t, J = 9.7 Hz, 1H, H-4), 3.96 (dd. / = 3.5, 1.9 Hz, 1H, H-2), 3.90 (ddd. / = 9.8, 4.4, 1.9 Hz, 1H, H-5), 3.84 (dd. / = 10.9, 4.4 Hz, 1H, H-6), 3.77  $(dq, J = 9.6, 7.1 Hz, 1H, CHHCH_3 Et), 3.74 (dd, J = 10.9, 1.9 Hz, 1H, H-6), 3.50 (dq, J = 9.6, 7.0 Hz, 1H, CHHCH_3 Et),$ 1.21 (t, J = 7.1 Hz, 3H, CH<sub>3</sub> Et); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.5 (C=0 Nico), 153.6, 151.1 (CH<sub>arom</sub> Nico), 138.3, 138.0, 137.9 (Cq), 137.2 (CH<sub>arom</sub> Nico), 128.5, 128.4, 128.4, 128.1, 127.9, 127.8, 127.8, 127.8, 127.7 (CH<sub>arom</sub>), 126.08 (C<sub>q</sub>), 123.4 (CH<sub>arom</sub> Nico), 97.6 (C-1), 76.2 (C-2), 75.1 (C-3), 75.0 (CH<sub>2</sub> Bn), 73.8 (C-4), 73.7 (CH<sub>2</sub> Bn), 73.0 (CH<sub>2</sub> Bn), 71.6 (C-5), 69.0 (C-6), 63.4 (CH<sub>2</sub>CH<sub>3</sub> Et), 15.1 (CH<sub>3</sub> Et); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>):  $\delta$  97.6 ( $I_{CLH1}$  = 168.5 Hz, C-1  $\alpha$ ); Diagnostic peaks  $\beta$ -anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSOC, HMBC):  $\delta$  9.09 (dd, J = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.78 (dd, J = 4.8, 1.7 Hz, 1H, CH<sub>arom</sub> Nico), 8.09 (dt, J = 7.9, 1.9 Hz, 1H, CH<sub>arom</sub> Nico), 7.67 - 7.63 (m, 1H, CH<sub>arom</sub> Nico), 7.39 - 7.01 (m, 15H, CH<sub>arom</sub>), 5.08 (dd, *J* = 9.7, 3.3 Hz, 1H, H-3), 4.69 (d, J = 12.0 Hz, 1H, CHH Bn), 4.61 (d, J = 0.9 Hz, 1H, H-1), 4.55 (d, J = 11.1 Hz, 1H, CHH Bn), 4.12 (t, J = 9.7 Hz, 1H, H-4), 4.08 (dd, J = 3.4, 0.8 Hz, 1H, H-2), 4.05 (dq, J = 9.5, 7.1 Hz, 1H, CHHCH<sub>3</sub> Et), 3.83 – 3.81 (m, 1H, H-6), 3.59 (dq, J = 9.7, 7.2 Hz, 1H, CHHCH $_3$  Et), 3.56 (ddd, J = 9.5, 4.7, 2.7 Hz, 1H, H-5);  $^{13}$ C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.4 (C=0 Nico), 153.6, 151.1 (CH<sub>arom</sub> Nico), 138.4, 138.4, 137.9 (C<sub>q</sub>), 137.2 (CH<sub>arom</sub> Nico), 129.5, 128.4, 128.2, 128.1, 127.5 (CH<sub>arom</sub>), 125.8 (C<sub>q</sub>), 123.3 (CH<sub>arom</sub> Nico), 101.1 (C-1), 76.9 (C-1) 3), 75.8 (C-5), 75.3 (C-2), 74.7 (CH<sub>2</sub> Bn), 73.6 (C-4), 69.4 (C-6), 65.7 (CH<sub>2</sub>CH<sub>3</sub> Et), 15.4 (CH<sub>3</sub> Et); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>): δ 101.1 (J<sub>C1,H1</sub> = 154.1 Hz, C-1 β); HRMS: [M+H]+ calcd for C<sub>35</sub>H<sub>38</sub>NO<sub>7</sub> 584.2643, found 584.2638.

**2-Fluoroethyl 2,4,6-tri-0-benzyl-3-nicotinoyl-p-mannopyranoside** (S30). The title compound was prepared from donor **8** and 2-fluoroethanol using the general procedure for  $Tf_2O/Ph_2SO$  mediated glycosylations. Flash column chromatography (100:0  $\rightarrow$  60:40, pentane:EtOAc, v:v) yielded glycosylation product S30 (36.1 mg, 0.060 mmol, 60%, α:β = 85:15). TLC:  $R_f$  0.55, (60:40, pentane:EtOAc, v:v); Data for the

α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 9.18 (dd, J = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.81  $(dd, J = 4.8, 1.7 Hz, 1H, CH_{arom} Nico), 8.19 (ddd, J = 7.9, 2.2, 1.7 Hz, 1H, CH_{arom} Nico), 7.42 - 7.38 (m, 1H, CH_{arom}), 7.42 - 7.38 (m, 1H, CH_{aro$ 7.38 (ddd, J = 7.9, 4.8, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 7.33 - 6.98 (m, 14H, CH<sub>arom</sub>), 5.54 (dd, J = 9.5, 3.4 Hz, 1H, H-3), 5.02 (d, J = 1.9 Hz, 1H, H-1), 4.75 (d, J = 12.0 Hz, 1H, CHH Bn), 4.71 (d, J = 12.2 Hz, 1H, CHH Bn), 4.63 (d, J = 11.1Hz, 1H, CHH Bn), 4.62 - 4.58 (m, 2H, CH<sub>2</sub>CH<sub>2</sub>F), 4.57 (d, I = 11.0 Hz, 1H, CHH Bn), 4.55 (d, I = 12.1 Hz, 1H, CHH Bn), 4.55 (d, / = 11.3 Hz, 1H, CHH Bn), 4.25 (t, / = 9.6 Hz, 1H, H-4), 4.06 (dd, / = 3.5, 1.9 Hz, 1H, H-2), 3.95 (ddd, / = 10.0, 4.4, 2.0 Hz, 1H, H-5), 3.94 (dddd, / = 31.3, 12.3, 5.1, 2.8 Hz, 1H, CHHCH<sub>2</sub>F), <math>3.86 (dd, / = 10.9, 4.5 Hz, 1H, CHHCH<sub>2</sub>F)H-6), 3.79 (dddd, J = 27.4, 12.2, 6.1, 2.9 Hz, 1H, CHHCH<sub>2</sub>F), 3.76 (dd, J = 10.9, 1.9 Hz, 1H, H-6); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.3 (C=0 Nico), 153.5, 151.0 (CH<sub>arom</sub> Nico), 138.2, 137.8, 137.6 (C<sub>q</sub>), 137.1, 128.4, 128.3, 128.3, 127.9, 127.8, 127.8, 127.7, 127.7, 127.7 (CH<sub>arom</sub>), 125.9 (C<sub>q</sub>), 123.3 (CH<sub>arom</sub> Nico), 98.1 (C-1), 82.5  $(d, I = 169.9 \text{ Hz}, CH_2CH_2F)$ , 75.8 (C-2), 74.8 (CH<sub>2</sub> Bn), 74.7 (C-3), 73.6 (CH<sub>2</sub> Bn), 73.5 (C-4), 73.0 (CH<sub>2</sub> Bn), 71.7 (C-5), 68.8 (C-6), 66.8 (d, J = 20.1 Hz,  $CH_2CH_2F$ ); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>):  $\delta$  98.1 ( $J_{C1,H1} = 169.8$  Hz, C-1 α); Diagnostic peaks β-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 9.12 (dd, / = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.81 (dd, J = 4.8, 1.7 Hz, 1H, CH<sub>arom</sub> Nico), 8.12 (ddd, J = 7.9, 2.2, 1.8 Hz, 1H, CH<sub>arom</sub> Nico), 7.37 (ddd, / = 7.9, 3.1, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 7.33 - 7.04 (m, 15H, CH<sub>arom</sub>), 5.11 (dd, / = 9.8, 3.4 Hz, 1H, H-3), 4.71 (d, J = 0.8 Hz, 1H, H-1), 4.18 (dddd, J = 34.3, 12.2, 4.2, 2.4 Hz, 1H, CHHCH<sub>2</sub>F), 4.17 (dd, J = 3.1, 0.7 Hz, 1H, H-2), 4.16 (t, J = 9.6 Hz, 1H, H-4), 3.88 (dddd, J = 23.9, 11.8, 4.3, 2.6 Hz, 1H,  $CHHCH_2F$ ), 3.60 (ddd, J = 9.5, 4.4, 3.0 Hz, 1H, H-5); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.3 (C=O Nico), 153.5, 151.0 (CH<sub>arom</sub> Nico), 138.2, 138.1, 137.7 (Cq), 137.1 (CH<sub>arom</sub> Nico), 128.4, 128.4, 128.1, 128.0, 127.7, 127.7, 127.5 (CH<sub>arom</sub>), 125.6 (Cq), 123.2  $(CH_{arom} Nico)$ , 101.3 (C-1), 82.8 (d, J = 169.7 Hz,  $CH_2CH_2F$ ), 76.5 (C-3), 75.7 (C-5), 75.0 (CH<sub>2</sub> Bn), 74.9 (C-2), 74.7  $(CH_2 Bn)$ , 73.6  $(CH_2 Bn)$ , 73.4 (C-4), 69.2 (C-6), 68.8  $(d_1 I = 19.8 Hz, CH_2 CH_2 F)$ ; <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>); δ 101.3 ( $J_{C1,H1}$  = 155.7 Hz, C-1 β); HRMS: [M+H]<sup>+</sup> calcd for C<sub>35</sub>H<sub>37</sub>FNO<sub>7</sub> 602.2549, found 602.2544.

2,2-Difluoroethyl 2,4,6-tri-0-benzyl-3-nicotinoyl-p-mannopyranoside (S31). The title compound was prepared from donor 8 and 2,2-difluoroethanol using the general procedure for Tf2O/Ph2SO mediated glycosylations. Flash column chromatography (100:0  $\rightarrow$  60:40, pentane:EtOAc, v:v) yielded glycosylation product **S31** (42.7 mg, 0.069 mmol, 69%,  $\alpha$ : $\beta$  = 85:15). TLC: R<sub>f</sub> 0.64, (60:40, pentane:EtOAc, v:v); Data for the α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 9.18 (dd, / = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.82 (dd, J = 4.8, 1.7 Hz, 1H, CH<sub>arom</sub> Nico), 8.19 (ddd, J = 7.9, 2.2, 1.8 Hz, 1H, CH<sub>arom</sub> Nico), 7.41 – 7.38 (m, 1H, CH<sub>arom</sub>), 7.38 (ddd, J = 7.9, 4.8, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 7.33 - 7.04 (m, 14H, CH<sub>arom</sub>), 5.96 (dd, J = 55.2, 4.8, 3.6 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.50 (dd, J = 9.3, 3.4 Hz, 1H, H-3), 5.01 (d, J = 2.1 Hz, 1H, H-1), 4.74 (d, J = 12.0 Hz, 1H, CHH Bn), 4.70 (d, *J* = 12.3 Hz, 1H, C*H*H Bn), 4.65 (d, *J* = 11.2 Hz, 1H, C*H*H Bn), 4.57 (d, *J* = 12.0 Hz, 1H, C*HH* Bn), 4.56 (d, *J* = 11.2 Hz, 1H, CHH Bn), 4.56 (d, / = 12.2 Hz, 1H, CHH Bn), 4.24 (t, / = 9.5 Hz, 1H, H-4), 4.06 (dd, / = 3.5, 2.0 Hz, 1H, H-2), 3.92 (ddd, J = 9.7, 4.5, 1.9 Hz, 1H, H-5), 3.90 - 3.87 (m, 1H, CHHCHF2), 3.85 (dd, J = 10.9, 4.5 Hz, 1H, H-6), 3.81 -3.78 (m, 1H, CHHCHF<sub>2</sub>), 3.76 (dd, J = 10.9, 2.0 Hz, 1H, H-6);  $^{13}$ C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC):  $\delta$ 164.5 (C=O Nico), 153.7, 151.1 (CH<sub>arom</sub> Nico), 138.1, 137.8, 137.5 (C<sub>a</sub>), 137.2 (CH<sub>arom</sub> Nico), 128.5, 128.5, 128.4,  $128.0, 128.0, 128.0, 127.8, 127.8, 127.8, (CH_{arom}), 125.9 (C_0), 123.4 (CH_{arom} Nico), 114.1 (t, J = 241.2 Hz, CH_2 CHF_2),$ 98.8 (C-1), 75.6 (C-2), 74.9 (CH<sub>2</sub> Bn), 74.4 (C-3), 73.7 (CH<sub>2</sub> Bn), 73.4 (C-4), 73.2 (CH<sub>2</sub> Bn), 72.1 (C-5), 68.8 (C-6), 66.9 (t, I = 28.6 Hz,  $CH_2CHF_2$ ); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>):  $\delta$  98.8 ( $I_{C1,H1} = 171.0$  Hz, C-1  $\alpha$ ); Diagnostic peaks β-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 9.13 (dd, *J* = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.82 (dd, J = 4.8, 1.7 Hz, 1H, CH<sub>arom</sub> Nico), 8.13 (ddd, J = 7.9, 2.2, 1.7 Hz, 1H, CH<sub>arom</sub> Nico), 7.41 - 7.06 (m, 16H,  $CH_{arom}$  Nico,  $CH_{arom}$ ), 6.00 (dddd, J = 56.3, 54.7, 5.4, 2.9 Hz, 1H,  $CH_2CHF_2$ ), 5.11 (dd, J = 9.8, 3.3 Hz, 1H, H-3), 4.70 (d, J = 1.0 Hz, 1H, H-1), 4.65 (d, J = 11.2 Hz, 1H, CHH Bn), 4.61 (d, J = 12.2 Hz, 1H, CHH Bn), 4.18 (t, J = 9.6 Hz, 1H, LH)H-4), 4.17 (dd, J = 3.3, 0.8 Hz, 1H, H-2), 4.15 – 4.08 (m, 1H, CHHCHF<sub>2</sub>), 3.60 (ddd, J = 9.5, 5.0, 2.3 Hz, 1H, H-5); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.4 (C=O Nico), 153.7, 151.1 (CH<sub>arom</sub> Nico), 138.2, 138.0, 137.7 (C<sub>q</sub>), 137.2 (CH<sub>arom</sub> Nico), 128.5, 128.5, 128.4, 128.2, 128.1, 127.9, 127.7 (CH<sub>arom</sub>), 125.6 (C<sub>q</sub>), 123.3 (CH<sub>arom</sub> Nico), 114.3 (d, / = 240.0, 242.8 Hz, CH<sub>2</sub>CHF<sub>2</sub>), 101.5 (C-1), 76.4 (C-3), 75.9 (C-5), 75.1 (CH<sub>2</sub> Bn), 74.9 (CH<sub>2</sub> Bn), 74.9 (C-2), 73.7 (CH<sub>2</sub> Bn), 73.2 (C-4), 69.1 (C-6), 68.6 (dd, J = 30.9, 26.1 Hz,  $CH_2CHF_2$ );  $^{13}C$ -GATED NMR (214) MHz, CDCl<sub>3</sub>):  $\delta$  101.5 ( $J_{C1,H1}$  = 157.0 Hz, C-1  $\beta$ ); HRMS: [M+H]<sup>+</sup> calcd for  $C_{35}H_{36}F_{2}NO_{7}$  620.2454, found 620.2450.

**2,2,2-Trifluoroethyl 2,4,6-tri-0-benzyl-3-nicotinoyl-n-mannopyranoside (S32)**. The title compound was prepared from donor **8** and 2,2,2-trifluoroethanol using the general procedure for  $Tf_2O/Ph_2SO$  mediated glycosylations. Flash column chromatography ( $100:0 \rightarrow 60:40$ , pentane:EtOAc, v:v) yielded glycosylation product **S32** (38.2 mg, 0.060 mmol, 60%,  $\alpha:\beta = 86:14$ ). TLC:  $R_f 0.73$ , (60:40, pentane:EtOAc, v:v); Data for the

α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSOC, HMBC): δ 9.15 (dd, / = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.79 (dd, / = 4.8, 1.7 Hz, 1H, CH<sub>arom</sub> Nico), 8.16 (ddd, / = 7.9, 2.2, 1.8 Hz, 1H, CH<sub>arom</sub> Nico), 7.47 - 7.42 (m, 1H, CH<sub>arom</sub>), 7.36 (ddd, J = 7.9, 4.8, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 7.33 - 7.04 (m, 14H, CH<sub>arom</sub>), 5.48 (dd, J = 9.2, 3.4 Hz, 1H, H-3), 5.02 (d, / = 2.1 Hz, 1H, H-1), 4.70 (d, / = 12.0 Hz, 1H, CHH Bn), 4.67 (d, / = 12.2 Hz, 1H, CHH Bn), 4.62 (d, / = 11.2 Hz, 1H CHH Bn), 4.54 (d, I = 12.4 Hz, 1H, CHH Bn), 4.53 (d, I = 11.3 Hz, 1H, CHH Bn), 4.53 (d, I = 12.0 Hz, 1H, CHH Bn), 4.22 (t, J = 9.4 Hz, 1H, H - 4), 4.06 (dd, J = 3.5, 2.1 Hz, 1H, H - 2), 3.99 (dq, J = 12.4, 8.8 Hz, 1H,  $CHHCF_3$ ), 3.93(dq, / = 12.4, 8.5 Hz, 1H, CHHCF<sub>3</sub>), 3.87 (ddd, / = 9.6, 4.3, 1.9 Hz, 1H, H-5), 3.81 (dd, / = 10.9, 4.4 Hz, 1H, H-6), 3.72 (dd, J = 10.9, 1.9 Hz, 1H, H-6); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSOC, HMBC): δ 164.4 (C=0 Nico), 153.7, 151.1 (CH<sub>arom</sub> Nico), 138.1, 137.7, 137.4 (Cq), 137.3 (CH<sub>arom</sub> Nico), 128.5, 128.5, 128.4, 128.0, 128.0, 128.0, 127.9, 127.9 (CH<sub>arom</sub>), 125.9 (C<sub>q</sub>), 123.8 (q, *J* = 278.5 Hz, CF<sub>3</sub>), 123.4 (CH<sub>arom</sub> Nico), 98.7 (C-1), 75.5 (C-2), 74.9 (CH<sub>2</sub> Bn), 74.2 (C-3), 73.7 (CH<sub>2</sub> Bn), 73.4 (C-4), 73.3 (CH<sub>2</sub> Bn), 72.4 (C-5), 68.7 (C-6), 64.4 (q, J = 35.0 Hz,  $CH_2CF_3$ );  $^{13}C$ -GATED NMR (214 MHz, CDCl<sub>3</sub>):  $\delta$  98.7 ( $I_{C1.H1}$  = 171.3 Hz, C-1  $\alpha$ ); Diagnostic peaks  $\beta$ -anomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 9.10 (dd, J = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.79 (dd, J = 4.8, 1.7 Hz, 1H, CH<sub>arom</sub> Nico), 8.10 (ddd, / = 7.9, 2.2, 1.8 Hz, 1H, CH<sub>arom</sub> Nico), 7.49 - 7.01 (m, 16H, CH<sub>arom</sub> Nico, CH<sub>arom</sub>), 5.08 (dd, / = 9.7, 3.3 Hz, 1H, H-3), 4.73 (d, I = 0.9 Hz, 1H, H-1), 4.15 (t, I = 9.7 Hz, 1H, H-4), 3.57 (ddd, I = 9.5, 5.0, 2.2 Hz, 1H, H-5);  $^{13}$ C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.4 (C=O Nico), 153.7, 151.1 (CH<sub>arom</sub> Nico), 138.2, 137.9, 137.7 (C<sub>0</sub>), 137.3 (CH<sub>arom</sub> Nico), 129.5, 128.5, 128.5, 128.1, 127.9, 127.8, 125.6 (CH<sub>arom</sub>), 124.9 (C<sub>0</sub>), 123.4 (CH<sub>arom</sub> Nico), 101.0 (C-1), 76.2 (C-3), 76.0 (C-5), 75.1 (CH<sub>2</sub> Bn), 74.8 (CH<sub>2</sub> Bn), 74.4 (C-2), 73.8 (CH<sub>2</sub> Bn), 73.2 (C-4), 69.0 (C-1), 76.2 (C-3), 76.2 (C-4), 69.0 (C-1), 76.2 (C-3), 76.2 (C-3), 76.2 (C-4), 69.0 (C-1), 76.2 (C-3), 76 6), 66.1 (g, I = 34.8 Hz,  $CH_2CF_3$ );  $^{13}C$ -GATED NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  101.0 ( $I_{C1,H1} = 157.4$  Hz, C-1  $\beta$ ); HRMS: [M+H]+ calcd for C<sub>35</sub>H<sub>35</sub>F<sub>3</sub>NO<sub>7</sub> 638.2360, found 638.2356.

Ethyl 2.4.6-tri-O-benzyl-3-isonicotinoyl-p-mannopyranoside (\$33). The title compound was prepared from donor 9 and ethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography ( $100:0 \rightarrow 60:40$ , pentane:EtOAc, v:v) yielded glycosylation product \$33 (26.8 mg, 0.046 mmol, 46%, α:β = 90:10). TLC: R<sub>f</sub> 0.68, (60:40, pentane: EtOAc, v:v); Data for the α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.89 – 8.60 (m, 1H, CH<sub>arom</sub> i-Nico), 7.79 – 7.64 (m, 1H, CH<sub>arom</sub> i-Nico), 7.53 – 6.89 (m, 15H,  $CH_{arom}$ ), 5.50 (dd, I = 9.6, 3.5 Hz, 1H, H-3), 4.95 (d, I = 1.9 Hz, 1H, H-1), 4.74 (d, I = 12.0 Hz, 1H, CHH Bn), 4.69 (d, / = 12.3 Hz, 1H, CHH Bn), 4.58 (d, / = 11.1 Hz, 1H, CHH Bn), 4.55 (d, / = 11.9 Hz, 1H, CHH Bn), 4.52 (d, / = 11.2 Hz, 1H, CHH Bn), 4.51 (d, I = 12.2 Hz, 1H, CHH Bn), 4.22 (t, I = 9.7 Hz, 1H, H-4), 3.95 (dd, I = 3.5, 1.9 Hz, 1H, H-2), 3.91 - 3.87 (ddd, J = 9.7, 4.3, 1.9 Hz, 1H, H-5), 3.85 (dd, J = 10.8, 4.3 Hz, 1H, H-6), 3.77 (dq, J = 9.7, 7.2 Hz, 1H, CHHCH3 Et), 3.74 (dd, J = 10.8, 1.9 Hz, 1H, H-6), 3.50 (dq, J = 9.6, 7.1 Hz, 1H, CHHCH3 Et), 1.21 (t, J = 7.1 Hz, 3H, CH<sub>3</sub> Et); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.2 (C=0 i-Nico), 150.6 (CH<sub>arom</sub> i-Nico), 138.2, 137.8, 137.8, 137.2 (Cq), 131.1, 129.4, 128.4, 128.3, 128.3, 128.0, 127.7, 127.7, 124.8 (CH<sub>arom</sub>), 122.9 (CH<sub>arom</sub> i-Nico), 97.4 (C-1), 76.1 (C-2), 75. (C-3), 74.9 (CH<sub>2</sub> Bn), 73.7 (CH<sub>2</sub> Bn), 73.6 (C-4), 72.9 (CH<sub>2</sub> Bn), 71.5 (C-5), 68.9 (C-6), 63.3 (CH<sub>2</sub>CH<sub>3</sub> Et), 15.0 (CH<sub>3</sub> Et);  $^{13}$ C-GATED NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  97.4 ( $f_{C1,H1}$  = 168.8 Hz, C-1  $\alpha$ ); Diagnostic peaks β-anomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.74 – 8.73 (m, 1H, CH<sub>arom</sub> i-Nico), 7.79 - 7.64 (m, 1H, CH<sub>arom</sub> i-Nico), 7.53 - 6.89 (m, 15H, CH<sub>arom</sub>), 5.06 (dd, J = 9.8, 3.4 Hz, 1H, H-3), 4.72 - $4.67 \text{ (m, 2H, CHH Bn, CHH Bn)}, 4.61 \text{ (d, } J = 0.8 \text{ Hz, 1H, H-1)}, 4.13 \text{ (t, } J = 9.7 \text{ Hz, 1H, H-4)}, 4.05 \text{ (dq, } J = 9.5, 7.1 \text{ Hz, } J = 9.7 \text{ Hz, 1H, H-4}, 4.05 \text{ (dq, } J = 9.5, 7.1 \text{ Hz, } J = 9.5 \text{ H$ 1H,  $CHHCH_3$  Et), 3.59 (dq, I = 9.4, 7.1 Hz, 1H,  $CHHCH_3$  Et), 3.56 (dt, I = 9.5, 3.6 Hz, 1H, H-5), 1.21 (t, I = 7.1 Hz, 3H, CH<sub>3</sub> Et); <sup>13</sup>C-APT NMR (101 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 101.0 (C-1), 75.7 (C-2), 75.2 (C-3), 75.0 (CH<sub>2</sub> Bn), 74.6 (CH<sub>2</sub> Bn), 73.7 (CH<sub>2</sub> Bn), 73.5 (C-4), 71.5 (C-5), 69.2 (C-6), 65.6 (CH<sub>2</sub>CH<sub>3</sub> Et), 15.0 (CH<sub>3</sub> Et); <sup>13</sup>C-GATED NMR (101 MHz, CDCl<sub>3</sub>): δ 101.0 (J<sub>C1,H1</sub> = 154.2 Hz, C-1 β); HRMS: [M+H]<sup>+</sup> calcd for C<sub>35</sub>H<sub>38</sub>NO<sub>7</sub> 584.2643, found 584.2641.

**2-Fluoroethyl 2,4,6-tri-***O***-benzyl-3-isonicotinoyl-p-mannopyranoside** (**S34**). The title compound was prepared from donor **9** and 2-fluoroethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0  $\rightarrow$  60:40, pentane:EtOAc, v:v) yielded glycosylation product **S34** (19.8 mg, 0.033 mmol, 33%, α:β = 88:12). TLC: R<sub>f</sub> 0.59, (60:40, pentane:EtOAc, v:v); Data for the α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.75 – 8.74 (m, 2H, CH<sub>arom</sub> *i*-Nico), 7.73 – 7.71 (m, 2H, CH<sub>arom</sub> *i*-Nico), 7.39 – 7.00 (m, 15H, CH<sub>arom</sub>), 5.50 (dd, *J* = 9.5, 3.5 Hz, 1H, H-3), 5.00 (d, *J* = 1.9 Hz, 1H, H-1), 4.73 (d, *J* = 12.0 Hz, 1H, CHH Bn), 4.69 (d, *J* = 12.3 Hz, 1H, CHH Bn), 4.62 – 4.59 (m, 1H, CH<sub>2</sub>CHHF), 4.58 (d, *J* = 11.1 Hz, 1H, CHH Bn), 4.54 (d, *J* = 12.2 Hz, 1H, CHH Bn), 4.51 (d, *J* = 12.3 Hz, 1H, CHH Bn), 4.51 (d, *J* = 12.3 Hz, 1H, CHH Bn), 4.51 (d, *J* = 12.3 Hz, 1H, CHH Bn), 4.51 (d, *J* = 12.3 Hz, 1H, H-4), 4.02 (dd, *J* = 3.5, 1.9 Hz, 1H, H-2), 3.92 (ddd, *J* = 10.0, 4.5, 2.2 Hz, 1H, H-5), 3.91 (dddd, *J* = 31.3, 12.2, 5.1, 2.7 Hz, 1H, CHHCH<sub>2</sub>F), 3.84 (dd, *J* = 10.9, 4.3

Hz, 1H, H-6), 3.78 (dddd, J = 27.4, 12.2, 6.0, 2.9 Hz, 1H, CHHCH $_2$ F), 3.74 (dd, J = 10.9, 1.9 Hz, 1H, H-6);  $^{13}$ C-APT NMR (214 MHz, CDCl $_3$ , HSQC, HMBC): δ 164.3 (C=0 i-Nico), 150.7 (CH $_{arom}$  i-Nico), 138.3, 137.9, 137.8, 137.2 (C $_0$ ), 128.5, 128.5, 128.5, 128.1, 128.0, 127.9, 127.9, 127.9, 127.8 (CH $_{arom}$ ), 123.0 (CH $_{arom}$  i-Nico), 98.2 (C-1), 82.6 (d, J = 170.0 Hz, CH $_2$ CH $_2$ F), 75.9 (C-2), 75.1 (C-3), 74.9 (CH $_2$  Bn), 73.7 (CH $_2$  Bn), 73.6 (C-4), 73.1 (CH $_2$  Bn), 71.8 (C-5), 68.9 (C-6), 66.9 (d, J = 20.1 Hz, CH $_2$ CH $_2$ F);  $^{13}$ C-GATED NMR (214 MHz, CDCl $_3$ ): δ 98.2 (JC<sub>1,H1</sub> = 169.8 Hz, C-1α); Diagnostic peaks β-anomer:  $^{14}$ H NMR (850 MHz, CDCl $_3$ , HH-COSY, HSQC, HMBC): δ 8.74 – 8.73 (m, 2H, CH $_{arom}$  i-Nico), 7.68 – 7.64 (m, 2H, CH $_{arom}$  i-Nico), 7.44 – 6.95 (m, 15H, CH $_{arom}$ ), 5.07 (dd, J = 9.7, 3.4 Hz, 1H, H-3), 4.68 (d, J = 0.7 Hz, 1H, H-1), 4.17 (dddd, J = 32.1, 12.1, 4.3, 2.4 Hz, 1H, CHHCH $_2$ F), 4.15 (t, J = 9.6 Hz, 1H, H-4), 3.87 (dddd, J = 26.7, 11.7, 4.3, 2.6 Hz, 1H, CHHCH $_2$ F), 3.57 (ddd, J = 9.5, 4.8, 2.4 Hz, 1H, H-5);  $^{13}$ C-APT NMR (214 MHz, CDCl $_3$ ), HSQC, HMBC): δ 164.3 (C=0 i-Nico), 150.7 (CH $_{arom}$  i-Nico), 138.3, 137.9, 137.8, 136.9 (C $_4$ ), 128.4, 128.3, 128.2, 127.8, 127.7 (CH $_{arom}$ ), 123.0 (CH $_{arom}$  i-Nico), 101.4 (C-1), 82.9 (d, J = 169.9 Hz, CH $_2$ CH $_2$ F), 76.9 (C-3), 75.0 (C-2), 74.9 (CH $_2$  Bn), 73.8 (CH $_2$  Bn), 73.4 (C-4), 73.1 (CH $_2$  Bn), 69.2 (C-6), 68.9 (d, J = 19.8 Hz, CH $_2$ CH $_2$ F);  $^{13}$ C-GATED NMR (214 MHz, CDCl $_3$ ): δ 101.4 (JC<sub>1,H1</sub> = 155.8 Hz, C-1 β); HRMS: [M+H]\* calcd for C3<sub>2</sub>H<sub>3</sub>7;FNO<sub>7</sub> 602.2549, found 602.2551.

2,2-Difluoroethyl 2,4,6-tri-0-benzyl-3-isonicotinoyl-p-mannopyranoside (\$35). The title compound was prepared from donor 9 and 2,2-difluoroethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0 → 60:40, pentane:EtOAc, v:v) yielded glycosylation product **S35** (32.2 mg, 0.052 mmol, 52%,  $\alpha$ : $\beta$  = 86:14). TLC: R<sub>f</sub> 0.68, (60:40, pentane:EttOAc, v:v); Data for the α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.78 – 8.73 (m, 2H, CH<sub>arom</sub> i-Nico), 7.74 – 7.69 (m, 2H, CH<sub>arom</sub> i-Nico), 7.37 – 7.02 (m, 15H, CH<sub>arom</sub>), 5.93 (tdd, J = 55.3, 4.8, 3.7 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.44 (dd, J = 9.3, 3.4 Hz, 1H, H-3), 4.98 (d, J = 2.0 Hz, 1H, H-1), 4.72 (d, J = 12.1 Hz, 1H, CHH Bn), 4.67 (d, J = 12.2 Hz, 1H, CHH Bn), 4.59 (d, J = 11.2 Hz, 1H, CHH Bn), 4.53 (d, J = 12.0 Hz, 1H, CHH Bn), 4.52 (d, J = 11.2 Hz, 1H, CHH Bn), 4.52(d, / = 12.3 Hz, 1H, CHH Bn), 4.21 (t, / = 9.5 Hz, 1H, H-4), 4.01 (dd, / = 3.5, 2.0 Hz, 1H, H-2), 3.88 (ddd, / = 9.8, 4.5, 1.9 Hz, 3.73 (dd, J = 10.9, 2.0 Hz, 1H, H-6); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSOC, HMBC): δ 164.4 (C=0 i-Nico), 150.8 (CH<sub>arom</sub> i-Nico), 138.1, 137.8, 137.5, 137.1 (C<sub>q</sub>), 131.3, 129.5, 129.2, 128.5, 128.5, 128.1, 127.9, 127.9, 124.9 (CH<sub>arom</sub>), 123.0 (CH<sub>arom</sub> i-Nico), 114.1 (t, J = 241.2 Hz, CH<sub>2</sub>CHF<sub>2</sub>), 98.7 (C-1), 75.6 (C-2), 74.9 (CH<sub>2</sub>Bn), 74.8 (C-3), 73.7 (CH<sub>2</sub> Bn), 73.4 (C-4), 73.2 (CH<sub>2</sub> Bn), 72.2 (C-5), 68.8 (C-6), 67.0 (t, J = 28.6 Hz, CH<sub>2</sub>CHF<sub>2</sub>); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>): δ 98.7 (I<sub>C1,H1</sub> = 170.7 Hz, C-1 α); Diagnostic peaks β-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.73 – 8.71 (m, 2H, CH<sub>arom</sub> i-Nico), 7.64 – 7.62 (m, 2H, CH<sub>arom</sub> i-Nico), 7.49 – 6.92 (m, 15H,  $CH_{arom}$ ), 6.03 (dddd, J = 56.0, 54.7, 5.4, 2.9 Hz, 1H,  $CH_2CHF_2$ ), 5.20 (dd, J = 9.8, 3.4 Hz, 1H, H-3), 4.67 (d, J = 9.8), 5.20 (dd, J = 9.8), 5.4 Hz, 1H, H-3), 4.67 (d, J = 9.8), 5.20 (dd, J = 9.8), 5.4 Hz, 1H, H-3), 4.67 (d, J = 9.8), 5.20 (dd, J = 9.8), 5.4 Hz, 1H, H-3), 4.67 (d, J = 9.8), 5.4 Hz, 1H, H-3), 0.8 Hz, 1H, 1H, 1H, 1.36 (dd, I = 3.4, 1.1 Hz, 1H, 1.2 Hz, 1.1 Hz,  $1.1 \text{$ H-5); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.5 (C=0 i-Nico), 150.7 (CH<sub>arom</sub> i-Nico), 101.5 (C-1), 76.7 (C-3), 76.2 (CH<sub>2</sub> Bn), 75.9 (C-5), 75.1 (CH<sub>2</sub> Bn), 73.8 (CH<sub>2</sub> Bn), 73.4 (C-2), 73.2 (C-4), 69.0 (C-6); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>):  $\delta$  101.5 ( $f_{C1,H1}$  = 156.6 Hz, C-1  $\beta$ ); HRMS: [M+H]+ calcd for C<sub>35</sub>H<sub>36</sub>F<sub>2</sub>NO<sub>7</sub> 620.2454, found 620.2451.

2,2,2-Trifluoroethyl 2,4,6-tri-0-benzyl-3-isonicotinoyl-p-mannopyranoside (S36). The title compound was prepared from donor 9 and 2,2,2-trifluoroethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0  $\rightarrow$  60:40, pentane:EtOAc, v:v) yielded glycosylation product **S36** (28.7 mg, 0.045 mmol, 45%,  $\alpha$ : $\beta$  = 84:16). TLC: R<sub>f</sub> 0.73, (60:40, pentane:EtOAc, v:v); Data for the α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.77 – 8.73 (m, 2H, CH<sub>arom</sub> i-Nico), 7.73 – 7.70 (m, 2H, CH<sub>arom</sub> i-Nico), 7.37 - 7.03 (m, 15H, CH<sub>arom</sub>), 5.46 (dd, J = 9.1, 3.4 Hz, 1H, H-3), 5.02 (d, J = 2.1 Hz, 1H, H-1), 4.71 (d, J = 11.9 Hz, 1H, CHH Bn), 4.67 (d, J = 12.2 Hz, 1H, CHH Bn), 4.59 (d, J = 11.1 Hz, 1H, CHH Bn), 4.52 (d, J = 11.1 Hz, 1H, CHH Bn), J = 11.1 Hz, 1H, CHH Bn, J = 11.1 Hz, J = 11.1 Hz J = 11.2 Hz, 1H, CHH Bn), 4.22 (t, J = 9.4 Hz, 1H, H-4), 4.05 (dd, J = 3.5, 2.1 Hz, 1H, H-2), 3.99 (dq, J = 12.5, 8.7 Hz, 1H, CHHCF<sub>3</sub>), 3.93 (dq, *J* = 12.4, 8.5 Hz, 1H, CHHCF<sub>3</sub>), 3.86 (ddd, *J* = 9.7, 4.3, 1.9 Hz, 1H, H-5), 3.82 (dd, *J* = 11.0, 4.2 Hz, 1H, H-6), 3.72 (dd, J = 10.9, 1.9 Hz, 1H, H-6);  $^{13}$ C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC):  $\delta$  164.3 (C=0 i-Nico, 150.8 (CH<sub>arom</sub> i-Nico), 138.1, 137.7, 137.5, 137.1 (C<sub>q</sub>), 128.6, 128.5, 128.5, 128.1, 128.0, 128.0, 127.9, 127.9, 127.9 (CH<sub>arom</sub>), 125.1 (q, J = 278.8 Hz, CF<sub>3</sub>), 123.0 (CH<sub>arom</sub> i-Nico), 98.6 (C-1), 75.5 (C-2), 74.9 (CH<sub>2</sub> Bn), 74.5 (C-3), 73.7 (CH<sub>2</sub> Bn), 73.3 (CH<sub>2</sub> Bn), 73.3 (C-4), 72.4 (C-5), 68.6 (C-6), 64.4 (q, J = 35.0 Hz,  $CH_2CF_3$ );  $^{13}C_7$ GATED NMR (214 MHz, CDCl<sub>3</sub>):  $\delta$  98.6 ( $I_{Cl,H1}$  = 171.6 Hz, C-1  $\alpha$ ); Diagnostic peaks  $\beta$ -anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.79 – 8.74 (m, 2H, CH<sub>arom</sub> i-Nico), 7.67 – 7.66 (m, 2H, CH<sub>arom</sub> i-Nico), 7.38 – 7.01 (m, 15H,  $CH_{arom}$ ), 5.07 (dd, J = 9.7, 3.3 Hz, 1H, H-3), 4.72 (d, J = 0.9 Hz, 1H, H-1), 4.16 (t, J = 9.6 Hz, 1H, H-4), 4.14 (dd, J = 3.4, 0.9 Hz, 1H, H-2), 3.57 (ddd, J = 9.5, 5.0, 2.1 Hz, 1H, H-5).;  $^{13}$ C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.3 (C=0 i-Nico), 150.7 (CH<sub>arom</sub> i-Nico), 138.1, 137.9, 137.6, 136.8 (C<sub>q</sub>), 128.5, 128.5, 128.3, 128.1, 128.0 (CH<sub>arom</sub>), 127.8 (CH<sub>arom</sub> i-Nico), 125.0 (q, J = 278.8 Hz, CF<sub>3</sub>), 101.0 (C-1), 76.5 (C-3), 76.0 (C-5), 75.1 (CH<sub>2</sub> Bn), 74.4 (C-2), 73.8 (CH<sub>2</sub> Bn), 73.1 (C-4), 68.9 (C-6), 66.1 (d, J = 34.8 Hz, CH<sub>2</sub>CF<sub>3</sub>);  $^{13}$ C-GATED NMR (214 MHz, CDCl<sub>3</sub>): δ 101.0 (J<sub>C1,H1</sub> = 157.0 Hz, C-1 J<sub>B</sub>); HRMS: [M+H]+ calcd for C<sub>35</sub>H<sub>35</sub>F<sub>3</sub>NO<sub>7</sub> 638.2360, found 638.2356.

Ethyl 2.4.6-tri-O-benzyl-3-picoloyl-p-glucopyranoside (S37). The title compound was prepared from donor 2 and ethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography ( $100:0 \rightarrow 60:40$ , pentane:EtOAc, v:v) yielded glycosylation product \$37 (25.0 mg, 0.043 mmol, 43%, α:β = 28:72). TLC: R<sub>f</sub> 0.55, (60:40, pentane: EtOAc, v:v); Data for the β-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.79 (ddd, / = 4.7, 1.8, 0.9 Hz, 1H, CH<sub>arom</sub> Pico), 8.01 (dt, / = 7.8, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.82 (td, / = 7.7, 1.7 Hz, 1H, CH<sub>arom</sub>), 7.50 (ddd, / = 7.6, 4.7, 1.2 Hz, 1H, CH<sub>arom</sub> Pico), 7.41 - 7.02 (m, 15H,  $CH_{Arom}$ ), 5.58 (t. I = 9.5 Hz. 1H, H-3), 4.84 (d. I = 11.9 Hz. 1H, CHH Bn), 4.68 (d. I = 12.1 Hz. 1H, CHH Bn), 4.64 (d. J = 11.8 Hz, 1H, CHH Bn), 4.58 (d, J = 10.9 Hz, 1H, CHH Bn), 4.57 (d, J = 12.1 Hz, 1H, CHH Bn), 4.56 (d, J = 7.8 Hz, 1H, H-1), 4.50 (d, J = 11.1 Hz, 1H, CHH Bn), 4.06 (dq, J = 9.6, 7.1 Hz, 1H, CHHCH<sub>3</sub> Et), 3.93 (t, J = 9.5 Hz, 1H H-4),  $3.79 \text{ (dd, } J = 9.0, 1.8 \text{ Hz, } 1\text{H, } 1\text{H-6}), 3.70 - 3.67 \text{ (m, } 1\text{H, } 1\text{H-6}), 3.68 \text{ (dq, } J = 9.6, 6.6 \text{ Hz, } 1\text{H, } CHHCH_3 \text{ Et)}, 3.62 - 3.59 \text{ (m, } 1\text{H, } 1\text{$ (m, 1H, H-5), 3.60 (dd, J = 9.7, 7.8 Hz, 1H, H-2), 1.30 (t, J = 7.1 Hz, 3H, CH<sub>3</sub> Et); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSOC. HMBC): δ 164.5 (C=O Pico), 149.9 (CH<sub>arom</sub> Pico), 148.1, 138.3, 138.2, 137.8 (C<sub>q</sub>), 137.0 (CH<sub>arom</sub> Pico), 128.5, 128.3, 128.3, 128.2, 128.2, 128.1, 128.0, 127.8, 127.7 (CH<sub>arom</sub>), 126.9, 125.6 (CH<sub>arom</sub> Pico), 103.6 (C-1), 79.2 (C-2), 77.6 (C-3), 76.2 (C-4), 74.9 (C-5), 74.7 (CH<sub>2</sub> Bn), 74.2 (CH<sub>2</sub> Bn), 73.7 (CH<sub>2</sub> Bn), 68.8 (C-6), 65.9 (CH<sub>2</sub>CH<sub>3</sub> Et), 15.4 (CH<sub>3</sub> Et);  $^{13}$ C-GATED NMR (214 MHz, CDCl<sub>3</sub>): δ 103.6 ( $J_{C1,H1}$  = 159.0 Hz, C-1 β); Diagnostic peaks α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.78 (ddd, / = 4.7, 1.8, 0.9 Hz, 1H, CH<sub>arom</sub> Pico), 8.10 (dt, / = 7.8, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.82 (td, I = 7.7, 1.8 Hz, 1H, CH<sub>arom</sub> Pico), 7.48 - 7.46 (m, 1H CH<sub>arom</sub> Pico), 7.39 -6.97 (m. 15H, CH<sub>arom</sub>), 5.89 (dd, / = 10.0, 9.2 Hz, 1H, H-3), 4.84 (d, / = 3.6 Hz, 1H, H-1), 4.64 (d, / = 12.1 Hz, 1H, CHH Bn), 4.61 (d, / = 12.6 Hz, 1H, CHH Bn), 4.57 (d, / = 12.6 Hz, 1H, CHH Bn), 4.56 (d, / = 10.9 Hz, 1H, CHH Bn), 4.47 (d, J = 12.1 Hz, 1H, CHH Bn), 4.42 (d, J = 10.9 Hz, 1H, CHH Bn), 3.98 (t, J = 9.6 Hz, 1H, H-4), 3.72 (dq, J = 9.7, 7.1 Hz, 1H, CHHCH<sub>3</sub> Et), 3.50 (dq, J = 9.7, 7.0 Hz, 1H, CHHCH<sub>3</sub> Et), 1.25 (t, J = 6.5 Hz, 3H, CH<sub>3</sub> Et);  $^{13}$ C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.6 (C=O Pico), 149.9 (CH<sub>arom</sub> Pico), 148.4, 138.2, 138.0, 137.9 (C<sub>a</sub>), 137.0 (CH<sub>arom</sub> Pico), 128.5, 128.4, 128.1, 127.9, 127.8, 127.8, 127.7, 127.7, 127.5 (CH<sub>arom</sub>), 126.9, 125.7 (CH<sub>arom</sub> Pico), 96.7 (C-1), 77.5 (C-2), 76.3 (C-4), 75.8 (C-3), 74.7 (CH<sub>2</sub> Bn), 73.7 (CH<sub>2</sub> Bn), 72.9 (CH<sub>2</sub> Bn), 70.1 (C-5), 68.5 (C-6), 63.7 (CH<sub>2</sub>CH<sub>3</sub> Et), 15.1 (CH<sub>3</sub> Et); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>): δ 96.7 (J<sub>C1,H1</sub> = 167.3 Hz, C-1 α); HRMS: [M+H]+ calcd for C<sub>35</sub>H<sub>38</sub>NO<sub>7</sub> 584.2643, found 584.2640.

2-Fluoroethyl 2,4,6-tri-0-benzyl-3-picoloyl-p-glucopyranoside (S38). The title compound was prepared from donor 2 and 2-fluoroethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography ( $100:0 \rightarrow 60:40$ , pentane: EtOAc, v:v) yielded glycosylation product \$38 (23.4 mg, 0.039 mmol, 39%,  $\alpha$ : β = 36:66). TLC:  $R_f$  0.39, (60:40, pentane: EtOAc, v:v); Data for the β-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.80 (ddd, / = 4.7, 1.8, 0.9 Hz, 1H, CH<sub>arom</sub> Pico), 8.02 (dt, / = 7.8, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.83 (td, / = 7.7, 1.8 Hz, 1H, CH<sub>arom</sub> Pico), 7.51 (ddd, / = 7.6, 4.7, 1.2 Hz, 1H, CH<sub>arom</sub> Pico), 7.41 – 6.99 (m, 15H, CH<sub>arom</sub>), 5.59 (t, / = 9.5 Hz, 1H, H-3), 4.86 (d, / = 11.8 Hz, 1H, CHH Bn), 4.70 (dddd, / = 40.4, 10.5, 7.1, 2.5 Hz, 1H,  $CH_2CHHF$ ), 4.67 (d, J = 12.2 Hz, 1H, CHH Bn), 4.64 (d, J = 11.9 Hz, 1H, CHH Bn), 4.60 (d, J = 7.7 Hz, 1H, H-1), 4.58 (d, J = 11.0 Hz, 1H, CHH Bn), 4.57 (d, J = 12.2 Hz, 1H, CHH Bn), 4.55 - 4.51 (m, 1H, CH<sub>2</sub>CHHF), 4.50 (d, / = 11.0 Hz, 1H, CHH Bn), 4.19 (dddd, / = 32.4, 12.1, 4.9, 2.5 Hz, 1H, CHHCH<sub>2</sub>F), 3.94 (t, / = 9.6 Hz, 1H, H-4), H-2), 3.61 (ddd, J = 9.7, 3.9, 2.4 Hz, 1H, H-5); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSOC, HMBC): δ 164.5 (C=O Pico), 149.9 (CH<sub>arom</sub> Pico), 148.1, 138.2, 138.2 (C<sub>q</sub>), 137.8 (CH<sub>arom</sub> Pico), 137.0, 128.5, 128.3, 128.3, 128.2, 128.1, 128.0, 127.8, 127.8, 127.5 (CH<sub>arom</sub>), 127.0, 125.7 (CH<sub>arom</sub> Pico), 103.9 (C-1), 82.7 (d, J = 169.9 Hz, CH<sub>2</sub>CH<sub>2</sub>F), 79.0 (C-2), 77.4 (C-3), 76.1 (C-4), 75.0 (C-5), 74.7 (CH<sub>2</sub> Bn), 74.2 (CH<sub>2</sub> Bn), 73.7 (CH<sub>2</sub> Bn), 69.13 (d, *J* = 20.2 Hz, CH<sub>2</sub>CH<sub>2</sub>F), 68.69 (C-6);  $^{13}$ C-GATED NMR (214 MHz, CDCl<sub>3</sub>): δ 103.9 ( $I_{C1,H1}$  = 159.7 Hz, C-1 β); Diagnostic peaks α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.78 (ddd, J = 4.7, 1.8, 0.9 Hz, 1H, CH<sub>arom</sub> Pico), 8.10 (dt, J = 7.8, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.83 (td, J = 7.7, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.48 (ddd, J = 7.6, 4.7, 1.2 Hz, 1H, CH<sub>arom</sub> Pico), 5.89 (dd, J = 10.0, 8.9 Hz, 1H, H-3), 4.88 (d, J = 3.6 Hz, 1H, H-1), 4.47 (d, J = 12.1 Hz, 1H, CHH Bn), 4.43 (d, I = 10.9 Hz, 1H, CHH Bn), 4.00 (t, I = 9.6 Hz, 1H, H-4);  $^{13}$ C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSOC, HMBC): δ 164.6 (C=O Pico), 149.9 (CH<sub>arom</sub> Pico), 148.3, 138.1, 138.0 (C<sub>q</sub>), 137.9 (CH<sub>arom</sub> Pico), 137.0, 128.4, 128.3, 128.1, 128.1, 128.0, 127.9, 127.7 (CH<sub>arom</sub>), 127.0, 125.8 (CH<sub>arom</sub> Pico), 97.4 (C-1), 82.7 (d, J = 169.7 Hz, CH<sub>2</sub>CH<sub>2</sub>F), 76.2 (CH<sub>2</sub>Bn), 76.1 (C-2), 75.5 (C-3), 75.1 (CH<sub>2</sub>Bn), 74.7 (C-4), 74.6 (CH<sub>2</sub>Bn), 70.2 (C-5), 68.4 (C-6), 67.4 (d, J = 20.4 Hz, CH<sub>2</sub>CH<sub>2</sub>F);  $^{13}$ C-GATED NMR (214 MHz, CDCl<sub>3</sub>):  $\delta$  97.4 (J<sub>C1,H1</sub> = 169.3 Hz, C-1  $\alpha$ ); HRMS: [M+H]+ calcd for C<sub>35</sub>H<sub>37</sub>FNO<sub>7</sub> 602.2549, found 602.2551.

2,2-Difluoroethyl 2,4,6-tri-O-benzyl-3-picoloyl-p-glucopyranoside (S39). The title compound was prepared from donor 2 and 2,2-difluoroethanol using the general procedure for Tf2O/Ph2SO mediated glycosylations. Flash column chromatography (100:0  $\rightarrow$  60:40, pentane:EtOAc, v:v) yielded glycosylation product **S39** (31.0 mg, 0.050 mmol, 50%,  $\alpha$ :β = 46:54). TLC: R<sub>f</sub> 0.55, (60:40, pentane: EtOAc, v:v); Data for the βanomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.76 (ddd, / = 4.7, 1.8, 0.9 Hz, 1H, CH<sub>arom</sub> Pico), 7.98 (dt, / = 7.8, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.81 (td, / = 7.7, 1.8 Hz, 1H, CH<sub>arom</sub> Pico), 7.48 (ddd, / = 7.4, 4.7, 1.3 Hz, 1H, CH<sub>arom</sub> Pico), 7.38 - 6.99 (m, 15H, CH<sub>arom</sub>), 5.97 (tt, *J* = 55.4, 4.4 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.55 (t, *J* = 9.5 Hz, 1H, H-3), 4.78 (d, I = 11.8 Hz, 1H, C/H Bn), 4.63 (d, I = 12.3 Hz, 1H, C/H Bn), 4.56 (d, I = 7.6 Hz, 1H, H-1), 4.54 (d, I = 1.012.1 Hz, 1H, CHH Bn), 4.47 (d, / = 11.1 Hz, 1H, CHH Bn), 4.47 (d, / = 12.0 Hz, 1H, CHH Bn), 4.43 (d, / = 10.9 Hz, 1H, CHH Bn), 3.93 (t, J = 9.5 Hz, 1H, H-4), 3.78 - 3.67 (m, 2H, CHHCHF<sub>2</sub>, CHHCHF<sub>2</sub>), 3.74 (d, J = 3.1 Hz, 2H, H-6, H-6), 3.61 (dd, J = 9.6, 7.6 Hz, 1H, H-2), 3.58 (dt, J = 9.8, 3.1 Hz, 1H, H-5);  $^{13}$ C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC):  $\delta$  164.4 (C=O Pico), 149.9 (CH<sub>arom</sub> Pico), 148.0, 138.0, 137.9, 137.7 (C<sub>q</sub>), 137.0 (CH<sub>arom</sub> Pico), 128.6, 128.5, 128.3, 128.3, 128.2, 128.1, 128.1, 128.1, 128.0 (CH<sub>arom</sub>), 127.0, 125.7 (CH<sub>arom</sub> Pico), 114.2 (t, *J* = 241.3 Hz, CH<sub>2</sub>CHF<sub>2</sub>), 104.0 (C-1), 78.9 (C-2), 77.3 (C-3), 75.9 (C-4), 75.0 (C-5), 74.7 (CH<sub>2</sub>Bn), 74.3 (CH<sub>2</sub>Bn), 73.9 (CH<sub>2</sub>Bn), 68.5 (C-6), 67.5 (t, J = 29.3 Hz,  $CH_2CHF_2$ ); <sup>13</sup>C-GATED NMR (214 MHz,  $CDCl_3$ ):  $\delta$  104.0 ( $J_{C1,H1} = 162.1$  Hz, C-1  $\beta$ ); Diagnostic peaks α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.78 (ddd, *J* = 4.7, 1.8, 0.9 Hz, 1H, CH<sub>arom</sub> Pico), 8.11 (dt, / = 7.8, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.83 (td, / = 7.7, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.48 (ddd, / = 7.4, 4.7, 1.3 Hz, 1H, CH<sub>arom</sub> Pico), 7.40 - 6.97 (m, 15H, CH<sub>arom</sub>), 6.02 (dddd, f = 55.9, 55.0, 5.2, 3.3 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>), 5.84 (t, *J* = 9.7 Hz, 1H, H-3), 4.83 (d, *J* = 3.6 Hz, 1H, H-1), 4.06 (dddd, *J* = 21.8, 11.8, 8.3, 3.3 Hz, 1H, CHHCHF<sub>2</sub>), 3.99 (t, / = 9.6 Hz, 1H, H-4), 3.90 (ddd, / = 10.0, 3.5, 2.0 Hz, 1H, H-5), 3.83 (dddd, / = 21.3, 13.0, 11.7, 5.2 Hz, 1H, CHHCHF<sub>2</sub>), 3.77 (dd, J = 10.1, 3.7 Hz, 1H, H-2); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC):  $\delta$  164.6 (C=O Pico), 149.9 (CH<sub>arom</sub> Pico), 148.2, 138.0, 137.8, 137.8 (C<sub>q</sub>), 137.1 (CH<sub>arom</sub> Pico), 128.5, 128.3, 128.2, 128.0, 127.9, 127.9, 127.8, 127.7, 127.6 (CH<sub>arom</sub>), 127.0, 125.8 (CH<sub>arom</sub> Pico), 114.2 (dd, J = 242.2, 240.0 Hz, CH<sub>2</sub>CHF<sub>2</sub>), 97.9 (C-1), 77.3 (C-2), 75.9 (C-3), 75.3 (C-4), 74.8 (CH<sub>2</sub> Bn), 73.7 (CH<sub>2</sub> Bn), 73.2 (CH<sub>2</sub> Bn), 70.7 (C-5), 68.9 (dd, I = 30.5, 27.0 Hz,  $CH_2CHF_2$ ), 68.2 (C-6); <sup>13</sup>C-GATED NMR (214 MHz,  $CDCl_3$ ):  $\delta$  97.9 ( $I_{C1,H1}$  = 169.8 Hz, C-1  $\alpha$ ); HRMS: [M+H]<sup>+</sup> calcd for C<sub>35</sub>H<sub>36</sub>F<sub>2</sub>NO<sub>7</sub> 620.2454, found 620.2451.

2,2,2-Trifluoroethyl 2,4,6-tri-0-benzyl-3-picoloyl-p-glucopyranoside (S40). The title compound was prepared from donor 2 and 2,2,2-trifluoroethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0 → 60:40, pentane:EtOAc, v:v) yielded glycosylation product **S40** (35.0 mg, 0.055 mmol, 55%,  $\alpha:\beta = 49:51$ ). TLC:  $R_f 0.61$ , (60:40, pentane:EtOAc, v:v); Data for the α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.78 (ddd, J = 4.7, 1.8, 0.9 Hz, 1H, CH<sub>arom</sub> Pico), 8.11 (dt, J = 7.8, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.98 (dt, J = 7.8, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.87 - 7.78 (m, 1H, CH<sub>arom</sub> Pico), 7.52 - 6.98 (m, 15H, CH<sub>arom</sub>), 5.86 (t, I = 9.7 Hz, 1H, H-3), 4.85 (d, I = 3.6 Hz, 1H, H-1), 4.80 (d, I = 11.7 Hz, 1H, CHH Bn), 4.64 (d, J = 11.9 Hz, 1H, CHH Bn), 4.58 (d, J = 11.7 Hz, 1H, CHH Bn), 4.54 (d, J = 12.1 Hz, 1H, CHH Bn), 4.46 (d, J = 12.0 Hz, 1H, CHH Bn), 4.43 (d, J = 10.9 Hz, 1H, CHH Bn), 4.24 (dq, J = 12.3, 8.7 Hz, 1H, 4.01 (t, J = 9.7 Hz, 1H, H-4), 3.99 - 3.96 (m, 1H, CHHCF<sub>3</sub>), 3.91 - 3.86 (m, 1H, H-5), 3.79 (dd, <math>J = 10.1, 3.7 Hz, 1H, H-2), 3.77 (dd, I = 10.8, 3.3 Hz, 1H, H-6), 3.65 (dd, I = 10.9, 2.1 Hz, 1H, H-6); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): 8 164.4 (C=O Pico), 149.9 (CH<sub>arom</sub> Pico), 147.9, 138.0, 137.8, 137.7 (C<sub>q</sub>), 137.0 (CH<sub>arom</sub> Pico), 128.2, 128.1, 128.1, 128.1, 128.0, 128.0, 127.9, 127.8, 127.7 (CH<sub>arom</sub>), 127.0, 125.7 (CH<sub>arom</sub> Pico), 123.8 (q, J = 278.6 Hz, CF<sub>3</sub>), 98.0 (C-1), 78.6 (C-2), 75.7 (C-3), 75.1 (C-4), 74.7 (CH<sub>2</sub> Bn), 73.7 (CH<sub>2</sub> Bn), 73.1 (CH<sub>2</sub> Bn), 71.0 (C-5), 68.1 (C-6), 65.2 (q, J = 35.1 Hz,  $CH_2CF_3$ );  $^{13}C$ -GATED NMR (214 MHz, CDCl<sub>3</sub>):  $\delta$  98.0 ( $J_{C1,H1} = 172.1 \text{ Hz}$ , C-1  $\alpha$ ); Diagnostic peaks β-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.77 (ddd, J = 4.7, 1.8, 0.9 Hz, 1H, CH<sub>arom</sub> Pico), 7.98 (dt, J = 7.8, 1.1 Hz, 1H, CH<sub>arom</sub> Pico), 7.81 (td, J = 7.7, 1.7 Hz, 1H, CH<sub>arom</sub> Pico), 7.49 – 7.47 (m, 1H, CH<sub>arom</sub> Pico), 7.40 – 6.94 (m, 15H, CH<sub>arom</sub>), 5.55 (t, J = 9.4 Hz, 1H, H-3), 4.63 (d, J = 7.3 Hz, 1H, H-1), 3.94 3.6, 2.6 Hz, 1H, H-5); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.6 (C=O Pico), 150.0 (CH<sub>arom</sub> Pico), 148.2, 138.0, 137.8, 137.8 (Cq), 137.1 (CH<sub>arom</sub> Pico), 128.6, 128.5, 128.4, 128.4, 128.3, 128.2, 128.0, 128.0, 127.9  $(CH_{arom})$ , 127.0, 125.8  $(CH_{arom})$  Pico), 123.6  $(q, J = 278.2 \text{ Hz}, CF_3)$ , 103.8 (C-1), 78.6 (C-2), 75.8 (C-3), 75.2 (C-4),

74.8 (CH<sub>2</sub> Bn), 74.2 (CH<sub>2</sub> Bn), 73.7 (CH<sub>2</sub> Bn), 71.0 (C-5), 68.4 (C-6), 66.3 (q, J = 34.9 Hz, CH<sub>2</sub>CF<sub>3</sub>); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>):  $\delta$  103.8 (J<sub>C1,H1</sub> = 162.5 Hz, C-1  $\beta$ ); HRMS: [M+H]<sup>+</sup> calcd for C<sub>35</sub>H<sub>35</sub>F<sub>3</sub>NO<sub>7</sub> 638.2360, found 638.2357.

Ethyl 2,4,6-tri-O-benzyl-3-nicotinoyl-p-glucopyranoside (S41). The title compound was prepared from donor 3 and ethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography ( $100:0 \rightarrow 60:40$ , pentane:EtOAc, v:v) yielded glycosylation product **S41** (28.0 mg, 0.048 mmol, 48%, α:β = 20:80). TLC: R<sub>f</sub> 0.68, (60:40, pentane: EtOAc, v:v); Data for the β-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC):  $\delta$  8.96 (dd, J = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.76 (dd, J = 4.8, 1.8 Hz, 1H, CH<sub>arom</sub> Nico), 8.06 (dt, / = 7.9, 1.9 Hz, 1H, CH<sub>arom</sub> Nico), 7.65 (dd, / = 8.2, 1.5 Hz, 1H, CH<sub>arom</sub> Nico), 7.53 - 6.93 (m, 15H, CH<sub>arom</sub>), 5.43 (t, J = 9.4 Hz, 1H, H-3), 4.78 (d, J = 12.0 Hz, 1H, CHH Bn), 4.67 (d, J = 12.2 Hz, 1H, CHH Bn), 4.59 (d, J = 12.0 Hz, 1H, CHH Bn), 4.56 (d, I = 12.3 Hz, 1H, CHH Bn), 4.52 (d, I = 7.7 Hz, 1H, H-1), 4.45 (d, I = 11.2 Hz, 1H, CHH Bn), 4.39 (d, I = 11.2 Hz, 1H, CHH Bn), 4.04 (dq, I = 9.6, 7.1 Hz, 1H, CHHCH<sub>3</sub> Et), 3.76 (t, I = 9.6 Hz, 1H, H-4), 3.76 -3.74 (m, 2H, H 6, H-6), 3.66 (dq, J = 9.6, 7.1 Hz, 1H, CHHCH<sub>3</sub> Et), 3.54 (ddd, J = 9.7, 3.6, 2.5 Hz, 1H, H-5), 3.44 (dd, J = 9.6, 7.7 Hz, 1H, H-2), 1.31 (t, J = 7.1 Hz, 3H, CH<sub>3</sub> Et); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.4 (C=0 Nico), 153.4, 151.0 (CH<sub>arom</sub> Nico), 138.1, 138.0, 137.6 (C<sub>q</sub>), 137.3, 129.5, 128.5, 128.4, 128.4, 128.3, 128.1, 128.1, 127.9, 127.8, 127.7 (CH<sub>arom</sub>), 126.0 (C<sub>q</sub> Nico), 124.9, 123.3 (CH<sub>arom</sub> Nico), 103.7 (C-1), 78.5 (C-2), 76.7 (C-1) 3), 76.2 (C-4), 74.8 (C-5), 74.5 (CH<sub>2</sub> Bn), 73.9 (CH<sub>2</sub> Bn), 73.8 (CH<sub>2</sub> Bn), 68.6 (C-6), 65.9 (CH<sub>2</sub>CH<sub>3</sub> Et), 15.5 (CH<sub>3</sub> Et); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>): δ 103.7 (/<sub>C1,H1</sub> = 159.1 Hz, C-1 β); Diagnostic peaks α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC):  $\delta$  9.07 (dd, J = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.77 (dd, J = 4.8, 1.7 Hz, 1H, CH<sub>arom</sub> Nico), 8.17 (dt, J = 7.9, 2.0 Hz, 1H, CH<sub>arom</sub> Nico), 7.65 (dd, J = 8.2, 1.5 Hz, 1H, CH<sub>arom</sub> Nico), 7.49 - 6.94  $(m, 15H, CH_{arom}), 5.77 (t, l = 9.6 Hz, 1H, H-3), 4.89 (d, l = 3.5 Hz, 1H, H-1), 3.91 - 3.88 (m, 1H, H-5), 3.81 (t, l = 1.88 Hz, 1.88 Hz, 1.89 Hz, 1.89$ 9.5 Hz, 1H, H-4), 3.79 (dd, / = 10.8, 3.2 Hz, 1H, H-2), 3.61 (dd, / = 10.0, 3.5 Hz, 1H, H-6), 1.26 (t, / = 7.1 Hz, 3H, CH<sub>3</sub> Et); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.3 (C=O Nico), 153.4, 151.0 (CH<sub>arom</sub> Nico), 137.9, 137.8, 137.7 (C<sub>q</sub>), 128.6, 128.5, 128.3, 128.1, 128.1, 128.0 (CH<sub>arom</sub>), 127.8, 126.3 (C<sub>q</sub>), 124.9, 123.4 (CH<sub>arom</sub> Nico), 96.4 (C-1), 78.5 (C-2), 76.2 (C-3), 74.8 (C-4), 74.6 (CH<sub>2</sub> Bn), 73.8 (CH<sub>2</sub> Bn), 72.6 (CH<sub>2</sub> Bn), 70.0 (C-5), 68.3 (C-6), 63.8 ( $CH_2CH_3$  Et), 15.1 ( $CH_3$  Et);  $^{13}C$ -GATED NMR (214 MHz,  $CDCl_3$ ):  $\delta$  96.4 ( $I_{CLH1}$  = 168.8 Hz, C-1  $\alpha$ ); HRMS: [M+H]+ calcd for C<sub>35</sub>H<sub>38</sub>NO<sub>7</sub> 584.2643, found 584.2640.

2-Fluoroethyl 2,4,6-tri-0-benzyl-3-nicotinoyl-p-glucopyranoside (S42). The title compound was prepared from donor 3 and 2-fluoroethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0  $\rightarrow$  60:40, pentane:EtOAc, v:v) yielded glycosylation product S42 (30.1 mg, 0.050 mmol, 50%, α: $\beta$  = 40:60). TLC: R<sub>f</sub> 0.57, (60:40, pentane: EtOAc, v:v); Data for the β-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.97 (dd, *I* = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.77 (dd, *I* = 4.8, 1.8 Hz, 1H, CH<sub>arom</sub> Nico), 8.07 (dt, J = 7.9, 1.9 Hz, 1H, CH<sub>arom</sub> Nico), 7.41 – 6.96 (m, 16H, CH<sub>arom</sub> Nico, CH<sub>arom</sub>), 5.44 (t, J = 9.4 Hz, 1H, H-3), 4.79 (d, J = 12.0 Hz, 1H, CHH Bn), 4.68 (dddd, J = 40.5, 10.6, 7.0, 2.5 Hz, 1H, CH<sub>2</sub>CHHF), 4.66 (d, J = 40.5), 4.79 (d, J = 40.5), 4.7912.2 Hz, 1H, CHH Bn), 4.59 (dddd, J = 38.9, 10.1, 7.3, 2.3 Hz, 1H, CH<sub>2</sub>CHHF), 4.59 (d, J = 12.1 Hz, 1H, CHH Bn), 4.57 (d, J = 7.6 Hz, 1H, H-1), 4.56 (d, J = 12.3 Hz, 1H, CHH Bn), 4.45 (d, J = 11.3 Hz, 1H, CHH Bn), 4.39 (d, J = 11.3Hz, 1H, CHH Bn), 4.17 (dddd, J = 32.0, 12.0, 4.9, 2.5 Hz, 1H, CHHCH<sub>2</sub>F), 3.91 (dddd, J = 25.6, 12.0, 7.0, 2.6 Hz, 1H,  $CHHCH_2F$ ), 3.78 (t, J = 9.6 Hz, 1H, H-4), 3.75 (d, J = 3.1 Hz, 2H, H-6, H-6), 3.55 (dt, J = 9.7, 3.0 Hz, 1H, H-5), 3.48 (dd, I = 9.6, 7.7 Hz, 1H, H-2);  $^{13}$ C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC):  $\delta$  164.3 (C=0 Nico), 153.5, 151.0 (CH<sub>arom</sub> Nico), 138.0, 137.8, 137.5 (Cq), 137.3 (CH<sub>arom</sub> Nico), 128.6, 128.5, 128.4, 128.3, 128.1, 128.1, 128.0, 127.9, 127.8 (CH<sub>arom</sub>), 126.0 (C<sub>q</sub> Nico), 123.3 (CH<sub>arom</sub> Nico), 103.9 (C-1), 82.7 (d, J = 170.0 Hz, CH<sub>2</sub>CH<sub>2</sub>F), 78.3 (C-2), 76.6 (C-3), 76.0 (C-4), 74.8 (C-5), 74.6 (CH<sub>2</sub> Bn), 73.9 (CH<sub>2</sub> Bn), 73.8 (CH<sub>2</sub> Bn), 69.1 (d, J = 20.1 Hz,  $CH_2CH_2F$ ), 68.42 (C-6);  $^{13}$ C-GATED NMR (214 MHz, CDCl<sub>3</sub>): δ 103.9 ( $^{1}$ C<sub>LH1</sub> = 159.2 Hz, C-1 β); Diagnostic peaks α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 9.06 (dd, / = 2.1, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.77 (dd, / = 4.8, 1.8 Hz, 1H, CH<sub>arom</sub> Nico), 8.18 (dt, *J* = 7.9, 2.0 Hz, 1H, CH<sub>arom</sub> Nico), 7.43 – 6.96 (m, 16H, CH<sub>arom</sub> Nico, CH<sub>arom</sub>), 5.77 (t, J = 9.6 Hz, 1H, H-3), 4.94 (d, J = 3.5 Hz, 1H, H-1), 3.95 (dt, J = 10.0, 2.7 Hz, 1H, H-5), 3.83 (t, J = 9.6 Hz, 1H, H-5)4), 3.67 (dd, / = 10.8, 2.1 Hz, 1H, H-6), 3.63 (dd, / = 10.0, 3.5 Hz, 1H, H-2); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.3 (C=0 Nico), 153.4, 151.0 (CH<sub>arom</sub> Nico), 138.0, 137.8, 137.7 (C<sub>q</sub>), 137.4 (CH<sub>arom</sub> Nico), 128.6, 128.5, 128.4, 128.3, 128.1, 128.1, 128.1, 128.0, 127.8 (CH<sub>arom</sub>), 126.2 (C<sub>q</sub> Nico), 123.4 (CH<sub>arom</sub>), 97.0 (C-1), 82.7  $(d, J = 169.7 \text{ Hz}, CH_2CH_2F), 77.1 (C-2), 76.0 (C-4), 74.8 (C-3), 74.5 (CH_2 Bn), 73.8 (CH_2 Bn), 72.6 (CH_2 Bn), 70.1 (C-2), 76.0 (CH_2 Bn), 70.1 (C-3), 74.5 (CH_2 Bn), 73.8 (CH_2 Bn), 73.8 (CH_2 Bn), 70.1 (C-3), 74.8 (C-3), 74.8 (C-3), 74.5 (CH_2 Bn), 73.8 (CH_2 Bn), 73.8 (CH_2 Bn), 73.8 (CH_2 Bn), 70.1 (C-3), 74.8 (C-3)$ (C-5), 68.2 (C-6), 67.4 (d, J = 20.3 Hz,  $CH_2CH_2F$ );  $^{13}C$ -GATED NMR (214 MHz, CDCl<sub>3</sub>):  $\delta$  97.0 ( $J_{C1,H1} = 169.2$  Hz, C-6.1) 1  $\alpha$ ); HRMS: [M+H]<sup>+</sup> calcd for C<sub>35</sub>H<sub>37</sub>FNO<sub>7</sub> 602.2549, found 602.2545.

2,2-Difluoroethyl 2,4,6-tri-0-benzyl-3-nicotinoyl-p-glucopyranoside (\$43). The title compound was prepared from donor 3 and 2,2-difluoroethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography ( $100:0 \rightarrow 60:40$ , pentane:EtOAc, v:v) yielded glycosylation product **S43** (29.1 mg, 0.047 mmol, 47%,  $\alpha$ : $\beta$  = 41:59). TLC: R<sub>f</sub> 0.63, (60:40, pentane:EtOAc, v:v); Data for the βanomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.95 (dd, J = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.77 (dd, J = 4.8, 1.7 Hz, 1H, CH<sub>arom</sub> Nico), 8.06 (dt, J = 7.9, 2.0 Hz, 1H, CH<sub>arom</sub> Nico), 7.41 - 6.98 (m, 16H, CH<sub>arom</sub> Nico,  $CH_{arom}$ ), 6.05 - 5.90 (dddd, I = 55.6, 54.3, 5.2, 3.7 Hz, 1H,  $CH_2CHF_2$ ), 5.43 (t, I = 9.4 Hz, 1H, H-3), 4.76 (d, I = 12.0Hz, 1H, CHH Bn), 4.65 (d, / = 12.2 Hz, 1H, CHH Bn), 4.56 (d, / = 12.3 Hz, 1H, CHH Bn), 4.56 (d, / = 7.5 Hz, 1H, H-1), 4.55 (d, / = 11.7 Hz, 1H, CHH Bn), 4.46 (d, / = 11.3 Hz, 1H, CHH Bn), 4.39 (d, / = 11.3 Hz, 1H, CHH Bn), 4.08 (dddd, / = 22.6, 11.6, 10.4, 3.4 Hz, 1H, CHHCHF<sub>2</sub>), 3.88 - 3.81 (m, 1H, CHHCHF<sub>2</sub>), 3.79 (t, /= 9.5 Hz, 1H, H-4), 3.77 -3.73 (m, 2H, H-6, H-6), 3.55 (ddd, J = 9.8, 3.7, 2.3 Hz, 1H, H-5), 3.49 (dd, J = 9.5, 7.6 Hz, 1H, H-2);  $^{13}$ C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.3 (C=0 Nico), 153.5, 151.0 (CH<sub>arom</sub> Nico), 137.8, 137.6, 137.4 (C<sub>q</sub>), 137.3 (CH<sub>arom</sub> Nico), 128.6, 128.5, 128.4, 128.3, 128.3, 128.1, 128.0, 127.9, 127.8 (CH<sub>arom</sub>), 125.9 (C<sub>0</sub>), 123.3 (CH<sub>arom</sub> Nico), 114.2 (dd, J = 242.2, 240.2 Hz, CH<sub>2</sub>CHF<sub>2</sub>), 104.1 (C-1), 78.2 (C-2), 76.4 (C-3), 75.7 (C-4), 74.9 (C-5), 74.6 (CH<sub>2</sub> Bn), 74.0 (CH<sub>2</sub> Bn), 73.8 (CH<sub>2</sub> Bn), 68.9 (dd, J = 30.2, 27.0 Hz, CH<sub>2</sub>CHF<sub>2</sub>), 68.2 (C-6); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>):  $\delta$  104.1 ( $J_{C1,H1}$  = 160.9 Hz, C-1  $\beta$ ); Diagnostic peaks  $\alpha$ -anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 9.06 (dd, *J* = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.78 (dd, *J* = 4.8, 1.8 Hz, 1H, CH<sub>arom</sub> Nico), 8.17 (dt, *J* = 7.9, 2.0 Hz, 1H, CH<sub>arom</sub> Nico), 7.39 - 6.96 (m, 16H, CH<sub>arom</sub> Nico, CH<sub>arom</sub>), 5.91 (dddd, J = 55.5, 54.3, 5.0, 3.4 Hz, 1H,  $CH_2CHF_2$ ), 5.73 (t, J = 9.6 Hz, 1H, H-3), 4.89 (d, J = 3.6 Hz, 1H, H-1), 4.76 (d, J = 12.0 Hz, 1H, CHH Bn), 4.65 (d, J = 12.0 Hz, 1H, 12.1 Hz, 1H, CHH Bn), 4.53 (d, J = 12.4 Hz, 1H, CHH Bn), 4.50 (d, J = 12.1 Hz, 1H, CHH Bn), 4.43 (d, J = 11.2 Hz, 1H, CHH Bn), 4.40 (d, J = 11.3 Hz, 1H, CHH Bn), 3.89 (ddd, J = 9.9, 3.2, 2.1 Hz, 1H, H-5), 3.66 (dd, J = 10.9, 2.1 Hz, 1H, H-6), 3.63 (dd, / = 10.0, 3.6 Hz, 1H, H-2); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.3 (C=O Nico), 153.5, 150.9 (CH<sub>arom</sub> Nico), 137.6, 137.6, 137.5 (C<sub>q</sub>), 137.4 (CH<sub>arom</sub> Nico, 128.6, 128.4, 128.3, 128.2, 128.1, 128.1, 128.0, 127.9 (CH<sub>arom</sub>), 126.1 (C<sub>q</sub>), 123.4 (CH<sub>arom</sub> Nico), 114.2 (t, J = 241.2 Hz, CH<sub>2</sub>CHF<sub>2</sub>), 97.5 (C-1), 77.0 (C-2), 75.8 (C-4), 74.6 (CH<sub>2</sub> Bn), 73.9 (C-3), 72.9 (CH<sub>2</sub> Bn), 70.6 (CH<sub>2</sub> Bn), 68.0 (C-5), 67.5 (t, I = 29.1 Hz, CH<sub>2</sub>CHF<sub>2</sub>); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>):  $\delta$  97.5 ( $J_{C1,H1}$  = 167.9 Hz, C-1  $\alpha$ ); HRMS: [M+H]+ calcd for C<sub>35</sub>H<sub>36</sub>F<sub>2</sub>NO<sub>7</sub> 620.2454, found 620.2448.

2,2,2-Trifluoroethyl 2,4,6-tri-0-benzyl-3-nicotinoyl-p-glucopyranoside (S44). The title compound was prepared from donor 3 and 2,2,2-trifluoroethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0 → 60:40, pentane:EtOAc, v:v) yielded glycosylation product **S44** (32.5 mg, 0.051 mmol, 51%,  $\alpha$ : $\beta$  = 47:53). TLC: R<sub>f</sub> 0.79, (60:40, pentane:EtOAc, v:v); Data for the βanomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.95 (dd, J = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.77 (dd, J = 4.9, 1.8 Hz, 1H, CH<sub>arom</sub> Nico), 8.06 (dt, J = 7.9, 1.9 Hz, 1H, CH<sub>arom</sub> Nico), 7.50 - 6.96 (m, 16H, CH<sub>arom</sub> Nico, CH<sub>arom</sub>), 5.43 (t, J = 9.4 Hz, 1H, H-4), 4.77 (d, J = 12.0 Hz, 1H, CHH Bn), 4.65 (d, J = 12.2 Hz, 1H, CHH Bn), 4.62 (d, J = 7.6 Hz, 1H, H-1), 4.56 (d, J = 12.2 Hz, 1H, CHH Bn), 4.50 (d, J = 12.1 Hz, 1H, CHH Bn), 4.45 (d, J = 11.2 Hz, 1H, CHH Bn), 4.39 (d, J = 11.2 Hz, 1H, CHH Bn), 4.25 (dq, J = 12.2, 8.6 Hz, 1H,  $CHHCF_3$ ), 3.99 (dq, J = 12.2, 8.4 Hz, 1H,  $CHHCF_3$ ), 3.80 (t, J = 9.5 Hz, 1H, H-4), 3.76 (dd, J = 11.0, 3.7 Hz, 1H, H-6), 3.74 (dd, J = 11.0, 2.1 Hz, 1H, H-6), 3.55 (ddd, / = 9.8, 3.8, 2.1 Hz, 1H, H-5), 3.50 (dd, / = 9.5, 7.5 Hz, 1H, H-2); 13C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.3 (C=0 Nico), 153.5, 151.0 (CH<sub>arom</sub> Nico), 137.8, 137.6, 137.4 (C<sub>q</sub>), 137.3 (CH<sub>arom</sub> Nico), 128.6, 128.6, 128.6, 128.4, 128.3, 128.1, 128.1, 128.1, 127.9 (CH<sub>arom</sub>), 125.9 (C<sub>q</sub> Nico), 123.8 (q, J = 278.4 Hz, CF<sub>3</sub>), 123.3(CH<sub>arom</sub> Nico), 103.7 (C-1), 77.9 (C-2), 76.2 (C-3), 75.6 (C-4), 75.0 (C-5), 74.6 (CH<sub>2</sub> Bn), 73.8 (CH<sub>2</sub> B Bn), 68.1 (C-6), 66.3 (q, J = 35.1 Hz,  $CH_2CF_3$ ); 13C-GATED NMR (214 MHz,  $CDCl_3$ ):  $\delta$  103.7 ( $J_{C1,H1} = 162.3$  Hz, C-1 β); Diagnostic peaks α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 9.06 (dd, *J* = 2.2, 0.9 Hz, 1H, CH<sub>arom</sub> Nico), 8.77 (dd, J = 4.9, 1.8 Hz, 1H, CH<sub>arom</sub> Nico), 8.18 (dt, J = 7.9, 1.9 Hz, 1H, CH<sub>arom</sub> Nico), 7.39 - 6.97 (m, 16H, CH<sub>arom</sub> Nico, CH<sub>arom</sub>), 5.74 (dd, J = 10.0, 9.1 Hz, 1H, H-3), 4.91 (d, J = 3.6 Hz, 1H, H-1), 4.77 (d, J = 12.0Hz, 1H, CHH Bn), 4.65 (d, J = 12.1 Hz, 1H, CHH Bn), 4.55 (d, J = 12.0 Hz, 1H, CHH Bn), 4.50 (d, J = 12.1 Hz, J = 12.1 Hz, J = 12.1 Hz, J = 12.1 Hz, J = 12CHH Bn), 4.43 (d, J = 11.2 Hz, 1H, CHH Bn), 4.40 (d, J = 11.2 Hz, 1H, CHH Bn), 3.88 (dt, J = 9.8, 2.5 Hz, 1H, H-5), 3.67 (dd, / = 10.1, 2.0 Hz, 1H, H-6), 3.64 (dd, / = 10.0, 3.6 Hz, 1H, H-2); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSOC, HMBC): δ 164.3 (C=0 Nico), 153.5, 150.9 (CH<sub>arom</sub> Nico), 137.6, 137.5, 137.4 (C<sub>q</sub>), 137.3 (CH<sub>arom</sub> Nico), 128.6, 128.6, 128.6, 128.4, 128.2, 128.1, 128.0, 127.9, 127.9 (CH<sub>arom</sub>), 126.1 (C<sub>q</sub> Nico), 123.4 (CH<sub>arom</sub> Nico), 97.7 (C-1), 76.8 (C-2), 75.7 (C-4), 74.7 (CH<sub>2</sub> Bn), 74.2 (C-3), 73.9 (CH<sub>2</sub> Bn), 72.8 (CH<sub>2</sub> Bn), 70.9 (C-5), 67.9 (C-6), 65.2 (q, J=10.8 (CH<sub>2</sub> Bn), 70.9 (C-5), 67.9 (C-6), 67.9 (C-7), 67.9 (C-35.2 Hz, CH<sub>2</sub>CF<sub>3</sub>); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>): δ 97.7 (J<sub>C1,H1</sub> = 172.7 Hz, C-1 α); HRMS: [M+H]<sup>+</sup> calcd for C35H35F3NO7 638.2360, found 638.2356.

Ethyl 2,4,6-tri-O-benzyl-3-isonicotinoyl-p-glucopyranoside (S45). The title compound was prepared from donor 4 and ethanol using the general procedure for Tf2O/Ph2SO mediated glycosylations. Flash column chromatography ( $100:0 \rightarrow 60:40$ , pentane: EtOAc, v:v) yielded glycosylation product **S45** (26.8 mg, 0.046 mmol, 46%, α:β = 19:81). TLC: R<sub>2</sub> 0.65, (60:40, pentane: EtOAc, v:v); Data for the β-anomer: <sup>1</sup>H NMR (850 MHz. CDCl<sub>3</sub>. HH-COSY, HSOC, HMBC):  $\delta$  8.73 – 8.68 (m. 2H, CH<sub>arom</sub> i-Nico), 7.61 – 7.56 (m. 2H, CH<sub>arom</sub> i-Nico), 7.46 – 6.95 (m. 15H,  $CH_{arom}$ ), 5.41 (t, J = 9.5 Hz, 1H, H-3), 4.77 (d, J = 12.1 Hz, 1H, CHH Bn), 4.67 (d, J = 12.1 Hz, 1H, CHH Bn), 4.59 (d, *J* = 12.0 Hz, 1H, CH*H* Bn), 4.56 (d, *J* = 12.2 Hz, 1H, CH*H* Bn), 4.52 (d, *J* = 7.7 Hz, 1H, H-1), 4.45 (d, *J* = 11.2 Hz, 1H, CHH Bn), 4.37 (d, J = 11.2 Hz, 1H, CHH Bn), 4.04 (dq, J = 9.6, 7.1 Hz, 1H, CHHCH<sub>3</sub> Et), 3.76 (d, J = 3.0 Hz, 2H, H-6, H-6), 3.76 (t, J = 9.5 Hz, 1H, H-4), 3.66 (dq, J = 9.6, 7.0 Hz, 1H, CHHCH<sub>3</sub> Et), 3.54 (dt, J = 9.7, 3.0 Hz, 1H, H-5), 3.43 (dd, J = 9.6, 7.7 Hz, 1H, H-2), 1.32 (t, J = 7.1 Hz, 3H, CH<sub>3</sub> Et);  $^{13}$ C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.3 (C=0 i-Nico), 150.5 (CH<sub>arom</sub> i-Nico), 138.0, 137.9, 137.5, 137.2 (C<sub>0</sub>), 128.6, 128.4, 128.4, 128.3, 128.1, 128.1, 127.9, 127.9 (CH<sub>arom</sub>), 127.8 (CH<sub>arom</sub> i-Nico), 103.7 (C-1), 78.4 (C-2), 77.1 (C-3), 76.1 (C-4), 74.8 (C-5), 74.5 (CH<sub>2</sub> Bn), 73.9 (CH<sub>2</sub> Bn), 73.8 (CH<sub>2</sub> Bn), 68.5 (C-6), 65.9 (CH<sub>2</sub>CH<sub>3</sub> Et), 15.5 (CH<sub>3</sub> Et); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>): δ 103.7 (J<sub>C1,H1</sub> = 159.3 Hz, C-1 β); Diagnostic peaks α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSOC, HMBC):  $\delta$  8.75 – 8.73 (m, 2H, CH<sub>arom</sub> i-Nico), 7.72 – 7.66 (m, 2H, CH<sub>arom</sub> i-Nico), 7.40 – 6.95 (m, 15H,  $CH_{arom}$ ), 5.75 (t, J = 9.6 Hz, 1H, H-3), 4.90 (d, J = 3.5 Hz, 1H, H-1), 4.81 (d, J = 11.2 Hz, 1H, CHH Bn), 4.75 (d, J = 9.7Hz, 1H, CHH Bn), 4.56 (d, J = 12.7 Hz, 1H, CHH Bn), 4.49 (d, J = 12.6 Hz, 1H, CHH Bn), 4.42 (d, J = 11.1 Hz, 1H, CHH Bn), 4.37 (d, / = 11.1 Hz, 1H, CHH Bn), 3.89 (dt, / = 9.9, 2.6 Hz, 1H, H-5), 3.81 (t, / = 9.5 Hz, 1H, H-4), 3.79 (dd, / = 10.8, 3.3 Hz, 1H, H-6), 3.73 (dd, / = 9.7, 7.1 Hz, 1H, H-6), 3.60 (dd, / = 9.9, 3.5 Hz, 1H, H-2), 1.32 (t, / = 7.1 Hz, 3H, CH<sub>3</sub> Et); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.2 (C=0 i-Nico), 150.6 (CH<sub>arom</sub> i-Nico), 137.8, 137.8, 137.6, 137.5 (C<sub>0</sub>), 128.6, 128.6, 128.5, 128.4, 128.1, 128.1, 128.0, 128.0, 127.9 (CH<sub>arom</sub>), 123.0 (CH<sub>arom</sub> *i*-Nico), 96.3 (C-1), 77.1 (C-2), 76.2 (C-4), 75.2 (C-3), 74.6 (CH<sub>2</sub> Bn), 73.9 (CH<sub>2</sub> Bn), 72.5 (CH<sub>2</sub> Bn), 70.0 (C-5), 68.3 (C-6), 63.8 (CH<sub>2</sub>CH<sub>3</sub> Et), 15.1 (CH<sub>3</sub> Et);  $^{13}$ C-GATED NMR (214 MHz, CDCl<sub>3</sub>):  $\delta$  96.3 ( $f_{CLH1}$  = 167.4 Hz, C-1  $\alpha$ ); HRMS: [M+H]+ calcd for C<sub>35</sub>H<sub>38</sub>NO<sub>7</sub> 584.2643, found 584.2637.

2-Fluoroethyl 2,4,6-tri-0-benzyl-3-isonicotinoyl-p-glucopyranoside (\$46). The title compound was prepared from donor \$27 and 2-fluoroethanol using the general procedure for Tf2O/Ph2SO mediated glycosylations. Flash column chromatography (100:0  $\rightarrow$  60:40, pentane:EtOAc, v:v) yielded glycosylation product **S46** (30.1 mg, 0.050 mmol, 50%, α: $\beta$  = 32:68). TLC: R<sub>f</sub> 0.59, (60:40, pentane:EtOAc, v:v); Data for the βanomer: 1H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): 88.78 - 8.69 (m, 2H, CH<sub>arom</sub> i-Nico), 7.67 - 7.56 (m, 2H, CH<sub>arom</sub> i-Nico), 7.43 - 6.97 (m, 15H, CH<sub>arom</sub>), 5.45 (t, J = 9.4 Hz, 1H, H-3), 4.81 (d, J = 12.0 Hz, 1H, CHH Bn), 4.69 (d, / = 12.2 Hz, 1H, CHH Bn), 4.73 - 4.64 (m, 1H, CH<sub>2</sub>CHHF), 4.63 - 4.60 (m, 1H, CH<sub>2</sub>CHHF), 4.61 (d, / = 12.1 Hz, 1H, CHH Bn), 4.59 (d, I = 7.6 Hz, 1H, H-1), 4.59 (d, I = 11.8 Hz, 1H, CHH Bn), 4.48 (d, I = 11.3 Hz, 1H, CHH Bn), 4.40 (d, / = 11.2 Hz, 1H, CHH Bn), 4.19 (dddd, / = 32.3, 12.0, 4.9, 2.5 Hz, 1H, CHHCH<sub>2</sub>F), 3.94 (dddd, / = 25.6, 12.1, 7.0, 2.6 Hz, 1H, CH $_2$ F), 3.80 (t,  $_1$  = 9.6 Hz, 1H, H-4), 3.79 – 3.76 (m, 2H, H-6, H-6), 3.57 (ddd,  $_1$  = 9.7, 3.6, 2.4 Hz, 1H, H-5), 3.50 (dd, J = 9.6, 7.7 Hz, 1H, H-2); 13C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.2 (C=0 i-Nico), 150.6 (CH<sub>arom</sub> i-Nico), 138.0, 137.8, 137.5, 137.2 (C<sub>q</sub>), 128.6, 128.5, 128.4, 128.3, 128.1, 128.1, 128.0, 128.0, 127.8 (CH<sub>arom</sub>), 123.1 (CH<sub>arom</sub> i-Nico), 103.9 (C-1), 82.7 (d, j = 170.1 Hz, CH<sub>2</sub>CH<sub>2</sub>F), 78.2 (C-2), 76.9 (C-3), 75.9 (C-4), 74.8 (C-5), 74.6 (CH<sub>2</sub> Bn), 73.9 (CH<sub>2</sub> Bn), 73.8 (CH<sub>2</sub> Bn), 69.1 (d, J = 20.1 Hz, CH<sub>2</sub>CH<sub>2</sub>F), 68.4 (C-6); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>): δ 103.9 (J<sub>Cl,H1</sub> = 161.2 Hz, C-1 β); Diagnostic peaks α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.75 – 8.73 (m, 2H, CH<sub>arom</sub> i-Nico), 7.72 – 7.64 (m, 2H, CH<sub>arom</sub> i-Nico), 7.41 – 6.93 (m, 15H, CH<sub>arom</sub>), 5.75 (t, *I* = 9.6 Hz, 1H, H-3), 4.95 (d, *I* = 3.5 Hz, 1H, H-1), 4.50 (d, *I* = 12.3 Hz, 1H, CH*H* Bn), 4.43 (d, J = 11.1 Hz, 1H, CHH Bn), 3.82 (t, J = 9.6 Hz, 1H, H-4), 3.67 (dd, J = 10.8, 2.0 Hz, 1H, H-6), 3.62 (dd, J = 10.0, 3.5 Hz, 1H, H-2); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.2 (C=0 *i*-Nico), 150.6 (CH<sub>arom</sub> *i*-Nico), 137.7, 137.6, 137.5 (C<sub>q</sub>), 128.6, 128.5, 128.4, 128.4, 128.3, 128.1, 128.1, 128.0, 127.9 (CH<sub>arom</sub>), 123.1  $(CH_{arom} i-Nico)$ , 97.0 (C-1), 82.7 (d, J = 169.9 Hz,  $CH_2CH_2F$ ), 77.1 (C-2), 76.0 (C-3), 75.0 (C-4), 74.5 (CH<sub>2</sub>Bn), 73.8  $(CH_2 Bn)$ , 72.6  $(CH_2 Bn)$ , 70.1 (C-5), 68.2 (C-6), 67.4  $(d, J = 20.3 Hz, CH_2 CH_2 F)$ ; <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>): δ 97.0 ( $I_{C1.H1}$  = 169.1 Hz, C-1 α); HRMS: [M+H]+ calcd for  $C_{35}H_{37}FNO_7$  602.2549, found 602.2548.

2,2-Difluoroethyl 2,4,6-tri-0-benzyl-3-isonicotinoyl-p-glucopyranoside (S47). The title compound was prepared from donor 4 and 2,2-difluoroethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography ( $100:0 \rightarrow 60:40$ , pentane:EtOAc, v:v) yielded glycosylation product **S47** (32.2 mg, 0.052 mmol, 52%, α: $\beta$  = 50:50). TLC: R<sub>f</sub> 0.66, (60:40, pentane:EtOAc, v:v); Data for the  $\beta$ anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSOC, HMBC):  $\delta$  8.76 – 8.72 (m, 2H, CH<sub>arom</sub> i-Nico), 7.62 – 7.58 (m, 2H, CH<sub>arom</sub> i-Nico), 7.44 - 6.96 (m, 15H, CH<sub>arom</sub>), 5.93 (dddd, J = 55.9, 54.8, 8.5, 1.8 Hz, 1H, CH<sub>2</sub>CHF<sub>2</sub>)5.44 (t, J = 9.4 Hz. 1H. H-3), 4.77 (d. I = 12.0 Hz. 1H CHH Bn), 4.68 (d. I = 12.2 Hz. 1H. CHH Bn), 4.59 (d. I = 7.7 Hz. 1H. H-1). 4.57 (d, / = 12.0 Hz, 1H, CHH Bn), 4.53 (d, / = 12.0 Hz, 1H, CHH Bn), 4.48 (d, / = 11.3 Hz, 1H, CHH Bn), 4.40 (d, / = 9.7, 3.7, 2.1 Hz, 1H, H-5), 3.50 (dd, J = 9.5, 7.6 Hz, 1H, H-2); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.2 (C=0 i-Nico), 150.6 (CH<sub>arom</sub> i-Nico), 137.8, 137.6, 137.4, 137.1 (C<sub>q</sub>), 128.7, 128.6, 128.6, 128.6, 128.4, 128.1, 128.1, 127.9 (CH<sub>arom</sub>), 127.9 (CH<sub>arom</sub> i-Nico), 104.1 (C-1), 78.2 (C-2), 76.8 (C-3), 74.9 (C-4), 74.6 (C-5), 73.8 (CH<sub>2</sub> Bn), 72.8 (CH<sub>2</sub> Bn), 70.6 (CH<sub>2</sub> Bn), 68.0 (C-6), 67.5 (t, / = 29.1 Hz, CH<sub>2</sub>CHF<sub>2</sub>); <sup>13</sup>C-GATED NMR (214 MHz, CDCl<sub>3</sub>): δ 104.1 (/<sub>C1,H1</sub> = 162.0 Hz, C-1 β); Diagnostic peaks α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.77 – 8.73 (m, 2H, CH<sub>arom</sub> i-Nico), 7.70 – 7.66 (m, 2H, CH<sub>arom</sub> i-Nico), 7.40 – 6.93 (m, 15H, CH<sub>arom</sub>), 5.76 -5.66 (t, J = 9.7 Hz, 1H, H-3), 4.90 (d, J = 3.6 Hz, 1H, H-1), 3.89 (dt, J = 10.3, 2.7 Hz, 1H, H-5), 3.83 (t, J = 9.6 Hz, 1H, H-4), 3.67 (dd, / = 10.9, 2.1 Hz, 1H, H-6), 3.62 (dd, / = 10.0, 3.6 Hz, 1H, H-2); 13C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.2 (C=0 i-Nico), 150.7, 137.6, 137.6, 137.5 (Cq), 137.3, 128.4, 128.2, 128.1 (CH<sub>arom</sub>), 128.0 (CH<sub>arom</sub> i-Nico), 97.5 (C-1), 77.0 (C-2), 75.8 (C-3), 74.7 (C-4), 74.6 (CH<sub>2</sub> Bn), 74.0 (CH<sub>2</sub> Bn), 73.9 (CH<sub>2</sub> Bn), 70.6 (C-5), 68.9 (t, J = 23.6 Hz,  $CH_2CHF_2$ ), 68.2 (C-6);  $^{13}C$ -GATED NMR (214 MHz,  $CDCl_3$ ):  $\delta$  97.5 ( $J_{C1,H1} = 168.8$  Hz, C-1  $\alpha$ ); HRMS: [M+H]+ calcd for C<sub>35</sub>H<sub>36</sub>F<sub>2</sub>NO<sub>7</sub> 620.2454, found 620.2454.

2,2,2-Trifluoroethyl 2,4,6-tri-O-benzyl-3-isonicotinoyl-p-glucopyranoside (S48). The title compound was prepared from donor 4 and 2,2,2-trifluoroethanol using the general procedure for Tf<sub>2</sub>O/Ph<sub>2</sub>SO mediated glycosylations. Flash column chromatography (100:0 → 60:40, pentane:EtOAc, v:v) yielded glycosylation product **S48** (19.8 mg, 0.031 mmol, 31%,  $\alpha:\beta = 65:35$ ). TLC:  $R_{\ell}$  0.65, (60:40, pentane:EtOAc, v:v); Data for the α-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.76 – 8.74 (m, 2H, CH<sub>arom</sub> i-Nico), 7.69 – 7.67  $(m, 2H, CH_{arom} i-Nico), 7.52 - 6.86 (m, 15H, CH_{arom}), 5.72 (dd, J = 10.0, 9.1 Hz, 1H, H-3), 4.93 (d, J = 3.6 Hz, 1H, H-3)$ 1), 4.81 (d, J = 11.2 Hz, 1H, CHH Bn), 4.67 (d, J = 11.9 Hz, 1H, CHH Bn), 4.58 (d, J = 12.0 Hz, 1H, CHH Bn), 4.47 (d, J = 11.3 Hz, 1H, CHH Bn), 4.43 (d, J = 11.2 Hz, 1H, CHH Bn), 4.39 (d, J = 11.3 Hz, 1H, CHH Bn), 3.88 (dt, J = 9.9, 2.6 Hz, 1H, H-5), 3.85 - 3.78 (m, 4H, H-4, H-6, CHHCF<sub>3</sub>, CHHCF<sub>3</sub>), 3.66 (dd, J = 10.9, 2.0 Hz, 1H, H-6), 3.64 (dd, J = 10.0, 3.6 Hz, 1H, H-2); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.1 (C=0 *i*-Nico), 150.7 (CH<sub>arom</sub> *i*-Nico), 137.6, 137.5, 137.4, 137.3 (Cq), 129.2, 128.6, 128.4, 128.4, 128.4, 128.1, 128.1, 128.0 (CH<sub>arom</sub>), 127.9 (CH<sub>arom</sub> i-Nico), 97.6 (C-1), 76.8 (C-2), 75.8 (C-3), 75.7 (C-4), 74.7 (CH<sub>2</sub> Bn), 73.9 (CH<sub>2</sub> Bn), 72.7 (CH<sub>2</sub> Bn), 70.9 (C-5), 67.9 (C-6), 65.3 (q, J = 35.3 Hz,  $CH_2CF_3$ );  $^{13}C$ -GATED NMR (214 MHz,  $CDCl_3$ ):  $\delta$  97.6 ( $J_{C1,H1} = 171.6$  Hz, C-1  $\alpha$ ); Diagnostic peaks β-anomer: <sup>1</sup>H NMR (850 MHz, CDCl<sub>3</sub>, HH-COSY, HSQC, HMBC): δ 8.73 – 8.71 (m, 2H, CH<sub>arom</sub> i-Nico), 7.62 - 7.60 (m, 2H, CH<sub>arom</sub> i-Nico), 7.49 - 6.93 (m, 15H, CH<sub>arom</sub>), 5.41 (t, J = 9.4 Hz, 1H, H-3), 4.62 (d, J = 7.5) Hz, 1H, H-1), 3.99 (dq, / = 12.1, 8.4 Hz, 1H, CHHCF<sub>3</sub>), 3.74 (dd, / = 10.9, 2.0 Hz, 1H, H-6), 3.55 (ddd, / = 9.8, 3.7, 2.1 Hz, 1H, H-5), 3.49 (dd, J = 9.5, 7.6 Hz, 1H, H-2); <sup>13</sup>C-APT NMR (214 MHz, CDCl<sub>3</sub>, HSQC, HMBC): δ 164.1 (C=0 i-Nico), 150.6 (CH<sub>arom</sub> i-Nico), 137.6, 137.5, 137.4, 137.0 (Cq), 128.7, 128.6, 128.4, 128.2, 128.2, 128.1, 128.0, 127.9 (CH<sub>arom</sub>), 127.9 (CH<sub>arom</sub> i-Nico), 103.8 (C-1), 77.8 (C-2), 76.6 (C-4), 75.6 (C-3), 75.0 (C-5), 74.6 (CH<sub>2</sub> Bn), 73.8 (CH<sub>2</sub> Bn), 72.7 (CH<sub>2</sub> Bn), 68.1 (C-6), 66.3 (q, J = 35.0 Hz,  $CH_2CF_3$ );  $^{13}C$ -GATED NMR (214 MHz, CDCl<sub>3</sub>):  $\delta$ 103.8 ( $I_{C1,H1} = 162.6 \text{ Hz}$ , C-1  $\beta$ ); HRMS:  $[M+H]^+$  calcd for  $C_{35}H_{35}F_3NO_7$  638.2360, found 638.2362.

# References

- Vidal, S. Protecting Groups: Strategies and Applications in Carbohydrate Chemistry; Wiley-VCH: Weinheim, 2019.
- (2) Ghosh, B.; Kulkarni, S. S. Advances in Protecting Groups for Oligosaccharide Synthesis. Chem. Asian J. 2020, 15 (4), 450–462.
- (3) Volbeda, A. G.; Marel, G. A. van der; Codée, J. D. C. Protecting Group Strategies in Carbohydrate Chemistry. In *Protecting Groups*; John Wiley & Sons, Ltd, 2019; pp 1–27.
- (4) Hansen, T.; van der Vorm, S.; Tugny, C.; Remmerswaal, W. A.; van Hengst, J. M. A.; van der Marel, G. A.; Codée, J. D. C. Stereoelectronic Effects in Glycosylation Reactions. In *Reference Module in Chemistry*, Molecular Sciences and Chemical Engineering; Elsevier, 2021.
- (5) Demchenko, A. V. Handbook of Chemical Glycosylation: Advances in Stereoselectivity and Therapeutic Relevance; Wiley-VCH: Weinheim, 2008.
- (6) Werz, D. B.; Vidal, S. Modern Synthetic Methods in Carbohydrate Chemistry: From Monosaccharides to Complex Glycoconjugates; Wiley-VCH: Weinheim, 2014.
- (7) Selective Glycosylations: Synthetic Methods and Catalysts; Bennett, C. S., Ed.; Wiley-VCH: Weinheim, Germany, 2017.
- (8) Demkiw, K. M.; Remmerswaal, W. A.; Hansen, T.; van der Marel, G. A.; Codée, J. D. C.; Woerpel, K. A. Halogen Atom Participation in Guiding the Stereochemical Outcomes of Acetal Substitution Reactions. Angew. Chem. Int. Ed. 2022, 61, e202209401.
- (9) Chun, Y.; Remmerswaal, W. A.; Codée, J. D. C.; Woerpel, K. A. Neighboring-Group Participation by C-2 Acyloxy Groups: Influence of the Nucleophile and Acyl Group on the Stereochemical Outcome of Acetal Substitution Reactions. Chem. – Eur. J. 2023, 29, e202301894.
- (10) Nukada, T.; Berces, A.; Zgierski, M. Z.; Whitfield, D. M. Exploring the Mechanism of Neighboring Group Assisted Glycosylation Reactions. J. Am. Chem. Soc. 1998, 120 (51), 13291–13295.
- (11) Loh, C. C. J. Exploiting Non-Covalent Interactions in Selective Carbohydrate Synthesis. Nat. Rev. Chem. 2021, 5 (11), 792–815.
- (12) Hansen, T.; Elferink, H.; van Hengst, J. M. A.; Houthuijs, K. J.; Remmerswaal, W. A.; Kromm, A.; Berden, G.; van der Vorm, S.; Rijs, A. M.; Overkleeft, H. S.; Filippov, D. V.; Rutjes, F. P. J. T.; van der Marel, G. A.; Martens, J.; Oomens, J.; Codée, J. D. C.; Boltje, T. J. Characterization of Glycosyl Dioxolenium Ions and Their Role in Glycosylation Reactions. *Nat. Commun.* 2020, 11 (1), 2664.
- (13) Marianski, M.; Mucha, E.; Greis, K.; Moon, S.; Pardo, A.; Kirschbaum, C.; Thomas, D. A.; Meijer, G.; von Helden, G.; Gilmore, K.; Seeberger, P. H.; Pagel, K. Remote Participation during Glycosylation Reactions of Galactose Building Blocks: Direct Evidence from Cryogenic Vibrational Spectroscopy. Angew. Chem. Int. Ed. 2020, 59 (15), 6166–6171.
- (14) Elferink, H.; Remmerswaal, W. A.; Houthuijs, K. J.; Jansen, O.; Hansen, T.; Rijs, A. M.; Berden, G.; Martens, J.; Oomens, J.; Codée, J. D. C.; Boltje, T. J. Competing C-4 and C-5-Acyl Stabilization of Uronic Acid Glycosyl Cations. *Chem. Eur. J.* **2022**, *28*, e202201724.
- (15) Remmerswaal, W. A.; Houthuijs, K. J.; van de Ven, R.; Elferink, H.; Hansen, T.; Berden, G.; Overkleeft, H. S.; van der Marel, G. A.; Rutjes, F. P. J. T.; Filippov, D. V.; Boltje, T. J.; Martens, J.; Oomens, J.; Codée, J. D. C. Stabilization of Glucosyl Dioxolenium Ions by "Dual Participation" of the 2,2-Dimethyl-2-(Ortho-Nitrophenyl)Acetyl (DMNPA) Protection Group for 1,2-Cis-Glucosylation. J. Org. Chem. 2022, 87 (14), 9139–9147.
- (16) de Kleijne, F. F. J.; Elferink, H.; Moons, S. J.; White, P. B.; Boltje, T. J. Characterization of Mannosyl Dioxanium Ions in Solution Using Chemical Exchange Saturation Transfer NMR Spectroscopy. Angew. Chem. Int. Ed. 2022, 61 (6), e202109874.
- (17) de Kleijne, F. F. J.; ter Braak, F.; Piperoudis, D.; Moons, P. H.; Moons, S. J.; Elferink, H.; White, P. B.; Boltje, T. J. Detection and Characterization of Rapidly Equilibrating Glycosylation Reaction Intermediates Using Exchange NMR. J. Am. Chem. Soc. 2023, 145 (48), 26190–26201.
- (18) Crich, D.; Hu, T.; Cai, F. Does Neighboring Group Participation by Non-Vicinal Esters Play a Role in Glycosylation Reactions? Effective Probes for the Detection of Bridging Intermediates. *J. Org. Chem.* **2008**, *73* (22), 8942–8953.
- (19) Upadhyaya, K.; Subedi, Y. P.; Crich, D. Direct Experimental Characterization of a Bridged Bicyclic Glycosyl Dioxacarbenium Ion by <sup>1</sup>H and <sup>13</sup>C NMR Spectroscopy: Importance of Conformation on Participation by Distal Esters. Angew. Chem. Int. Ed. 2021, 60 (48), 25397–25403.
- (20) Hettikankanamalage, A. A.; Lassfolk, R.; Ekholm, F. S.; Leino, R.; Crich, D. Mechanisms of Stereodirecting Participation and Ester Migration from Near and Far in Glycosylation and Related Reactions. *Chem. Rev.* **2020**, *120* (15), 7104–7151.
- (21) Ande, C.; Crich, D. Stereodirecting Effect of Esters at the 4-Position of Galacto- and Glucopyranosyl Donors: Effect of 4-C-Methylation on Side-Chain Conformation and Donor Reactivity, and Influence of Concentration and Stoichiometry on Distal Group Participation. J. Org. Chem. 2023, 88 (19), 13883– 13893.

- (22) Komarova, B. S.; Tsvetkov, Y. E.; Nifantiev, N. E. Design of α-Selective Glycopyranosyl Donors Relying on Remote Anchimeric Assistance. Chem. Rec. 2016, 16 (1), 488–506.
- (23) Komarova, B. S.; Orekhova, M. V.; Tsvetkov, Y. E.; Nifantiev, N. E. Is an Acyl Group at O-3 in Glucosyl Donors Able to Control α-Stereoselectivity of Glycosylation? The Role of Conformational Mobility and the Protecting Group at O-6. Carbohydr. Res. 2014, 384, 70–86.
- (24) Yasomanee, J. P.; Demchenko, A. V. Effect of Remote Picolinyl and Picoloyl Substituents on the Stereoselectivity of Chemical Glycosylation. J. Am. Chem. Soc. 2012, 134 (49), 20097–20102.
- (25) Mannino, M. P.; Demchenko, A. V. Hydrogen-Bond-Mediated Aglycone Delivery (HAD) and Related Methods in Carbohydrate Chemistry. 2020.
- (26) Baek, J. Y.; Shin, Y.-J.; Jeon, H. B.; Kim, K. S. Picolinyl Group as an Efficient Alcohol Protecting Group: Cleavage with Zn(OAc)<sub>2</sub>·2H<sub>2</sub>O under a Neutral Condition. *Tetrahedron Lett.* 2005, 46 (31), 5143–5147.
- (27) A. Geringer, S.; P. Mannino, M.; D. Bandara, M.; V. Demchenko, A. Picoloyl Protecting Group in Synthesis: Focus on a Highly Chemoselective Catalytic Removal. Org. Biomol. Chem. 2020, 18 (25), 4863–4871.
- (28) Khanam, A.; Kumar Mandal, P. Influence of Remote Picolinyl and Picoloyl Stereodirecting Groups for the Stereoselective Glycosylation. Asian J. Org. Chem. 2021, 10 (2), 296–314.
- (29) Patteti, M. P. M., Jagodige P. Yasomanee, Alexei V. Demchenko, Venukumar. Picoloyl-Protecting Group in Oligosaccharide Synthesis: Installation, H-Bond-Mediated Aglycone Delivery (HAD), and Selective Removal. In Carbohydrate Chemistry; CRC Press, 2017.
- (30) Ruei, J.-H.; Venukumar, P.; Ingle, A. B.; Mong, K.-K. T. C6 Picoloyl Protection: A Remote Stereodirecting Group for 2-Deoxy-β-Glycoside Formation. Chem. Commun. 2015, 51 (25), 5394–5397.
- (31) Alex, C.; Visansirikul, S.; Demchenko, A. V. A Versatile Approach to the Synthesis of Mannosamine Glycosides. Org. Biomol. Chem. 2020, 18 (34), 6682–6695.
- (32) Alex, C.; Visansirikul, S.; Demchenko, A. V. A Versatile Approach to the Synthesis of Glycans Containing Mannuronic Acid Residues. Org. Biomol. Chem. 2021, 19 (12), 2731–2743.
- (33) Cai, D.; Bian, Y.; Wu, S.; Ding, K. Conformation-Controlled Hydrogen-Bond-Mediated Aglycone Delivery Method for α-Xylosylation. J. Org. Chem. 2021, 86 (15), 9945–9960.
- (34) Wang, P.; Mo, Y.; Cui, X.; Ding, X.; Zhang, X.; Li, Z. Hydrogen-Bond-Mediated Aglycone Delivery: Synthesis of β-p-Fructofuranosides. Org. Lett. 2020, 22 (8), 2967–2971.
- (35) Liu, D.-M.; Wang, H.-L.; Lei, J.-C.; Zhou, X.-Y.; Yang, J.-S. A Highly α-Stereoselective Sialylation Method Using 4-O-4-Nitropicoloyl Thiosialoside Donor. Eur. J. Org. Chem. 2020, 2020 (5), 575–585.
- (36) Lei, J.-C.; Ruan, Y.-X.; Luo, S.; Yang, J.-S. Stereodirecting Effect of C3-Ester Groups on the Glycosylation Stereochemistry of L-Rhamnopyranose Thioglycoside Donors: Stereoselective Synthesis of α- and β-L-Rhamnopyranosides. Eur. J. Org. Chem. 2019, 2019 (37), 6377–6382.
- (37) Jones, B.; Behm, A.; Shadrick, M.; Geringer, S. A.; Escopy, S.; Lohman, M.; De Meo, C. Comparative Study on the Effects of Picoloyl Groups in Sialylations Based on Their Substitution Pattern. J. Org. Chem. 2019, 84 (23), 15052–15062.
- (38) Wu, Y.-F.; Tsai, Y.-F. Assistance of the C-7,8-Picoloyl Moiety for Directing the Glycosyl Acceptors into the α-Orientation for the Glycosylation of Sialyl Donors. Org. Lett. 2017, 19 (16), 4171–4174.
- (39) Escopy, S.; Geringer, S. A.; De Meo, C. Combined Effect of the Picoloyl Protecting Group and Triflic Acid in Sialylation. Org. Lett. 2017, 19 (10), 2638–2641.
- (40) Liu, Q.-W.; Bin, H.-C.; Yang, J.-S. β-Arabinofuranosylation Using 5-0-(2-Quinolinecarbonyl) Substituted Ethyl Thioglycoside Donors. Org. Lett. 2013, 15 (15), 3974–3977.
- (41) Pistorio, S. G.; Yasomanee, J. P.; Demchenko, A. V. Hydrogen-Bond-Mediated Aglycone Delivery: Focus on β-Mannosylation. Org. Lett. 2014, 16 (3), 716–719.
- (42) Yasomanee, J. P.; Demchenko, A. V. Effect of Remote Picolinyl and Picoloyl Substituents on the Stereoselectivity of Chemical Glycosylation. J. Am. Chem. Soc. 2012, 134 (49), 20097–20102.
- (43) Kayastha, A. K.; Jia, X. G.; Yasomanee, J. P.; Demchenko, A. V. 6-*O*-Picolinyl and 6-*O*-Picoloyl Building Blocks As Glycosyl Donors with Switchable Stereoselectivity. *Org. Lett.* **2015**, *17* (18), 4448–4451.
- (44) Vuluga, D.; Legros, J.; Crousse, B.; Slawin, A. M. Z.; Laurence, C.; Nicolet, P.; Bonnet-Delpon, D. Influence of the Structure of Polyfluorinated Alcohols on Brønsted Acidity/Hydrogen-Bond Donor Ability and Consequences on the Promoter Effect. J. Org. Chem. 2011, 76 (4), 1126–1133.
- (45) Xiao, K.; Hu, Y.; Wan, Y.; Li, X.; Nie, Q.; Yan, H.; Wang, L.; Liao, J.; Liu, D.; Tu, Y.; Sun, J.; Codée, J. D. C.; Zhang, Q. Hydrogen Bond Activated Glycosylation under Mild Conditions. Chem. Sci. 2022, 13 (6), 1600–1607.
- (46) Vorm, S. van der; Hansen, T.; S. Overkleeft, H.; Marel, G. A. van der; C. Codée, J. D. The Influence of Acceptor Nucleophilicity on the Glycosylation Reaction Mechanism. *Chem. Sci.* 2017, 8 (3), 1867–1875.
- (47) van der Vorm, S.; van Hengst, J. M. A.; Bakker, M.; Overkleeft, H. S.; van der Marel, G. A.; Codée, J. D. C. Mapping the Relationship between Glycosyl Acceptor Reactivity and Glycosylation Stereoselectivity. *Angew. Chem. Int. Ed.* 2018, 57 (27), 8240–8244.
- (48) Remmerswaal, W. A.; Elferink, H.; Houthuijs, K. J.; Hansen, T.; ter Braak, F.; Berden, G.; van der Vorm, S.; Martens, J.; Oomens, J.; van der Marel, G. A.; Boltje, T. J.; Codée, J. D. C. Anomeric Triflates versus Dioxanium Ions: Different Product-Forming Intermediates from 3-Acyl Benzylidene Mannosyl and Glucosyl Donors. J. Org. Chem. 2024, 89 (3), 1618–1625.

- (49) Mannino, M. P.; Demchenko, A. V. Synthesis of β-Glucosides with 3-O-Picoloyl-Protected Glycosyl Donors in the Presence of Excess Triflic Acid: Defining the Scope. Chem. – Eur. J. 2020, 26 (13), 2938– 2946.
- (50) Codée, J. D. C.; Litjens, R. E. J. N.; den Heeten, R.; Overkleeft, H. S.; van Boom, J. H.; van der Marel, G. A. Ph<sub>2</sub>SO/Tf<sub>2</sub>O: A Powerful Promotor System in Chemoselective Glycosylations Using Thioglycosides. *Org. Lett.* 2003, 5 (9), 1519–1522.
- (51) Frihed, T. G.; Bols, M.; Pedersen, C. M. Mechanisms of Glycosylation Reactions Studied by Low-Temperature Nuclear Magnetic Resonance. Chem. Rev. 2015, 115 (11), 4963–5013.
- (52) Mannino, M. P.; Demchenko, A. V. Synthesis of β-Glucosides with 3-0-Picoloyl-Protected Glycosyl Donors in the Presence of Excess Triflic Acid: A Mechanistic Study. Chem. – Eur. J. 2020, 26 (13), 2927– 2937.
- (53) For the picoloyl group, no pK<sub>a</sub>H values were available. Therefore, to provide reference values, the solution-phase basicity ( $\Delta G_{\rm basicity} = \Delta G_{\rm N} \Delta G_{\rm NH}^*$ ) of the ring nitrogen of donors **1-3** and the proton scavangers were computed. As expected, the trends of the solution-phase basicities of the proton scavengers closely follow the pKaH values (262.8, 266.8, 268.7 kcal mol<sup>-1</sup> for respectively 2,4,6-tri-*tert*-butylpyrimidine, 2,6-di-tert-butylpyrimidine and 2,4,6-tri-*tert*-butylpyridine). The computed solution-phase basicity of donors **1-3** were much lower, regardless of donor approximately ~258.8 kcal mol<sup>-1</sup>, than that of the proton scavanger.
- (54) Hengst, J. M. A. van; Hellemons, R. J. C.; Remmerswaal, W. A.; Vrande, K. N. A. van de; Hansen, T.; Vorm, S. van der; Overkleeft, H. S.; Marel, G. A. van der; Codée, J. D. C. Mapping the Effect of Configuration and Protecting Group Pattern on Glycosyl Acceptor Reactivity. Chem. Sci. 2023, 14 (6), 1532–1542.
- (55) Mannino, M. P.; Yasomanee, J. P.; Demchenko, A. V. Investigation of the H-Bond-Mediated Aglycone Delivery Reaction in Application to the Synthesis of β-Glucosides. Carbohydr. Res. 2018, 470, 1–7.
- (56) Baek, J. Y.; Lee, B.-Y.; Jo, M. G.; Kim, K. S. β-Directing Effect of Electron-Withdrawing Groups at *O*-3, *O*-4, and *O*-6 Positions and α-Directing Effect by Remote Participation of 3-*O*-Acyl and 6-*O*-Acetyl Groups of Donors in Mannopyranosylations. *J. Am. Chem. Soc.* 2009, *131* (48), 17705–17713.
- (57) Crich, D.; Cai, W.; Dai, Z. Highly Diastereoselective α-Mannopyranosylation in the Absence of Participating Protecting Groups. J. Org. Chem. 2000, 65 (5), 1291–1297.
- (58) Crich, D.; Chandrasekera, N. S. Mechanism of 4,6-O-Benzylidene-Directed β-Mannosylation as Determined by α-Deuterium Kinetic Isotope Effects. Angew. Chem. Int. Ed. 2004, 43 (40), 5386–5389.
- (59) Crich, D.; Sun, S. Are Glycosyl Triflates Intermediates in the Sulfoxide Glycosylation Method? A Chemical and <sup>1</sup>H, <sup>13</sup>C, and <sup>19</sup>F NMR Spectroscopic Investigation. J. Am. Chem. Soc. 1997, 119 (46), 11217–11223.
- (60) Crich, D.; Sun, S. Direct Chemical Synthesis of β-Mannopyranosides and Other Glycosides via Glycosyl Triflates. Tetrahedron 1998, 54 (29), 8321–8348.
- (61) Crich, D.; Sharma, I. Influence of the O3 Protecting Group on Stereoselectivity in the Preparation of C-Mannopyranosides with 4,6-O-Benzylidene Protected Donors. J. Org. Chem. 2010, 75 (24), 8383–8391.
- (62) Hansen, T.; Lebedel, L.; Remmerswaal, W. A.; van der Vorm, S.; Wander, D. P. A.; Somers, M.; Overkleeft, H. S.; Filippov, D. V.; Désiré, J.; Mingot, A.; Bleriot, Y.; van der Marel, G. A.; Thibaudeau, S.; Codée, J. D. C. Defining the S<sub>N</sub>1 Side of Glycosylation Reactions: Stereoselectivity of Glycopyranosyl Cations. ACS Cent. Sci. 2019, 5 (5), 781–788.
- (63) Spartan'14, Wavefunction, Inc., Irvine, CA.
- [64] Frisch, M. J.; Trucks, G. W.; Cheeseman, J. R.; Scalmani, G.; Caricato, M.; Hratchian, H. P.; Li, X.; Barone, V.; Bloino, J.; Zheng, G.; Vreven, T.; Montgomery, J. A.; Petersson, G. A.; Scuseria, G. E.; Schlegel, H. B.; Nakatsuji, H.; Izmaylov, A. F.; Martin, R. L.; Sonnenberg, J. L.; Peralta, J. E.; Heyd, J. J.; Brothers, E.; Ogliaro, F.; Bearpark, M.; Robb, M. A.; Mennucci, B.; Kudin, K. N.; Staroverov, V. N.; Kobayashi, R.; Normand, J.; Rendell, A.; Gomperts, R.; Zakrzewski, V. G.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H. Gaussian 09 Rev. D.01, 2009.
- (65) Ribeiro, R. F.; Marenich, A. V.; Cramer, C. J.; Truhlar, D. G. Use of Solution-Phase Vibrational Frequencies in Continuum Models for the Free Energy of Solvation. J. Phys. Chem. B 2011, 115 (49), 14556–14562.
- (66) Luchini, G.; Alegre-Requena, J. V.; Funes-Ardoiz, I.; Paton, R. S. GoodVibes: Automated Thermochemistry for Heterogeneous Computational Chemistry Data. F1000Research 2020, 9, 291.